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ABSTRACT 
The aim of this research was the development of mass spectrometry-based methodologies for 
the high-throughput quantitation of peptides in biological matrices. Glucagon and GLP-1, 
which are of interest as biomarkers and in the development of therapeutics, were chosen as 
model peptides. Immunoassays that are traditionally used to quantify these often perform 
poorly; therefore, necessitating the development of alternative methodologies. Application of 
mass spectrometry-based methodologies to these analytes has, however, been limited, 
primarily due to sensitivity challenges, but also due to analytical challenges associated with 
their endogenous nature and instability in biological matrices.  
Chapter 2 describes the development and qualification of the first liquid-chromatography 
coupled tandem mass spectrometry (LC-MS/MS) method for the quantitation of endogenous 
glucagon from human plasma. A novel 2D extraction procedure was developed to ensure 
robustness and sensitivity, whilst a novel surrogate matrix quantitation strategy took into 
account the endogenous nature of the analyte. A lower limit of quantitation (LLOQ) of 
25 pg/mL was qualified, which was a considerable improvement over that previously 
reported in the literature (250 pg/mL) for a LC-MS/MS method. Clinical samples were cross-
validated against a conventional radioimmunoassay (RIA), and similar pharmacokinetic (PK) 
profiles resulted, demonstrating that the methods were complementary. 
In Chapter 2 glucagon instability in biological matrix was noted. To characterise this further, 
in Chapter 3 in vitro glucagon metabolites were identified using high-resolution mass 
spectrometry (HRMS). Metabolites observed by others (glucagon19-29, glucagon3–29 and 
[pGlu]
3
glucagon3–29) in alternative matrices were identified, alongside novel metabolites 
(glucagon20-29 and glucagon21-29). Cross-interference of these metabolites in immunoassays 
may help to explain their poor performance, whilst knowledge of metabolism may also aid 
the development of future stabilisation strategies.  
The method developed in Chapter 2 was refined in Chapter 4 to improve sensitivity, 
robustness and throughput, and to add GLP-1 as a secondary analyte. The sensitivity 
achieved (glucagon: 15 pg/mL LLOQ, GLP-1: 25 pg/mL LLOQ) is the highest reported for 
both peptides for an extraction avoiding immunoenrichment. Specificity of endogenous 
glucagon quantitation was assured using a novel approach with a supercharging mobile phase 
additive to access a sensitive qualifier transition. A cross-validation against established 
iii 
immunoassays using physiological study samples demonstrated some similarities between the 
methods. Differences between the immunoassay results exemplified the need to develop 
alternative methodologies. The resulting LC-MS/MS method is considered a viable 
alternative to immunoassays, for the quantitation of endogenous glucagon, dosed glucagon 
and/or dosed GLP-1 in human plasma. 
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Chapter 1 Introduction  
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1.1 INTRODUCTION TO PEPTIDES AND BIOANALYSIS 
1.1.1 Peptides 
Naturally occurring peptides consist of combinations of -amino acids (Figure 1.1) linked 
by amide (or “peptide”) bonds. Twenty one such peptide-building amino-acids are found in 
eukaryotes, distinguished by their side chains (Chapter 6 (Appendix)(Figure 6.1)). 
Twenty of these (the “standard” amino acids) are directly encoded by DNA, with 
selenocysteine being the exception. Side chains may be electrically charged, polar, or 
hydrophobic, imparting various physicochemical properties upon the resulting peptide. 
With the exception of cyclic species, peptides have N-terminal and C-terminal residues at 
the ends of molecule. 
   R----- 
NH2-CH-COOH 
 
Figure 1.1 General formula for an -amino acid. 
Naturally occurring peptides consist of combinations of -amino acids. These have the amine and 
carboxylic acid group attached to the central () carbon atom, usually along with an organic side 
chain (“R”) and a hydrogen atom. The exceptions being glycine, which has a hydrogen atom in 
place of an organic R chain, and proline which due to its cyclic nature does not have a  hydrogen 
atom and is sometimes referred to as an imino acid. 
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Peptide structures can be represented using skeletal formula (Figure 1.2 a), although due to 
their common backbone, and for brevity, structures are usually represented by listing the 
order of incorporated amino acids (known as “residues”), using standardised three or one 
letter codes (Figure 1.2 b & c). 
 
 
HIS-SER-GLN-GLY-THR-PHE-THR-SER-ASP-TYR-SER-LYS-TYR-LEU-ASP-SER-
ARG-ARG-ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR 
 
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT 
 
Figure 1.2 A peptide represented by a) skeletal formula, b) three letter residue codes and 
c) one letter residue codes. 
a) Atom connectivities and functional groups are readily observed using skeletal formula. 
b+c) Listing the order of incorporated amino acids via three or one letter codes improves brevity, 
and draws focus away from the common peptide backbone. 
Figure 6.1 displays the full set of codes and the corresponding amino acids. 
 
The International Union of Pure and Applied Chemistry (IUPAC) states that short 
peptides, containing fewer than 10-20 residues, may also be termed oligopeptides, those 
with more as polypeptides, and those with greater than 50 as proteins [1]. However, as 
acknowledged by IUPAC, authors differ greatly on the transition between the terms. For 
example the 51 amino acid 5.8 kDa pancreatic hormone insulin is variously described as a 
peptide [2], polypeptide [3], or protein [4], or it is simply referred to by name avoiding 
such terminology [5]. 
Peptides within the scope of this project were not defined by size per se, but by analytical 
considerations. Specifically, that they do not require digestion for analysis, and that 
following electropsray ionisation they form ions with charge states ≤5+ within the mass-to-
charge range of a typical triple quadrupole mass spectrometer. These technologies are 
explained further in Section 1.4, but as a guide insulin is at the upper end of peptides 
within the scope of this project.  
a) 
b) 
c) 
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1.1.2 Peptides within the Human Body 
The first biologically active peptide was discovered in 1902 by Bayliss and Starling. They 
demonstrated stimulating a part of the small intestine (a loop of jejunum), continued to 
result in the secretion of pancreatic juices, despite all nervous connections to the pancreas 
being severed [6]. They showed that this was due to the action of a chemical, which they 
named secretin. Further studies demonstrated that this belonged to a new class of signalling 
molecules carried by the blood stream, which are now known as hormones.  
It is now known that many peptides primarily function as signalling or regulatory 
molecules. They do so for a broad variety of physiological processes, including immunity 
[7], stress [8], growth [9], homeostasis [8] and reproduction [10]. Although some peptides 
have other functions, including  uses as antibiotics [11] [12] or as antioxidants [13]. 
Signalling, or regulatory peptides may be secreted into the circulatory system to bind to 
receptors at distant organs to elicit a response (endocrine signalling), act locally (paracrine 
signalling), affect the cell from which they are released (autocrine signalling), or act as 
neurotransmitters. The same peptide may be involved in multiple signalling types, for 
example although natriuretic peptides in the heart are typically endocrine acting, they also 
have autocrine and paracrine effects [14]. Similarly, peptides from the tachykinin family, 
known as neurotransmitters, may also have roles in intra-cellular signalling [15]. 
Peptides show high specificity for particular receptors; however multiple tissues may have 
receptors for a particular peptide leading to a variety of physiological effects. For example 
gastric inhibitory polypeptide (GIP) receptors are present in adipose tissue, bone, brain and 
the pancreas [16]. Activation of these receptors results in increases in lipogenesis, bone 
formation, progenitor cell proliferation and insulin secretion respectively, amongst other 
effects [16]. 
Most biologically active peptides synthesised by the human body result from the 
translation of mRNA by ribosomes. Typically larger precursor forms, “propeptides” or 
“proproteins”, are initially produced before being enzymatically truncated, such that 
peptides are secondary gene products [8]. There are thought to be >1 million different 
protein/peptide species, compared to just 20-25,000 genes [17]. The increase in 
complexity is partly due to the ability of multiple mRNA species (on average 5-6 [18]) to 
form from each gene due to alternative promoters, alternative splicing, and mRNA editing, 
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but also as a result of post-translational modifications (PTM) [18] [19]. These are covalent 
modifications that can affect molecular interactions, protein localisation, metabolism, 
signal translation and activity, and are discussed further in Section 1.8.  
Many peptides within the body also result from the turnover of endogenous proteins and 
peptides [20] [21]. Less typically, peptides can be synthesised outside of the ribosome by 
enzymatic processes, for example glutathione is synthesised in the cytosol of mammalian 
cells [13]. 
Peptides within the body also originate from food sources. Some may be “bioactive” acting 
as agonists (or antagonists) to intestinal receptors, or following numerous possible 
absorption processes enter the circulation to act on other receptors [22]. Food-derived 
peptides, and in particularly those derived from milk [23] have been implicated in affecting 
blood pressure, immune response, memory and learning, and stress reactions, amongst 
many other physiological processes [23][24]. 
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1.1.3 Peptides as Biomarkers 
A biomarker may be defined as a “characteristic that is objectively measured and evaluated 
as an indicator of normal biological or pathogenic processes, disease progression or 
pharmacological responses to a therapeutic intervention” [25]. Examples of biomarkers 
range from basic clinical signs such as body temperature, pulse rate, and blood pressure, 
through to measuring basic blood chemistry, and to measuring specific biochemical 
entities, such as particular peptides.  
As peptides play a central role in many physiological processes, they can provide a good 
source of biomarkers. Some peptide biomarkers are well established, for example a blood 
test for C-peptide is used to determine endogenous insulin secretion in diabetic patients 
[26]. This is measured in preference to insulin itself, as insulin is rapidly metabolised by 
the liver with variable clearance, so that blood levels do not accurately reflect secretion. In 
addition direct determination would also quantify dosed native insulin taken by patients, 
and potentially insulin analogues depending on their nature and that of the analytical 
technique. The performance of C-peptide as a biomarker for insulin is clear from 
biochemical considerations, as both insulin and C-peptide are produced in equimolar 
amounts by the cleavage of proinsulin [26]. 
Other well established biomarkers include using natriuretic peptides, which are determined 
by a blood test, to assist in therapeutic decision making for patients with chronic heart 
failure, rather than using more invasive procedures [27]. B-type natriuretic peptide (BNP) 
and its amino-terminal propeptide equivalent (amino-terminal pro-B-type natriuretic 
peptide, NT-proBNP) are known, amongst other triggers, to be released as a result of 
myocardial stretch, and are commonly monitored. Particularly useful information is 
obtained by trends in the concentrations of these biomarkers over time [27]. 
Peptide biomarkers may be used as part of a panel to increase the specificity of diagnosis. 
The internationally accepted test for Alzheimer’s disease measures cerebrospinal fluid 
(CSF) levels of the peptide amyloid  (A)(1–42), which is thought to aggregate in the 
brain during Alzheimer’s disease, alongside concentrations of total tau and phosphorylated  
tau-181 proteins [28]. However, blood based biomarkers would be preferable for diagnosis, 
and monitoring disease progression, due to reduced invasiveness. Several studies have 
investigated the use of A(1–40), A(1–42), and genetic variants as plasma biomarkers for 
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Alzheimer’s disease, but there is insufficient evidence (and discrepancies between studies) 
regarding their effectiveness [29]. 
Peptide biomarkers may also derive from protein (or peptide) degradants rather than 
bioactive intact peptides, i.e. they are from the “degradome”. This was observed in one 
cancer biomarker discovery study, where all 46 of the positively identified putative 
biomarkers originated from the degradome [21]. 
Peptide biomarkers may be evaluated as part of clinical trials, usually as “secondary end 
points” to provide supporting evidence for the effectiveness of the intervention [30]. This 
is in contrast to primary “clinical end points” which characterise how the subject “feels, 
functions, or survives” [30]. However, they can also be monitored as “surrogate end 
points”, if primary clinical end points occur infrequently (e.g. long term prevention of 
cardiovascular events) or allow the cessation of potentially harmful treatments before 
clinical data becomes available [30]. 
1.1.4 Peptides as Drugs 
Peptides regulate many of the body’s functions, making them potentially excellent drug 
candidates. Indeed, insulin became one of the first therapeutics developed in the modern 
drug era when, in 1922, Banting et al demonstrated that their purified pancreas extract 
successfully treated (so thought) fatally-ill diabetic juveniles on a Canadian hospital ward 
[31][32].  
However, endogenous human peptides are often not ideal for therapeutic use, one reason is 
that they are typically rapidly degraded in vivo. Therefore, analogues which maintain 
pharmacological effect whilst improving stability are often used instead. Exenatide, the 
synthetic version of exendin-4 discovered in the venom of the Gila monster, is an analogue 
of the glucagon-like peptide 1 (GLP-1) incretin hormone, and is used in the treatment of 
type 2 diabetes by targeting the GLP-1 receptor [33][34]. Other peptides are not simple 
analogues, but contain structural moieties capable of receptor activation, for example the 
immunosuppressant drug cyclosporine consists of a 11 amino acid ring structure, yet it 
binds to a site usually occupied by a simple tetrapeptide [35]. 
In fact many peptide therapeutics derive from nature, and peptidomic studies of natural 
systems can be used to generate leads [36][37]. Alternatively leads can be generated by 
8 
 
screening synthetic peptide libraries, which may consist of natural peptide sequences, 
modified versions of these, or entirely artificial peptides. One such study identified a 
potent antagonist against tumour necrosis factor-α (TNFα) following the screening of 107 
peptides [38]. 
Lead molecules can be modified to improve their pharmacological properties. Stability can 
be improved by substitution of labile amino acids, incorporation of sugars, C-terminal 
amidation, N-terminal ring formations and isomerisation of selected peptide terminal 
residues (from L to D amino acids) [39][40]. Conjugation to large polymer molecules can 
also improve stability [39][41]. For example, albiglutide, a GLP-1 agonist peptide fused to 
human serum albumin (HSA), is sufficiently stable to enable weekly dosing, whereas 
native GLP-1 has a half-life in the order of minutes [41].  
However, currently the therapeutic peptide market is a relatively small proportion (2 % 
[42]) of the total drug market (US$ 1000 bn [43]), with just 19 peptide therapeutics being 
approved in the USA between 2001-2012 [41]. One disadvantage of peptide therapeutics is 
that 75% of current drugs [42] need to be administered via injection, due to their poor 
absorption and high levels of metabolism before reaching systematic circulation. This 
results in increased patient discomfort and lower compliance than other delivery 
mechanisms. In contrast, small molecule therapeutics are often orally bioavaliable with 
greater in vivo stability. 
Despite the prevalence of small molecule therapeutics, innovation in this field is declining, 
with fewer new drugs being released onto the market [39]. Potential advantages of peptide 
therapeutics include reduced side effects, immune responses, and toxicology. This is due to 
their high specificity for the intended target enabling smaller quantities to be dosed, as well 
as their structural similarity to endogenous peptides. Consequently the probability of 
market approval (20%) of peptide therapeutics entering clinical trials is more than double 
that of small molecule drugs [44]. This, in combination with the development of non-
intravenous delivery technologies [39][41][45] and the increasing prevalence of metabolic 
disorders that many peptide drugs in development target, is expected to lead to high market 
growth of this sector. Growth of 10.3% is predicted between 2015-2025 [46], and recent 
expansion is double that of the drug market as a whole [7][39][47].  
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1.1.5 Bioanalysis of Peptides 
Bioanalysis is defined as “the quantitative or qualitative measurement of analytes in 
biological matrices, including tissue, blood, serum, urine or other body fluids” [48]. 
Quantitative bioanalysis is an important part of the drug development process [49], 
regardless of whether the drug is a small or large molecule. It enables the determination of 
pharmacokinetic (PK) parameters, which describe whether drugs are absorbed, distributed, 
metabolised and excreted appropriately. It is also required for toxicokinetics, which 
describes the relationship between drug concentrations and toxicity. Peptide bioanalysis is 
also needed for applications of biomarkers, both within drug development (determining 
pharmacodynamics (PD); the effect that a drug has on the body), and for diagnostic or 
prognostic purposes. 
Regardless of the reason for quantitation, rapid and robust methods are needed to support 
peptide bioanalysis. This need will grow as the peptide therapeutics market grows, and as 
more peptides are discovered as biomarkers. Traditionally, immunochemistry technologies 
are used for quantitation. Approaches, such as enzyme-linked immunosorbent assay 
(ELISA), allow the rapid and highly sensitive quantitation of targeted proteins and 
peptides. However, antibodies may not be available leading to long development times, 
and some assays have poor performance, due, for example, to non-specific antibody 
binding. Mass spectrometry-based techniques are increasingly used for peptide 
quantitation, as they can overcome some of these challenges. 
This research focuses on the development of mass spectrometry-based techniques for the 
high throughput quantitation of peptides from biological matrices, and describes strategies 
applicable to the determination of both exogenous (i.e. therapeutic) and endogenous (i.e. 
biomarker) peptide quantitation. In this Introduction, immunoassays are briefly described, 
due to their traditional use in peptide quantitation and because they were used to cross-
validate the methods developed as part of this project. Immunoassays are then compared to 
mass spectrometry-based methodologies, before a discussion of the methodologies used in 
this project is undertaken. Peptide modifications and sample stabilisation are then 
considered, before the model peptides used for this research are introduced, and the 
specific aims of this project are summarised.  
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1.2 IMMUNOASSAYS 
Immunoassays are widely used for the quantitation of proteins and peptides. These consist 
of antibodies directed against an antigen (analyte), or more specifically particular region(s) 
(epitope(s)) of the antigen. The antibody-antigen binding is detected, in an assay dependent 
manner, enabling the presence and/or concentration of the antigen to be determined. 
Immunoassay methods can be very sensitive, with sensitivities typically in the low pg/mL 
region for 3 kDa peptides [50][51]. As immunoassays are an established technique for 
peptide bioanalysis, they were used to cross-validate mass spectrometry-based 
methodologies developed as part of this project (Chapter 2 & Chapter 4). 
1.2.1 Radioimmunoassays 
The fundamentals of radioimmunoassays (RIA) were first described by Berson et al in 
1956. They detailed a metabolism study using radioactive insulin-I
131
, which was known to 
bind to endogenous γ-globulin [52]. They noted that electrophoretic bands from plasma 
samples corresponding to free insulin-I
131
 and γ-globulin-bound insulin-I131were affected 
by pre-soaking the electrophoretic paper in non-radioactive insulin. Specifically, this 
process increased the free insulin-I
131 
band whilst reducing the bound insulin-I
131 
band. 
They attributed this to the displacement of radioactive insulin from γ-globulin by the non-
radioactive insulin from the electrophoretic paper. 
Berson later utilised these principles of displacement to create the first quantitative RIA 
[53]. An assay was created consisting of antibody bound insulin-I
131
, which could be at 
least be partially displaced by endogenous insulin from samples added to the assay. 
Subsequent electrophoresis, and measurement and comparison of I
131
 in the free and bound 
bands, compared to that achieved by calibrants, enabled quantitation. 
The use of radioactivity provides an easily measurable characteristic, and such assays are 
still commonly used, although modern immunoassays use alternative techniques to 
electrophoretic paper to separate free and bound fractions. For example, the use of a 
precipitating reagent to precipitate the antibody (with bound antigen/marker), and 
subsequent centrifugation and removal of supernatant containing the free fraction.[54]. An 
RIA was used to cross-validate one of the LC-MS/MS methods developed as part of the 
work described in this thesis (Section 2.3.5) 
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1.2.2 Enzyme-Linked Immunosorbent Assay  
The first ELISA was described in 1971 by Engvall and Perlmann [55]. This was developed 
to maintain the high sensitivity offered by RIAs whilst offering several advantages 
including improved kit stability and simplified means of detection, as well as reduced 
health risks. In their assay, an antigen (rabbit immunonglobulin G (IgG)) was covalently 
coupled to alkaline phosphatase, forming a labelled antigen. The immunosorbent antibody 
(prepared from a sheep-anti-rabbit IgG-serum) was conjugated to cellulose. Addition of 
sample (containing unlabelled antigen) and the aforementioned labelled antigen to the 
immunosorbent resulted in competitive binding to the antibody, in an analogous fashion to 
that in RIA. Subsequently isolation of the antibody-bound antigen (by centrifugation), and 
the addition of a substrate of alkaline phosphatase yielded a readily detectable colour 
change. The extent of which was dependent on the amount of labelled antigen, and hence 
inversely related to the unlabelled antigen in samples. Improvements in modern techniques 
include coating antibody or antigen to plastics creating a solid support simplifying the 
isolation of bound antibody-antigen complexes. The development of standard microtiter 
format plates has enabled automation and equipment standardisation [56]. 
The first ELISA described above is an example of what is now termed a “competitive” 
ELISA. Other variations, such as “direct” and “sandwich” ELISA have since been 
developed [57]. In a direct ELISA, antigen from the samples is adsorbed to a surface. The 
antibody, which is conjugated to the detection enzyme, is then added which binds to the 
immobilised antigen. Following washing to remove unbound antibody, the enzyme 
substrate is added, and the reaction (usually a colour change) is monitored to determine the 
presence of/quantify the antigen. However, one disadvantage of the direct ELISA is that 
the initial binding step to the surface is non-specific, therefore many binding sites are 
occupied by non-antigens, limiting antigen binding potential and, therefore, assay 
sensitivity [57].  
Sandwich assays (Figure 1.3) overcome this disadvantage by immobilising a capture 
antibody on the surface (1) that specifically captures the antigen (2), a detection antibody is 
then added which binds to this complex (3). This may itself be conjugated to an enzyme, or 
a secondary antibody (conjugated to an enzyme) may be added to bind to the detection 
antibody (4). A substrate is then added to yield a detectable signal (5). The advantage of 
using a secondary antibody is that the same reagent can be used for multiple detection 
12 
 
antibodies in different assays if it targets a common region (e.g. fragment crystallisable 
(Fc) region), negating the need to develop conjugated detection antibodies for each assay 
[57]. A sandwich ELISA (Merck Millipore, Darmstadt, Germany) [58] using a detection 
antibody conjugated to an enzyme was used as part of this project for cross-validation  
with the developed LC-MS/MS method (Section 4.3.7). 
 
 
Figure 1.3 A schematic of the binding processes of a sandwich ELISA. 
Sandwich ELISAs immobilise an antibody to the surface, shown in (1), which specifically captures 
the antigen (green ellipse) (2). The detection antibody, specific to the analyte, is then added 
forming a “sandwich” complex (3). Often the detection antibody does not contain a means of 
generating a detectable signal, therefore an antibody to it (a “secondary” antibody) is added, which 
is conjugated to an enzyme (black circle) (4). The enzyme substrate (white star) is then added to 
yield a detectable signal (red star).  
 
Figure reproduced from reference [57], with permission. 
 
1.2.3 Time Resolved Fluorescence Sandwich Immunoassay 
The principles of time resolved fluorescence immunoassays were first described by Mathis 
[59]. Here he described how the excitation of a europium cryptate (specifically 
trisbipyridine diamine(TBP) (Eu
3+
)(the “donor”)) by light could non-radioactively excite 
allophycocyanin (APC)(the “acceptor)”, providing it was in close proximity. In isolation 
APC has a short lived emission, however when excited by TBP Eu
3+
 its emission is long 
lived, matching the length of excitation from the donor. By coupling TBP Eu
3+ 
and APC to 
separate antibodies targeting neighbouring epitopes of the analyte of interest (prolactin), 
Mathis was able to ensure that the long lived emission only occurred when both antibodies 
were bound to the analyte increasing the specificity of detection. By introducing a time 
delay before measurement of the APC’s emission he was able to exclude the short lived 
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emission from unbound species. Hence allowing measurement of antigen derived signal in 
“homogenous” (non-separated) reaction mixture, significantly simplifying measurement 
compared to the techniques above (RIA and ELISA) where unbound reagents have to be 
removed. 
 
An assay using these principles (Homogenous Time Resolved Fluorescence (HTRF)) 
sandwich immunoassay (Cisbio, Codolet, France) [60]) was used during the cross 
validation of the LC-MS/MS method developed as part of this project (Section 4.3.7). This 
consisted of a Lumi4®-Tb cryptate donor and a d2 acceptor conjugated to separate analyte 
antibodies. 
1.2.4  Magnetic Bead Panel Immunoassays 
In the late 1970s, sandwich ELISAs were developed that covalently linked antibodies to 
magnetic beads [61]. This allowed easy separation of the beads from the matrix via use of 
a magnetic rack, rather than the multiple rounds of centrifugation needed to isolate 
traditional agarose beads. Some modern techniques also make use of magnetic beads, 
which can simplify separation/washing steps over conventional approaches. In the 1980s, 
multiplexed immunoassays were described; with the presence of multiple different 
antibodies enabling simultaneous quantitation of more than one analyte [62]. 
The final immunoassay used in this project (Milliplex Multi-Analyte Profiling (MAP) 
Human Metabolic Hormone Panel (Merck Millipore, Darmstadt, Germany)) [63] combines 
magnetic beads, multiple antibodies for multiplexed detection, and fluorescence detection. 
This was used during the cross validation of the LC-MS/MS method developed as part of 
this project (Section 4.3.7). 
The magnetic beads in the assay are coded with two fluorescent dyes, altering the precise 
concentrations of which enables the creation of up to 80 distinct magnetic microspheres 
[63]. Each type is coated with different specific antibodies, allowing multiplexed analyses. 
The assay’s format allows for up to thirteen plex analysis, although for this project only 
beads corresponding to the two analytes of interest were utilised.  
Following the capture of the analyte onto the bead, a specific biotinylated detection 
antibody is added, increasing specificity. A streptavidin conjugated reporter molecule 
(phycoerythrin) is then added which binds to the biotinylated portion of the detection 
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antibodies. This process is analogous to the use of secondary antibodies in sandwich 
ELISAs (Section 1.2.2). The beads are retained via use of a magnet whilst the supernatant 
is removed, the beads are then washed, and the plate is read. The plate reader consists of 
two spectrally distinct light emitting diodes (LEDs). One causes fluorescence of the beads, 
whereas the other causes fluorescence of the reporter molecule. The fluorescence is 
detected by avalanche photodiodes (APD) and a photomultiplier tube (PMT). The 
simultaneous detection of both types of fluorescence from a particular bead confirms 
binding of a specific analyte. The intensity of the reporter molecule fluorescence is directly 
proportional to the amount of analyte bound (Figure 1.4)[63][64][65]. 
 
Figure 1.4 Principles of the Milliplex MAP Human Metabolic Hormone Panel magnetic 
bead immunoassay.  
Luminex magnetic beads are coded with two fluorescent dyes. Beads of a particular code are bound 
to multiple identical capture antibodies specific to one analyte (one replicate is shown in the figure 
for simplicity). Bead types can be combined within an assay, enabling up to thirteen-plex analysis. 
During an assay, analyte is captured by the antibodies bound to the beads. An analyte specific 
biotinylated detection antibody is added, forming a sandwich complex. A reporter molecule 
(steptavidin-linked phycoerythrin) is then added, which binds to the biotinylated portion (blue 
circle) of the detection antibody. Finally, the beads are magnetically retained and washed. 
Illumination of the beads and reporter molecule by two spectrally distinct LEDs causes their 
fluorescence. The signal from the beads is detected by avalanche photodiodes (APD) and that from 
the reporter molecules by a photomultiplier tube (PMT). The simultaneously detection of both 
signals from a particular bead confirms analyte binding. The PMT signal is proportional to the 
quantity of analyte bound, whilst the APD signal gives the analyte identity. 
Figure reproduced from reference [65].  
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1.3 IMMUNOASSAY VS. MASS SPECTROMETRY-BASED 
METHODOLOGIES  
Traditionally, peptides were quantified using immunoassay-based approaches, such as 
those described in Section 1.2. However, precision and accuracy can be poor, as can be the 
correlation between assays [50][51][66][67][68][69]. This is often attributed to the 
potential for antibodies to cross-react with similar compounds, including inactive 
degradation fragments and metabolites.  
Mass spectrometry (MS) based methodologies have been successfully applied to the 
quantitation of small molecules for several decades. However, their application to peptide 
quantitation has been limited by additional challenges, such as sensitivity requirements for 
pharmacokinetic studies, which are often greater due to lower doses resulting from 
improved efficacy, whilst the splitting of ion current between multiple charge states makes 
such sensitivities harder to reach. However, recent advances in technology have increased 
the applicability of MS based methodologies to such applications [70][71]. 
MS based methodologies can help to overcome some of the challenges associated with 
immunoassay quantitation [50][70][71]. For example, specificity can be improved by 
selected reaction monitoring (SRM) transitions that incorporate the full length peptide and 
a related fragment ion, which will exclude many structurally similar compounds, and 
extraction methodologies and chromatographic separations can be tailored to the peptides 
of interest. MS based approaches can also have quicker development times (e.g. there is no 
need to raise antibodies to novel compounds), are highly amenable to multiplexing, and 
can have a larger dynamic range. They also avoid additional handling precautions 
necessitated in RIA due to the use of radioactivity. Such methodologies are, therefore, 
increasingly applied to pharmacokinetic studies of therapeutic peptides, such as the 
quantitation of octreotide [72]. 
However, one limitation to the adoption of the use of MS in clinical analysis, is that despite 
technological advantages some endogenous species remain below the limit of quantitation 
of existing methodologies [70]. Cost can also be a further limitation. Although consumable 
costs are lower, with the largest costs typically being a solid phase extraction (SPE) plate 
(Section 1.6.3) at a couple of hundred pounds (compared to several hundred pounds for 
immunoassays kits), instrumentation is considerably more expensive. Sensitive  
LC-MS/MS systems cost in the region of ~£200-400K, whereas plate readers can be 
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obtained for around 10 times less. However, as a platform technology it enables rapid 
amortisation of the capital cost of the mass spectrometer over multiple analytes. Despite 
these challenges, the use of MS within clinical laboratories is increasing. There is also 
potential to initiate specialist centres with access to instrumentation, which could set up 
and run a quantitative clinical peptide MS service.  
This project describes the development of methodologies to improve MS sensitivity, 
increasing the applicability of the technique to both the quantitation of therapeutic peptides 
and endogenous biomarkers. A multiplexed method is also described, considerably 
improving the efficiency of analysis compared to the commonly used single analyte 
immunoassays. Consideration is given to the need for the analysis to be high throughput, 
cost effective, and provide absolute quantitation. Therefore the focus was on 
methodologies that are amenable to these requirements. Relevant mass spectrometric and 
chromatographic principles are described in Section 1.4 and Section 1.5 respectively, 
whereas Section 1.6, Section 1.7, and Section 1.8 describe extraction techniques, 
quantitative strategies, and consider peptide modifications and stability. Finally, Section 
1.9 and Section 1.10 describe the model peptide analytes chosen for this project, and 
summarise the specific aims of this research. 
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1.4 MASS SPECTROMETRY 
Electrospray ionisation (ESI) combined with low resolution triple quadrupole mass 
analysers operating in SRM mode were used for peptide quantitation described in this 
thesis. 
To investigate metabolite formation, which may help to identify species causing cross 
interference in immunoassays, aid in the development of sample stabilisation strategies, 
and/or provide insights into biology, higher resolution instruments were utilised. 
Specifically, a higher mass resolution QTRAP mass analyser was used for putative 
metabolite identification, and a high mass resolution Orbitrap analyser was used for 
metabolite confirmation.  
The applications of these instruments within this project are described in Chapter 2, 
Chapter 3 and Chapter 4, whereas their basic principles are described below. This section 
begins with a discussion on peptide ionisation, before describing relevant mass analysers 
and instrumentation, and finally considering peptide fragmentation. 
1.4.1 Electrospray Ionisation 
The use of ESI to introduce ions into the mass spectrometer was first described by 
Malcolm Dole in 1968 [73], who investigated the technique for ionisation of a dilute 
polymer solution. However it was not until after Fenn’s developments in the 1980s 
[74][75] that the technique gained popularity. 
1.4.1.1 Basic Principles 
In ESI, the source applies a strong electric field under atmospheric pressure to a liquid, 
which may be a liquid chromatography flow (Section 1.5), passing through a capillary 
tube. If a positive polarity is applied then positive ions will be enriched near the surface of 
the droplet meniscus, and negative ions will be attracted towards the capillary tube. This 
leads to a distortion of the droplet at the end of the capillary, forming a shape known as a 
Taylor cone [76]. 
Under a sufficiently high voltage the cone tip will become unstable, overcoming surface 
tension, and a fine jet will be produced containing an excess of positive charge on its 
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surface. Repulsion between like charges in the jet will cause it to break up into smaller 
charged droplets (Figure 1.5) [76]. 
 
Figure 1.5. Illustration of major processes in the atmospheric pressure region of an ESI 
ion source run in positive ion mode.  
A strong positive electric field is applied to a liquid passing through a capillary tube. Positive ions 
are enriched at the droplet meniscus at the capillary tip, leading to a distortion known as a Taylor 
cone. Under sufficiently high potential (at the Rayleigh limit) the cone will destabilise forming a jet 
of positively charged ions. These droplets will shrink in size due to solvent evaporation. Eventually 
coulombic repulsion will overcome surface tension, and the droplets will explode into a series of 
smaller droplets. This process will repeat until free ions are ejected from very small and very 
highly charged droplets (ion evaporation model (IEM)) or they are formed by complete solvent 
evaporation (charged residue model (CRM)). 
 
In order to prevent an imbalance of charge from positive ion emission, electrons must be removed 
from the capillary. This occurs by oxidation of species in solution (e.g. OH
-
) at the capillary tip. 
Liberated electrons then flow to reduce positive ions at the end of their path. Effectively the ESI 
source is an electrochemical cell, with part of the charge transport in the gas phase. The total 
droplet current (TDC) is limited for a particular system; high salt content should be avoided in ESI, 
as salt ion emission limits current available for analyte ions. 
 
Figure reproduced from reference [76], with permission.  
 
These smaller charged droplets undergo solvent evaporation, and shrink in size, which is 
often aided by a drying gas. Eventually the increase in charge density overcomes the 
surface tension (the “Rayleigh limit” has been reached) and coulombic fission occurs 
creating charged droplets of smaller size [76].  
The process then repeats until very small and very highly charged droplets are formed. 
Two mechanisms have been proposed for the final formation of charged gas-phase ions. In 
the charged residue model (CRM) complete solvent evaporation from droplets containing a 
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single analyte ion occurs, resulting in the formation of a gas-phase analyte ion. The second 
mechanism, the ion evaporation model (IEM) predicts that direct ion emission from the 
droplet surface occurs after the radii of the droplets shrink to less than ~10 nm. The IEM is 
well supported for small ions, whereas for large ions (e.g proteins) the CRM is considered 
more plausible [76]. The majority of peptides are, therefore, likely to ionise via the CRM, 
although smaller peptides may ionise via IEM.  
1.4.1.2 Peptide Electrospray Ionisation 
Fenn demonstrated that the ESI of solutions of large molecules generated “charge 
envelopes” containing multiple charged ions [75]. This enables the detection of such 
species within the mass to charge ratio (m/z) range of bench-top mass spectrometers (often 
m/z  2000). For example, whilst a singly charged ion of glucagon (a 3483 Da peptide) 
may be above the m/z limit of the mass analyser, ESI produces a range of higher charge 
states within this limit (Figure 1.6). The number of charges acquired during ESI is related to 
peptide structure, and increases with the number of basic residues (Arg, Lys, His) present, 
which readily hold charges, as well as peptide length [77]. The charge state distribution of 
peptides can be altered by use of supercharging agents, which may lead to increases in 
sensitivity or specificity, as described in Section 1.4.1.3. 
 
Figure 1.6 Glucagon charge states observed in a mass spectrometer with a m/z 2000 limit, 
following ESI. 
Singly charged glucagon (a 3483 Da peptide) has an m/z beyond that of many bench top mass 
spectrometers (often m/z  2000). However, the multiply charged ions formed during ESI enable its 
detection. 
Figure reproduced from reference [78], with permission. 
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Isotopic clusters will be present for each charge state, but depending on the resolution of 
the mass analyser they may combine to form a single peak over several m/z, with its apex 
at the average m/z for that particular charge state of the peptide. Resolution between 
clusters becomes more challenging as charge states increase, due to the smaller differences 
in m/z between isotopes.  
If the resolution is sufficient for the monoisotopic mass to be observed, this will not be the 
most abundant peak for larger peptides due to the increased probability of them containing 
at least one 
13
C
 
isotope, rather than solely consisting of the most abundant 
12
C isotopes. 
The difference between the monoisotopic and average molecular mass of a given peptide 
or protein is about 1 Da per 1500 Da [79]. 
1.4.1.3 Supercharging Reagents  
Whilst the acquisition of multiple charge states in ESI enables peptide analysis by bench-
top mass spectrometers with limited m/z ranges, the same process also limits sensitivity. 
This is because during SRM analysis (Section 1.4.2.3) a single precursor (charge state) is 
usually selected for fragmentation, therefore not including large proportion of the ion 
current. Although multiple transitions derived from different charge states can be 
monitored, the increase in signal is often accompanied by a larger increase in noise 
eliminating any potential sensitivity gains, as generally the charge state with the best signal 
to noise is originally selected. 
In 2000, Iavarone et al investigated whether altering the ESI solvent could affect the 
charge state distribution of protein ions [80]. They noted (as expected) that a trend towards 
lower charges (high m/z) occurred upon increasing the gas phase basicity (GB) of the 
organic solvent from methanol to acetonitrile to isopropanol (GB=173, 179, 182 Kcal/mol 
respectively), as these solvents removed protons from the analyte. However, they also 
noted that adding even small amounts of the poorly-volatile compounds methoxyethanol 
(GB=174 kcal/mol) or ethylene glycol (GB=185 Kcal/mol) led to dramatic shifts to higher 
(more protontated, lower m/z) charge states, despite their appreciable GBs. The latter 
finding was the first observation of what is now known as “supercharging”, and clearly 
demonstrated that solvent factors aside from GBs could influence analyte charge states. 
The group later demonstrated that the poorly-volatile solvents glycerol and m-nitrobenzyl 
alcohol (m-NBA) also lead to supercharging, with the latter being most effective [81]. For 
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example, whilst 50% glycerol was needed to observe the 23+ charge state of cytochrome c, 
just 0.7% m-NBA is needed to observe the higher 24+ charge state. The presence of 1%  
m-NBA also narrowed the charge state distribution slightly compared to unmodified 
phases. Higher levels (5% m-NBA) led to more dramatic narrowing, however significant 
adduct formation occurred reducing sensitivity. The authors suggested that polarity, vapour 
pressure, and surface tension of the solvents may be involved in the supercharging 
mechanism, but this was not fully explored. Miladinović et al subsequently demonstrated 
that dimethyl sulfoxide (DMSO) and sulfolane also acted as supercharging reagents. 
Although they also considered m-NBA optimal, as it produced slightly higher average, and 
most abundant charge states, as well as fewer adducts than the other reagents [82]. 
A mechanism for supercharging was described by Iavarone and Williams in 2003[83]. In 
brief, they hypothesised that supercharging occurs when additives increase the surface 
tension of ESI droplets. This enables greater charge accumulation before subsequent 
coulombic fission. The final highly charged droplets will similarly have higher charge 
density than usual, which will be imparted onto the resulting gas phase ions following final 
solvent evaporation. 
Other supercharging reagents have since been identified including benzyl alcohol,  
m-nitroacetophenone, m-nitrobenzonitrile, o-nitrobenzyl alcohol, p-nitrobenzyl alcohol,  
m-nitrophenyl ethanol, and m-(trifluoromethyl)-benzyl alcohol [84]. However, it was noted 
that many reagents reduced surface tension, and therefore Iavarone’s mechanism could not 
apply to these. Instead the authors suggested that supercharging may result from the 
reagent’s low gas and solution phase basicities, in addition to direct interaction between 
analyte and supercharging reagents, the latter suggested by the prevalence of adducts at 
high charge states. However, they also noted that other factors may be involved, including 
surface tension, solution phase denaturation and droplet heating [84]. Combinations of 
supercharging reagents have been investigated by others [85], but ionisation was not found 
to be robust, possibly due to the low concentrations used. 
Most applications of supercharging described in the literature relate to enabling the 
analysis of large molecules otherwise beyond the upper m/z limit of the mass spectrometer, 
improving resolution (as this is often enhanced at lower m/z), or for the production of 
highly charged gas-phase ions for experiments that require these, such as electron capture 
dissociation [81][82][83][84][80]. The possibility of enhancing sensitivity as a result of  
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narrowing of the charge states distributions is only mentioned briefly in the literature [81], 
possibly because such focussing of intensity in a smaller number of charge states does not 
always occur. Possibilities to enhance sensitivity due to the more efficient fragmentation at 
lower m/z increasing the abundance of product ions, or due to an overall increase in 
ionisability are similarly only mentioned briefly [82]. However, applications of these 
approaches are not described. 
Prior to this project, there was a single paper in the peer-reviewed literature that described 
the use of supercharging reagents to improve the sensitivity of SRM peptide quantitation 
[86]. Here it was found that m-NBA improved the intensity of the most abundant charge 
state of oxyntomodulin in solutions by up to an order of magnitude. Increases in product 
ion intensity and SRM intensity were subsequently observed. However, whilst the method 
was applied to the analysis of plasma extracts, there was no direct comparison between the 
performance using standard mobile phases and supercharging m-NBA mobile phases using 
extracts. Such a comparison is important as the background in plasma extracts is more 
complex than that in pure solutions. It may, therefore, be more susceptible to 
supercharging, which could lower signal-to-noise, and therefore sensitivity. In addition 
there was no discussion of how supercharging improved precursor ion intensity, i.e. 
whether it was due to a reduction of charge state distribution or an overall increase in 
ionisability.  
As part of this project, the potential of supercharging reagents to improve peptide SRM 
sensitivity was explored further, in both solutions and extracts (Chapter 4).  
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1.4.2 Mass Analysers and Instrumentation  
Mass analysers are used to separate ions of different m/z ejected from the ion source so that 
they can be distinguished by the detector. They may be combined together to form hybrid 
instruments to allow greater functionality. The following discussion provides a brief 
description of the mass analysers and hybrid instruments used in this project. 
1.4.2.1 Quadrupole Mass Analyser 
A quadrupole is a device consisting of four parallel circular, or ideally hyperbolic, rods. A 
radio frequency (RF) voltage can be applied to the quadrupole causing opposite pairs of 
rods to cycle between positive and negative potentials, whilst maintaining opposite rods at 
the same potential to one another. Ions entering the quadrupole that are greater than a 
minimum m/z, determined by the RF voltage, will have a stable overall trajectory enabling 
them to travel the length of the quadrupole. This mode is utilised as an ion guide in some 
instruments [79]. 
The quadrupole’s utility as mass analyser arises from the ability to superimpose a direct 
current (DC) voltage onto rods. Only ions of a particular m/z will have a stable trajectory 
under the combined RF and DC fields, and thus traverse the mass analyser to the detector. 
The RF/DC voltages can be scanned allowing the successive detection of ions of 
increasing m/z to form a spectrum, or a particular RF/DC voltage can be selected to allow 
the detection of ions of a particular m/z [79].  
However, scanning the quadrupole over a wide m/z range is not generally used in 
quantitative analysis due to large losses of ion current, reducing sensitivity. For example, if 
a spectrum is acquired over 1-1000 m/z in 1 second, each m/z will be monitored for just 1 
ms; 99.9% of the signal will be lost. The duty cycle, which may be defined as the 
“proportion of time which a device or system is usefully operated” [79], i.e. each m/z is 
monitored, is consequently very low at 0.1%. Alternative mass analysers, such as ion traps, 
are better suited for full scan analysis, as described in Section 1.4.2.2 
In contrast, quadrupoles are well suited to the monitoring ions of a particular m/z (selected 
ion monitoring (SIM)). If just one ion is monitored then the duty cycle will be 100%, no 
ion current will be lost, and the sensitivity will be high. Even if several ions are monitored, 
duty cycles and ion transmission will remain much higher than in full scan mode, as will 
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sensitivity. Quadrupole-based instruments (Figure 1.7) are therefore the most sensitive type 
of instrument for such targeted analysis [87]. 
 
Figure 1.7 Quadrupole instrument consisting of ion source, focusing lenses, quadrupole 
mass analyser, and detector.  
An RF voltage is applied to the quadrupolar rods, causing opposite pairs of rods to cycle between 
positive and negative voltages, whilst maintaining the same potential as each other. Adjacent rods 
are out of phase with one another. A direct potential can be superimposed, giving a total field 
described by (U – V cost) and –( U – V cost), where  is the angular frequency (radians per 
second), U is the direct potential, and V is the ‘zero-to-peak’ RF amplitude.  
 
Ions emitted from the source pass through a series of focussing lenses and enter the quadrupole. 
When the quadrupole is operated in RF-only mode, all ions greater than a particular m/z have a 
stable overall trajectory, allowing them to traverse the quadrupole and reach the detector. However 
when a DC voltage is superimposed, only ions of a particular m/z will have a stable overall 
trajectory. These modes of operation are used for ion guides and mass analysers respectively. 
 
Figure reproduced from reference [79], with permission. 
 
1.4.2.2 Ion Trap Mass Analyser 
The two-dimensional (2D) ion trap, also known as a linear ion trap is based on a 
quadrupole, but additionally has chargeable lenses at each end. Ions are trapped in the 
radial dimension by application of a RF quadrupolar field, and in the axial dimension by 
application of a DC electric field applied to the lenses. The polarity of the DC field 
determines whether positive or negative ions are trapped. For example, if a positive field is 
applied then positive ions will be repelled from the lenses towards the centre of the trap. 
The ejection of ions of specific m/z can then be caused by applying an RF voltage to the 
trap, which may be scanned to obtain a spectrum. 
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Ion trap analysers lead to higher sensitivities than quadrupoles operated in scanning mode, 
as ions are stored until they are ready for detection leading to a higher duty cycle. They 
also offer better resolution (See Section 1.4.2.5), further increasing their applicability to 
qualitative work. However ion traps do not perform as well as quadrupoles when analysing 
very limited m/z ranges, due to the time taken to fill the trap, and inefficiencies in the 
trapping and ejection of ions. For example, only 20% of trapped ions may be extracted 
[88]. 
1.4.2.3 Triple Quadrupole Hybrid Instrument  
Two quadrupole analysers may be combined together with a collision chamber to form a 
hybrid instrument with enhanced functionality. This is commonly referred to as a triple 
quadrupole instrument because early versions used a third quadrupole as an ion guide in 
the collision chamber (Figure 1.8) [89]. 
 
Figure 1.8 Key components of a triple quadrupole mass spectrometer. 
Gaseous phase ions exit the ion source into the first qudrupole mass filter (mass analyser). In SRM 
mode a single precursor ion is selected, which traverses the quadrupole into the collision chamber 
where it fragments. One of these fragments (the product ion) is selected in the third quadrupole, 
which exits into a particle multiplier, enhancing ion detection. SRM mode allows specific and 
sensitive transitions to be monitored. 
 
Figure reproduced from reference [89], with permission. 
 
This can be used in SRM mode to combine the sensitivity associated with SIM for targeted 
analysis with additional specificity. Specificity is particularly important for complex 
matrices, such as plasma, which may have many ions with the same m/z that could 
otherwise be detected as interferences. Triple quadrupole instruments operating in SRM 
mode were, therefore, used for targeted quantitation in this project. 
In SRM mode the first quadrupole (Q1) selects the precursor ion, whilst the second (Q2) 
acts as an ion guide transporting the ions through the collision chamber. Here product ions 
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are formed by collision with an inert gas, which are selected by the third quadrupole (Q3). 
Hence, highly specific precursor-product ions pairs (transitions) are monitored. Overall 
sensitivity will depend on the intensity of the product ion monitored, as well as any signal 
from the background matrix. 
Interfering peaks in Q1 result from co-eluting species present at the same nominal m/z as 
the peptide of interest. Due to the multiply charged nature of peptides, a mass difference 
between peptides of up to 2 Da can cause overlapping isotopic distributions at unit 
resolution [90]. If fragments from interfering species are also coincidentally the same at the 
Q3 m/z monitored, then interferences will be present in the SRM response. Interfering 
peaks can be reduced by selecting a product ion with an m/z greater than the precursor ion, 
as only multiply charged species, such as peptides, can undergo such transitions. In 
addition, interferences may be avoided by selecting an alternative charge state or product 
ion, by altering the chromatography to prevent co-elution (Section1.5), or by developing a 
more specific extraction procedure (Section 1.6). 
For multianalyte analysis, when chromatographic separation of analytes (Section 1.5), is 
performed prior to MS analysis, SRM transitions can be scheduled to coincide with the 
elution of the corresponding analyte [91]. This can ensure that sufficient data points are 
obtained across each chromatographic peak for accurate peak definition, whilst 
simultaneously ensuring that the time spent monitoring each transition (dwell time) is 
reasonably high, ensuring precise and sensitive measurement. 
An AB SCIEX 5500 triple quadrupole mass spectrometer was used in SRM mode for 
targeted quantitation in this project (Chapter 4). 
1.4.2.4 QTRAP Hybrid Instrument 
In 2002, the first quadrupole-linear ion trap instrument was described [88]. This consisted 
of three quadrupoles enabling the instrument to operate as a conventional triple quadrupole 
instrument, as described above. However, either Q2 or Q3 could also operate as linear ion 
traps, enabling the acquisition of sensitive and high resolution scanning spectra. 
To acquire product ions spectra using this instrument a precursor ion was selected in Q1, 
and fragmented in Q2. Then either 1) Q2 was used as an ion trap to retain ions within the 
collision chamber, before being scanned out for detection (with Q3 acting solely as an ion 
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guide), or 2) Q2 was used exclusively as the collision chamber, and ions were trapped in 
Q3 before being scanned out [88]. The latter configuration was found to be most effective, 
for example better resolution was achieved per scan rate [88], and was used for future 
instruments [92]. In comparison to triple quadrupole mode, using the Q3 as an ion trap 
resulted in approximately 16x more intense product ion spectra, as well as better resolution 
for the same acquisition time [88]. 
An AB SCIEX 5500 QTRAP triple quadrupole-linear ion trap mass spectrometer  
(Figure 1.9) was used as a conventional triple quadrupole instrument in SRM mode for 
targeted quantitation in this project (Chapter 2 and Chapter 3). In addition the QTRAP’s 
ion trap functionality was used to generate sensitive and higher resolution precursor and 
product ion spectra that were used for putative metabolite identification (Chapter 3). 
 
 
Figure 1.9 Key components of the AB SCIEX 5500 QTRAP mass spectrometer.  
Components are similar to the early triple quadrupole instrument (Figure 1.8), however the third 
quadrupole has been replaced with an ion trap for enhanced functionality, and ion focussing is 
improved by additional ion guides. Ions are accelerated through a curved collision chamber, which 
reduces instrument footprint and improves performance compared to linear collision chambers.  
 
Figure reproduced from reference [92]. 
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1.4.2.5 Orbitrap  
The concept for the Orbitrap mass analyser was first described in 1999 in a patent by 
Makarov [93]. He explained that whilst quadrupole linear ion traps were relatively 
inexpensive they had relatively poor mass resolution and limited mass range, whilst high 
resolution Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometers were 
costly due to the use of superconducting magnets and liquid helium. The Orbitrap mass 
analyser was therefore designed to overcome these disadvantages and resulted in a mass 
analyser with high mass, resolution, and upper m/z limits (Table 1.1). 
Table 1.1 Representative characteristics of mass analysers. 
Orbitrap mass analysers have high m/z limits, mass accuracy and resolution. Although FTICR mass 
analysers have higher resolution they are considerably more expensive. 
Selected data reproduced from [79], used with permission. 
 Quadrupole Ion Trap FTICR Orbitrap 
m/z limit 4,000 6,000  30,000 50,000  
Resolution  (FWHM, m/z 1,000) 2,000 4,000 500,000 100,000 
Accuracy (ppm) 100  100  < 5  < 5  
Ion Sampling Continuous Pulsed Pulsed Pulsed 
Pressure (Torr) 10
-5
  10
-3
  10
-10
  10
-10
  
Mass accuracy is related to the stability and resolution of the instrument.  
Resolution = m/wh  where wh is the full (peak) width at half maximum height (FWHM). 
 
The Orbitrap mass analyser was a new concept for trapping and analysing ions. The 
trapping and analysis part of the instrument (Figure 1.10) [93] consists of a measurement 
chamber (labelled 17) with internal (labelled 14) and external (labelled 16) electrodes [93]. 
Ions enter the measurement chamber through the gap between the two halves of the 
external electrodes (labelled 23 and 24). The internal and external electrodes are so shaped 
to enable the formation of equipolar potential surfaces. When voltages are supplied to the 
electrodes their fields combine forming a so-called “hyper-logarithmic” field. This traps 
ions within its confines, causing them to oscillate back and forth and in a spiral trajectory 
around the central electrode with a frequency related to ion m/z. The induced current in the 
two halves of the external electrode caused by this collective motion, can then be Fourier 
transformed (FT) to determine individual frequencies of oscillations, and thereby 
individual ion m/z. 
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Figure 1.10 Trapping/measurement chamber of the Orbitrap mass spectrometer. 
The internal electrode (labelled 14) and external electrode (labelled 16) of the Orbitrap 
trapping/measurement chamber (labelled 17) are shaped to enable the formation of equipolar 
potential surfaces. When voltages are applied to the electrodes the fields combine forming a 
“hyper-logarithmic” field. Ions enter the gap between the two halves (labelled 23 and 24) of the 
external electrode. Under the electric field they oscillate back and forth in a spiral trajectory around 
the internal electrode at frequency related to their m/z. Individual m/z can be determined by Fourier 
transforming the resulting induced current. 
 
Figure reproduced from reference [93], with permission. 
 
 
The first commercial Orbitrap instrument was introduced by Thermo Electron Corporation 
in 2005 [94]. This consisted of a quadrupole before the Orbitrap analyser enabling ion 
selection prior to mass analysis. The Thermo Fisher Q-Exactive hybrid quadrupole-
Orbitrap was used in this project (Figure 1.11) [95][96]. This instrument was used to 
provide confirmation of metabolites putatively identified using the lower resolution 
QTRAP mass spectrometer described above (Section 1.4.2.4), and its application is 
described in Chapter 3. 
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Figure 1.11 Q-Exactive hybrid quadrupole-Orbitrap instrument configuration. 
Ions from the source enter the Q-Exactive through the capillary, and are focussed by the S-lens ion 
transmission device into the Flatapole ion transmission device. The Flatapole removes any neutral 
solvents/gases as these cannot follow its curved path. The quadrupole can be set to transmit ions of 
particular m/z (at quadrupolar resolution) if desired, otherwise all ions can be transmitted. Ions then 
enter the gas-filled curved linear trap (C-trap). If fragmentation is required, they pass into the HCD 
(Higher Energy Collisional Dissociation) cell where they collide with a collision gas before 
returning to the C-trap. In the C-trap, ions lose their kinetic energy with collisions with nitrogen. 
They are consequently ejected into the Oribtrap mass analyser without motion along the axis of the 
inner electrode. Such movement is therefore solely the result of the applied “hyper-logarithmic” 
field. [95] 
 
Figure reproduced from reference [96].  
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1.4.3 Peptide Fragmentation  
Electrospray is a soft ionisation mode resulting in little, if any, ion fragmentation, which is 
ideal for determining m/z of intact analytes. However fragmentation is required to 
determine structural information, and for certain MS modes, such as SRM. Collision-
induced dissociation (CID) is the most commonly used fragmentation technique, which 
involves collision of the precursor ion with inert gas in a collision chamber. Kinetic energy 
of the gas is transformed to vibrational energy of the precursor ion, which may be 
sufficient for fragmentation. 
Peptide fragments can derive from cleavage of a bond in the peptide chain, or from a bond 
in the amino acid side chain. The most common types of fragments in the low energy CID 
technique are those deriving from the cleavage of the peptide bond. Nomenclature for these 
was proposed by Roepstorff and Fohlman in 2004 [97]. When the charge is retained on the 
N-terminus the ion type is labelled bn, whilst if it is retained on the C-terminus it is labelled 
yn, where n is the number of the amino acids in the fragment. Cleavage at other positions 
along the peptide chain similarly produces an or cn ions or xn or zn ions  
(Figure 1.12). CID typically results in charged b or y ions (Figure 1.13). 
 
Figure 1.12 Main fragmentation paths of the peptide chain by CID.  
CID most commonly leads to fragments deriving from the cleavage of the peptide bond. These are 
labelled b or y, depending on whether charge is retained on the N-terminus or C-terminus 
respectively. Subscripts give the number of residues in the fragment. Fragments derived from 
cleavages at other positions are also possible (labelled a, c, x and z). 
  
Reproduced from reference [97], with permission. 
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Figure 1.13 Examples of b and y ions. 
The b2 fragment ion contains the first two residues from the N-terminus, whereas the y2 fragment 
ion contains the first two residues from the C-terminus. 
Reproduced from reference [97], with permission. 
 
Many other ions can also be present following fragmentation. Fragments can also result in 
the loss of small molecules such as water or ammonia from amino acid side chains, 
multiple cleavages from the peptide chain can produce internal fragment ions, and single 
constituent amino acids (immonium ions) may be observed in the low end of the mass 
spectra. Peptide structure  influences the fragment ions that are formed. [79]  
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1.5 PEPTIDE CHROMATOGRAPHY  
1.5.1 Introduction  
The SRM technique offers a high degree of selectivity, but efficient pre-mass spectrometer 
sample separation is nevertheless required to reduce matrix effects (e.g. signal suppression) 
and to resolve interferences within the targeted SRM window. Interferences in biological 
matrices, such as plasma and serum, are often more abundant than in small molecule 
analyses as numerous structurally similar endogenous proteins or peptides may be present 
Complete resolution of all compounds is almost impossible due to the limited separation 
power of even the most modern separation techniques; the degree of overlap can simply be 
reduced to improve method performance. Traditional proteomic separation techniques, 
such as two dimensional gel electrophoresis and HPLC (high performance liquid 
chromatography), are time consuming and consequently inappropriate for high throughput 
PK/PD applications which may involve the analysis of many thousands of samples. 
UHPLC (ultra high performance liquid chromatography) has been extensively used by the 
small molecule community to decrease analysis time, whilst maintaining or increasing 
resolution. It can also increase sensitivity as the sharper peaks obtained can lead to 
enhanced signal-to-noise (S/N) and its use has been reviewed for such small molecule 
separations [98] [99]. However, despite its advantages it has only recently been applied to 
the separation of proteins and peptides. This Section will begin with a brief introduction to 
UHPLC, consider the differences in chromatography between small and large molecules, 
and demonstrate the advantages of UHPLC over HPLC for peptide separations. The effect 
of altering various chromatographic parameters will also be considered. An expanded 
version of this section was published as a review paper as part of this project [100]. 
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1.5.2 Introduction to Chromatographic Theory  
Van Deemter published his landmark paper examining the mechanisms of 
chromatographic band broadening in 1956 using columns packed with 30 µm and 240 µm 
diameter particles [101]. Since then there has been a movement towards using smaller 
particle packing materials as these significantly reduce the height equivalent of a 
theoretical plate (H) described in his equations (Equation 1.1 and Equation 1.2), increasing 
column efficiency. In particular, smaller particles reduce the mass transfer (C) term of the 
equation due to the decrease in distance the analyte needs to travel between the stationary, 
stagnant mobile phase, and the flowing mobile phase. The reduction of the C term with 
particle size is large as it is proportional to the square of the particle diameter. In addition, 
the eddy diffusion (A) term is reduced when smaller particles are used due to the reduced 
variations in the distances between various routes through the chromatographic bed. 
 
H = Adp + B
Dm

+ C
dp
2

Dm
 
Equation 1.1  Full Van Deemter equation. 
H=plate height, A, B and C are constants, dp = particle diameter, Dm = analyte’s diffusion 
coefficient in the mobile phase, =linear velocity. 
 
H = A +
B

+ C 
Equation 1.2 Simplified Van Deemter equation. 
H=plate height, A=eddy diffusion constant, B=longitudinal diffusion constant, C=mass transfer 
kinetic constant, µ=linear velocity. 
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The optimal linear mobile phase velocity is increased with smaller particles as it is 
inversely proportional to the square of the particle size allowing faster optimal analysis 
(Equation 1.3). Furthermore, as the Van Deemter curves begin to flatten with smaller 
particle sizes (due to the C term), flow rates faster than optimal (μopt) can be used to further 
increase the speed of analysis with negligible loss of efficiency (Figure 1.14). 

opt
=
Dm
dp
√
B
C
 
Equation 1.3  Optimal linear velocity equation. 
opt=optimal linear flow rate, Dm=analyte’s diffusion coefficient in the mobile phase, 
dp= particle diameter, B=longitudinal diffusion constant, C=mass transfer kinetic constant. 
 
 
Figure 1.14 H vs  plots obtained for the small molecule acetophenone on Acquity and 
XBridge columns with various particle sizes. 
The flattening of the Van Deemter curves with smaller particle sized columns enables higher flow 
rates to be used, improving speed of analysis, with neglible loss of chromatographic efficiency 
(increases in H). 
Figure reproduced from reference [102], with permission. 
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Smaller particles do, however, lead to a larger pressure drop across a column, ΔP, as this is 
inversely proportional to the square of the particle diameter (Equation 1.4). Therefore, if 
small particle columns are to be used with conventional HPLC systems their lengths must 
be kept short so that they are below the systems pressure limit of typically ca. 6,000 psi. 
However the greater efficiency of small particles allows the use of shorter columns, 
reducing ΔP and analysis times, whilst maintaining or surpassing the performance of 
columns with larger particles [103]. 
ΔP =  L /dp
2
 
Equation 1.4  Pressure drop equation. 
ΔP=pressure drop across the column, =flow resistance factor, =solvent viscosity,  
L=length of the packed bed, µ=linear velocity dp=particle diameter.  
 
If greater separation efficiency is needed, longer columns can be chosen or if faster 
analysis is required flow rates can be increased. Both of these choices increase the pressure 
drop across the column and necessitate the use of UHPLC systems. MacNair describes 
early prototype ultra-high pressure instruments capable of producing pressures up to 
60,000 psi [104] and 130,000 psi [105]. However, due to the severe heat dissipation such 
high pressures cannot be used with conventional bore sub 2µm particles, which instead 
should be operated below 20,000 psi [105]. Such ultra-high pressure systems have been 
commercialized [106] and are frequently used in pharmaceutical analysis. UHPLC was 
used in the majority of the methods referenced in this chapter. The Waters Acquity 
UHPLC system, which has a pressure limit of 15,000 psi, was used in this project. 
Although Van Deemter plots are useful they do not take into account permeability 
considerations and, therefore, can be misleading as instrumental pressure limits may 
prevent the desired performance from being achieved. Alternative approaches, largely 
based on the kinetic plots of Giddings [107] are therefore used. Most commonly “Poppe 
plots” are constructed in which plate time (t0/N) is plotted against plate number (N)  
(Figure 1.15) [108]. These can be used to calculate the highest plate number that can be 
achieved within defined pressure limits and to visualise the compromise between 
efficiency and speed. The curved lines represent the most efficient analysis for a given 
particle size when working at a defined pressure limit. Any analysis on the left hand side of 
the line is possible at lower pressures, whereas analysis on the right hand side is 
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‘prohibited’ due the pressure limit. The vertical asymptotes are due to low flow rates 
required to accommodate the long columns needed for very high values of N. Analyses in 
this region are too long to be practical. 
 
Figure 1.15 Poppe plot with various particle sized columns.  
H=plate height, µ0=linear velocity at t0, t0=unretained time. Plate No= Number of theoretical plates 
(N). Maximum pressure drop= 4 x l0
7
 Pa.  
 
t0 describes the retention time of an unretained peak (i.e. the column dead-time), which is inversely 
related to linear velocity at t0, which is given by µ0.  The number of theoretical plates (N) is 
inversely related to their height (H). Hence the y axis can be expressed as H/µ0 or t0/N. 
 
The “plate time” (t0/N), describes the unretained time needed to generate one theoretical plate; 
shorter plate times are preferable as they lead to faster analysis. Plate times are affected by the 
required N, as well as particle size. 
 
The solid lines represent the most efficient analysis at a given maximum allowed pressure drop, but 
any analysis on the left hand side is possible at lower pressures. Analysis on the right hand side is 
prohibited due to the pressure limitations. 
 
Low levels of N can be achieved with shorter plate times, and consequently shorter chromatogram 
durations (in terms of unretained times), using smaller particle columns. For example for LogN 4 
a chromatogram duration of 100 seconds is required using 7.0 µm particles, but only 10 seconds 
using 1.4 µm particles. 
 
High levels of N can only be practically achieved using larger particle columns. For example, 
1.4µm particle columns cannot practically achieve LogN 4.8, whereas LogN 5.8 is possible 
using 7.0 µm particles. 
 
The vertical asymptotes result from the need to use long columns to generate high N, and the low 
flow rates needed to accommodate these within a given maximum pressure drop. 
 
Figure reproduced  from reference [108], with permission.  
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Kinetic plots may be used for assessing performance for isocratic separations, but they are 
not applicable for the gradient mode separations commonly used for peptide separations, as 
classical plate counts (N) are no longer applicable. In reversed-phase gradient mode, the 
relative concentration of organic solvent is slowly increased during the separation, whereas 
in an isocratic separation this is kept constant. Gradient mode separation is used to separate 
compounds with varying physicochemical properties within a reasonable time scale and/or 
to increase resolution, and was used for separations in this project. In gradient mode peak 
capacity (P), rather than efficiency, N, is used as a measure of performance [109]. The 
peak capacity is defined as the number of peaks that can be separated within a retention 
window, and it depends on N, column dead time, and gradient run time (tgrad). 
Schoenmakers [110] describes an approach that allows the construction of “gradient 
conditional peak capacity Poppe plots”, which plot tgrad/P versus P at a given pressure limit 
to give the chromatographic conditions that provide the best compromise between peak 
capacity (P) and analysis time (Figure 1.16). 
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Figure 1.16 Gradient conditional peak capacity Poppe plots of compounds of various 
molecular weights. 
Tgrad=gradient run time, P=peak capacity. 
 
Gradient conditional Poppe plots are effectively Poppe Plots (Figure 1.15) transformed for gradient 
analysis. The plot above describes the compromise between peak capacity and analysis time for 
various analytes analysed using UHPLC at the stated temperatures. 
 
Peak capacity improves as molecular weight increases for a given gradient run time. For example, 
for a gradient time of 1000 minutes, butylparaben (194 Da, 30C) achieves a peak capacity of 
500, whilst triptorelin (1312 Da, 30C) achieves a peak capacity of 1000. Peak capacity 
improves further for the higher molecular weight species glucagon (3483 Da) and insulin (5807 
Da), as well as with elevated temperature. Better resolution between higher molecular weight 
species, than between lower molecular weight species, in a mixture results from the improved peak 
capacity. 
 
Figure reproduced from reference [111], with permission. 
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1.5.3 Large vs. Small Molecule Chromatography  
The large size of peptides leads to different chromatographic behaviour to that of small 
molecules. Large molecules have lower diffusion coefficients (Dm) and consequently suffer 
from increased mass transfer effects (C term). For example, ivermectin (875 Da) gives C 
terms 2-7 times larger than when compared to the smaller molecules ethinylestradiol (296 
Da) or bicalutamide (430 Da) depending on the column chosen [112]. The higher C term 
for larger molecules leads to lower optimal linear velocities, µopt, increasing analysis time 
for isocratic elutions. The peptide triptorelin (1312 Da) therefore requires approximately 
six times the analysis time to achieve an N of 10,000 in comparison to the small molecule 
butylparaben (194 Da) [99]. Therefore, the reduction of C terms that occurs when using 
small particle columns gives a significant performance boost for isocratic separations of 
peptides. 
In contrast, gradient mode performance, measured in terms of peak capacity (P), improves 
as molecular weight increases. For example, the small molecule butylparaben required a 
longer gradient time to achieve a specific peak capacity than the three peptides analysed 
(triptorelin (1312 Da), glucagon (3483 Da) and insulin (5807 Da)), which themselves show 
a reduction in gradient time with increases in molecular weight (Figure 1.16) [111]. This 
effect is observed as, although P depends on the square root of isocratic efficiency (N) it 
depends more strongly on the S-parameter (slope of the plot of the logarithm of the 
retention versus solvent composition), which increases with molecular weight [111]. 
The larger S-parameter also causes differences in the elution behaviour between peptides 
and small molecules. In reversed phase chromatography, the particle surface is 
hydrophobic and analytes are retained by the adsorption of a hydrophobic face of the 
molecule to this surface. For small molecule separations, retention changes slowly with 
organic modifier strength, whereas for protein and peptide separations the analytes remain 
bound to the surface until a specific concentration of organic solvent is reached and then 
abruptly elute with only minor further interactions resulting in sharp peaks [113]. It is due 
to this abrupt elution that isocratic elution is rarely used for peptide separations as small 
differences in mobile phase preparation lead to irreproducible retention times. However 
despite the lack of interactions along the column, column length is still important for 
separations in complex matrices, such as plasma, to provide resolution from interferences. 
For example in the analysis of the peptide octreotide in human plasma an interference was 
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found to elute close to the analyte when using an Acquity UPLC BEH C18 2.1 mm x 50 
mm 1.7 µm column, but this was fully resolved when an equivalent 100 mm column was 
used [114]. 
It has been found that as temperature increases the reduction in % acetonitrile (ACN) 
needed in order to maintain a constant retention factor (K) is smaller with peptides than 
with small molecules [111]. Whereas a 5-10% decrease in ACN per 30 C temperature 
increase is typical with small molecules, a 2-3% decrease was needed for triptorelin and 
glucagon, whilst almost no decrease was needed for insulin [111]. It has been suggested 
that this phenomenon could be due to the presence of mixed interactions between peptides 
and the hydrophobic stationary phase or could be a general trend with increasing 
compound molecular weight. 
In addition to the higher molecular weight of proteins and peptides, their larger volume can 
also affect their chromatography. Columns with larger pore sizes may be required to 
accommodate larger peptides and proteins [115].  However for peptides (<5 kDa) that are 
the focus of this project, standard columns with pore sizes of 60-120 Å usually show 
sufficient performance, and were therefore used in the work described in this thesis.  
1.5.4 UHPLC vs. HPLC for Peptide Separations 
UHPLC has been used to significantly reduce analysis times in comparison to HPLC for a 
number of peptide separations due to its greater efficiency. The separation time of a 
peptide mixture containing triptorelin, glucagon, and insulin was reduced by up to 4-fold 
using UHPLC without compromising performance [111]. The application of UHPLC to 
tryptic digest separations reduced a 74 minute run time using capillary HPLC to 12.7 
minutes, whist maintaining equivalent or superior performance [116]. 
 
UHPLC can also reduce matrix effects compared to HPLC, which is attributed to the 
enhanced resolution between the analyte and matrix interferences [114][117]. For the 
analysis of the peptide octreotide in human plasma matrix effects were further reduced by 
using a guard column and switching valve to remove phospholipids prior to their injection 
onto the UHPLC analytical column [114]. The combination of UHPLC and online 
phospholipid removal led to a 4-5 fold increase in peak height and 2-fold increase in peak 
42 
 
area at the 25 pg/mL lower limit of quantitation (LLOQ) compared to the initial HPLC 
conditions.  
1.5.5 Effects of Altering Chromatographic Parameters for UHPLC Peptide 
Separations 
1.5.5.1 Mobile Phase Composition 
There is often little optimisation of mobile phase solvents and modifiers for protein and 
peptide separations using UHPLC. ACN is by far the most commonly used solvent as an 
organic mobile phase, and is nearly always used with formic acid (FA) or trifluoroacetic 
acid (TFA) modifiers. ACN is the mobile phase solvent of choice due to its low viscosity 
(allowing high flow rates and therefore throughput) and good selectivity properties based 
on its relative polarity, whereas the acidic counter ions from the modifiers are considered 
to pair with the positively charged and polar residues in peptides leading to good peak 
shape. The best chromatographic separations are commonly achieved using TFA as a 
modifier; however TFA causes mass spectrometer ion suppression, reducing overall 
sensitivity. Although TFA concentrations of 0.02-0.05% can strike a good balance between 
ion pairing and sensitivity [118]. 
 
Alternative organic phases, such as methanol [119] and isopropanol [120] can be used to 
give different selectivities. Isopropanol can also lead to less peak splitting, due to its 
increased efficiency at dissolving hydrophobic analytes, and its stronger elution strength 
can lead to shorter gradient times [120]. However its high viscosity (6 times ACN's) limits 
its application due to back pressure limitation of UHPLC systems.  
 
Adjusting the mobile phase pH or using ion pairing agents can result in significant changes 
in retention and resolution, due to the presence of ionisable amino acids. Basic mobile 
phases can lead to better chromatography for some analytes, such as Aβ peptides, where 
modification with NH4OH gave better resolution and peak shape than that achieved using 
typical acidic conditions [121]. 
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For the work described in this thesis, an organic mobile phase consisting of ACN with FA 
modifier was found to give good performance, and the resulting UHPLC methods are 
described in Chapter 2, Chapter 3 and Chapter 4. 
 
1.5.5.2 Mobile Phase Flow Rate 
Guillarme et al [99] confirmed previous work that suggested that whilst in isocratic mode 
one should work close to the optimal linear velocity to obtain the maximum efficiency, in 
gradient mode very high flow rates should be used. This is because whilst the value of P is 
proportional to the square root of isocratic efficiency (which is slightly lower at higher 
flow rates) it depends more strongly on column dead time, which is inversely proportional 
to flow rate. The flattening of Van Deemter curves and kinetic plots with small particles 
also suggests that high mobile phase rates should provide highly efficient analysis. High 
flow rates (1.0 mL/min) have been utilised in a method for the quantitation of the intact 
peptide exendin-4 from plasma and dried blood spot matrices to produce a rapid (ca. 2 
minutes) analysis [122]. However, high flow rates can sometimes lead to lower than 
expected sensitivities due to reduced desolvation efficiency at the electrospray source 
[120]. Typical flow rates used in the literature with ca. 2mm internal diameter columns 
vary from 0.4-1.0 mL/min with 5 cm columns, and 0.4-0.7 mL/min with 10 cm columns. 
To maximise sensitivity and throughputs, flow rates were optimised for the UHPLC 
methods developed in this project. 
 
Nanobore columns packed with small particles (<2.0 µm) have been used with nanoflow 
LC systems to increase performance, including methods for the separation of tryptic 
peptides [105]. Sensitivities can be much higher than higher flow conventional bore 
techniques due to small elution volumes increasing analyte concentrations, however 
analysis times are much longer, and such methods are, therefore, not considered in this 
thesis as they are not amenable to high throughput analysis. 
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1.5.5.3 Elution Gradient 
In general, the slower and shallower the gradient, the better the resolution. However, 
occasionally peculiar behaviour is observed where reducing the gradient slope reduces 
resolution, or even changes selectivity, altering elution order [123], and therefore the 
gradient slope must be carefully optimized.  
 
Steeper and/or shorter gradients are used for targeted analysis PK/PD, rather than for 
profiling experiments. For SRM targeted analysis, it is only necessary to resolve peptides 
of interest from interferences sharing a SRM transition and from species that cause 
significant matrix effects, and therefore, faster lower resolution gradients can be used to 
reduce run times. If stable isotopically labelled (SIL) peptide internal standards are used, 
matrix effects are less of a concern as they can be compensated for, although they may still 
need to be reduced to ensure sensitivity.  
1.5.5.4 Column Temperature 
Solvent viscosity, protein diffusivity and mobile phase polarity depend strongly on 
temperature. The manipulation of column temperature is, therefore, a crucial variable in 
the separation of peptides.  
 
Temperature can affect the gradient required for elution as the relative polarity of peptides 
increases with temperature [111]. It can also affect analyte selectivities, which may be due 
to conformational changes enabling the interaction of alternative residues with the column. 
For example, the retention order of insulin and lysozyme reverses as temperature increase 
[120]. 
 
High temperature UHPLC (HT-UHPLC), which uses elevated mobile phase temperatures 
(60 C < T < 90 C), is faster and leads to higher maximum efficiencies than standard 
UHPLC. The increases in speed and efficiency are attributed to decreased mobile phase 
viscosity at higher temperatures, increased analyte diffusion, and increased adsorption 
kinetics [124]. The benefits are much greater for larger molecules than small molecules, as 
their lower diffusion coefficients enable their kinetics to be enhanced by a greater extent. 
In addition, the modification of secondary interactions is thought to reduce broadening and 
lead to higher efficiencies [99]. For example, a UHPLC analysis of tryptic peptides from 
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three proteins (myoglobin, β-casein, and β-lactoglobulin) at 30 C, 60 C, and 90 C 
showed that peak capacities increased with temperature [111]. The increased performance 
at higher temperatures allows the development of faster methods whilst maintaining peak 
capacities obtained at lower temperatures. Hence, an analysis of a mixture of triptorelin, 
glucagon, and insulin showed that running UHPLC at 90 C, enabled a 3-4 fold reduction 
in analysis time compared to ambient temperature [111].  
 
Specialist HT-UHPLC equipment was not available for this project, however UHPLC 
methods developed in this thesis used relatively high column temperatures (60 C) to 
enable as efficient and rapid analysis as possible. Furthermore, such an intermediate 
temperature may reduce thermal degradation, that has been reported for some peptides at 
higher temperatures [111]. 
 
1.5.6 Carryover  
Analyte from one injection can be retained to the column, or other components of the LC 
system, and be detected in subsequent injections. Such carryover needs to be carefully 
controlled so that it does not affect quantitation of subsequent samples. Strategies include 
adding wash samples after high concentration samples, choosing a small calibration range, 
using an LC system with low carryover characteristics, and using post gradient column 
washes. The higher pressures used in UHPLC can, however, reduce carryover compared to 
HPLC, due to conformational changes altering the interaction with the stationary phase 
[125]. Higher temperatures can also reduce carryover by reducing adsorption [113]. 
It is common to increase the percentage of organic mobile phase to approximately 90% at 
the end of the analytical gradient in order to wash the column to prevent carryover into the 
next sample. The length of wash steps can vary significantly. For example, a UHPLC 
method for the analysis of tryptic peptides from influenza proteins contained a 3.2 minutes 
wash step [116], whilst a method for the analysis of the exendin-4 peptide contained just a 
0.1 minute wash without experiencing carryover [122]. Although different analytes and 
matrices will require different wash durations, it is important to ensure these times are 
optimised to maximize throughput, as was performed in the work described in this thesis.  
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The selection of mobile phases can also influence carryover particularly for highly 
ionisable peptides. It is know that Aβ peptides readily bind to surfaces (e.g. valve, injector 
port, sample loop and needle) and consequently often lead to carryover between injections 
[121]. Assembly and aggregation properties of Aβ peptides depend on pH, with low pH 
(<2) and high pH (>9) increasing solubility. It was found that a basic mobile phase 
dramatically reduced carryover between runs compared to typical acid conditions [121]. 
1.5.7 Columns 
Peak tailing, which reduces separation efficiency, can be severe for peptide separations, 
and, therefore, appropriate columns must be selected. Peak tailing can be caused by the 
hydrogen bonding of amine groups from peptides to free silanols on the silica stationary 
phase, forming secondary interactions. Contributions also occur due to ionic bonding 
between charged groups and free silanols. End capping can be used to reduce the numbers 
of free silanols, but some still remain.  
 
The majority of the analyses within the literature use particles with C18 ligands. 
Occasionally, C8 and C4 phases are used for the analysis of hydrophobic or very 
hydrophobic analytes respectively, due to their more appropriate retentive characteristics. 
Alternative phases such as phenyl, or those that incorporate charged groups, are seldom 
used, but can be investigated if unsatisfactory performance is achieved with hydrophobic 
phases. 
 
A commonly used UHPLC column used for protein or peptide separations is the Waters 
Acquity UPLC BEH C18 column, which was used for this project. The ethylene bridged 
hybrid (BEH) particle provides high mechanical strength with wide pH tolerability (pH 1-
12). These particles show similar selectivity to silica phases, but with significantly less 
tailing [126]. The high mechanical strength allows stability at elevated pressure (up to 
15,000 psi) enabling the use of high flow rates to increase throughput. Some studies use 
the specialist PST (peptide separation technology) columns, which are high pore size BEH 
columns quality control (QC) checked against peptide mixtures, although suitable 
performance was achieved in this project using standard BEH columns  
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Alternatives to UHPLC columns include superficially porous (also known as core-shell, 
fused-core or porous shell particles) and monolithic columns, as described in [100]. 
However, UHPLC generally offers highest throughput (for a reasonable peak capacity) 
(Figure 1.17), and these were therefore selected for this project. 
 
Figure 1.17 Comparison of the gradient-mode performance of columns with various 
packings in terms of throughput and maximum resolution for the model peptide triptorelin 
(1300 Da). 
 
UHPLC gives optimal performance in terms of peak capacity and throughput for a given 
temperature. Elevating the temperature significantly improves performance of both HPLC and 
UHPLC (marked HTLC and HT-UHPLC respectively).  
All columns expect the fused-core and monoliths consisted of totally porous particles. The fused 
core column contained 2.7 µm superficially porous particles (SPP), consisting of a 1.7 µm solid 
inner core, with a 0.5 µm porous outer core. As analyte can only diffuse into the outer core, the C 
term of the Van Deemeter equation is significantly reduced, improving performance compared to 
totally porous particles of the same diameter. The monolith column consisted of a single rod of 
porous material; such columns can lead to efficiencies similar to that of columns packed with small 
porous silica particles (3-3.5 µm), but with permeabilities equivalent to a column packed with 
larger (11 µm) particles enabling use with lower pressure LC systems. 
tgrad= gradient run time, P= peak capacity.  
 
Figure reproduced from reference [99], with permission. 
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1.6 EXTRACTION TECHNIQUES 
The nature of the study will determine the matrix to be sampled. In humans, bodily fluids 
(e.g. blood (whole blood/serum/plasma), urine, or saliva) are widely used matrices as they 
can be obtained at minimum cost with low invasiveness and have well-established sample 
collection and processing procedures. This project used plasma as a matrix and, therefore, 
this Section focuses upon techniques to extract peptides from plasma. 
Plasma is thought to contain over 10,000 different proteins and peptides present over a 
wide dynamic range; there is a difference in abundance of 10
10
 between serum albumin  
(35-50 mg/mL) and interleukin-6 (0.5 pg/mL) [127]. Extraction techniques must therefore 
be used to prevent the “masking” of low abundant species by highly abundant species. 
Masking may either be due to interferences in the mass spectrum of the peptide of interest, 
or due to matrix suppression caused by competition for ionisation in the ion source. 
Extraction techniques exploit the differences in physicochemical properties between the 
analyte of interest and matrix components to extract the analyte into a simpler matrix and 
to increase its relative abundance. 
1.6.1 Immunoaffinity 
Immunoaffinity based technologies use antibodies to remove specific high abundant 
proteins from the matrix (immunodepletion), or to selectively the extract analyte of interest 
(immunoenrichment). 
The first commercially available device was the Multiple Affinity Removal System 
(MARS), which contained antibodies to the top 6 plasma proteins (albumin, IgG, IgA,  
1-antitrypsin, transferrin, and haptoglobin) immobilised to a solid matrix in the form of 
HPLC columns or spin columns [128]. Many other products are now available which range 
from albumin-only depletion to 20 protein depletion columns [129]. Immunodepletion 
based approaches are, however, very expensive and time consuming for high-throughput 
analysis. The cost per 100 µL sample can range from $5 to over $250, whilst preparation 
times can range from approximately 30 minutes to several hours per sample [129]. In 
addition, many highly abundant proteins, including albumin, act as carriers for low 
molecular weight proteins and peptides. Depletion under native conditions may therefore 
also remove analytes of interest.  
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Conversely, immunoaffinity techniques can be used to very effectively enrich peptides of 
interest leading to high analyte sensitivity. Antibodies can be conjugated to magnetic beads 
to retain the peptide of interest during an approximate 1 hour incubation, after which they 
can be separated from the remainder of matrix and the analyte eluted [130]. However, this 
relies on the availability of appropriate antibodies, and adds cost, time and expense to the 
extraction procedure. Therefore, immunoaffinity techniques were not utilised in this 
project.  
1.6.2 Protein Precipitation 
The structural stability of proteins in solution is limited, due to the small free energy 
difference between the folded and denatured states. This results from similar entropic and 
enthalpic contributions to the folding process. The total entropy of the protein and 
associated water shell decrease with folding, whereas the enthalpy becomes more negative 
largely due to hydrogen bond formation [131]. Therefore, anything that disrupts the protein 
itself, or the hydration layer, which stabilises the protein in solution due to the interaction 
with exterior hydrophilic residues whilst keeping hydrophobic regions within the protein 
interior, can lead to denaturation. For example, altering pH can change the number of 
ionised groups, and therefore, the strength of interaction with the hydration layer, leading 
to denaturation [132]. The addition of chaotropes (e.g. ethanol, propanol, guanidinium 
chloride, urea) can induce disorder in the hydration layer weakening its effect, also leading 
to denaturation [131]. Denaturation can be followed by association reactions forming a 
pellet. Such “protein precipitation” reactions can be used analytically to remove high 
abundance proteins and peptides from the sample. The challenge for peptide bioanalysis is 
to retain the peptide of interest, whilst reducing the background of structurally similar 
endogenous proteins and peptides.  
The effectiveness of organic solvents at disrupting the hydration layer, and depleting 
proteins and peptides, depends on their nature and the ratio at which they are added to 
plasma (Table 1.2) [133].  
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Table 1.2 Plasma protein precipitation efficiency of organic solvents.  
Increasing the organic solvent:plasma ratio from 0.5:1 to 1:1 dramatically improves protein 
precipitation efficiency, further increases result in smaller improvements. Efficiency also depends 
on the nature of the organic solvent. 
 % Protein precipitation efficiency  
Organic Solvent 
(Ratio of solvent to plasma)  
0.5:1 1:1 1.5:1 2:1 2.5:1 3:1 4:1 
ACN 3.6  88.7 91.6 92.1 93.2 93.5 94.9 
EtOH 0.1 78.2 87.2 88.1 89.8 91.8 92.0 
MeOH 13.4 63.8 88.2 89.7 90.0 91.1 91.5 
% Protein precipitation efficiency= ([total plasma protein−protein remaining in supernatant]/total 
plasma protein)×100.  
Reproduced selected data from reference [133], with permission. 
The ratio also affects the masses of proteins and peptides remaining in the supernatant. 
Whilst similar numbers of low molecular weight peptides (800-1499 Da) were retained in 
the supernatant following plasma precipitations at 2:1 and 10:1 ACN:plasma ratios, 
significantly fewer higher mass peptides were detected using the higher ratio, with no 
peptides detected above 2000 Da [134]. Although even at the lower ratio, fewer peptides 
were detected in the 1500 Da region than with other extraction techniques (e.g. SPE) 
[134]. Aside from its use as a precipitation technique the addition of an organic solvent to 
plasma samples can also disrupt binding of proteins/peptides of interest to larger proteins 
improving recovery regardless of extraction technique [135]. 
In 2008 it was demonstrated that pre-dilution of serum before the addition of ACN could 
also enrich low molecular weight peptides and proteins, whilst depleting those of high 
molecular weight, which are often the most abundant proteins [136]. The approach used  
20 µL serum diluted with 40 µL water, before the addition of 90 µL ACN, i.e. 
volumetrically equivalent to adding 70% ACN (aq) in 6.5:1 solvent:serum ratio. The 
depletion significantly reduced the concentration of the large and abundant protein albumin 
(66.5 kDa) 1000-fold, and overall 99.6% of proteins were depleted. Large numbers of 
relatively small proteins remained in the supernatant, particularly apolipoproteins, which 
are of a hydrophobic nature, but also other types such as IGF-1 (7.6 kDa). Later work 
demonstrated similar results using plasma with a pre-diluted precipitation solvent (75% 
ACN (aq)), rather than a pre-diluted matrix, at a 6.5:1 solvent:plasma ratio [137]. 
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Compared to many other extraction techniques, protein precipitation is simple, quick, 
cheap and amendable to high throughput extractions due to compatibility with 96 well 
plates and associated automation technologies. It was, therefore, investigated as part of this 
thesis, including the optimisation of the nature, composition, and solvent:plasma ratio 
(Section 2.3.1.2.1 and Section 4.3.1.1). Conditions were optimised to maximise recovery 
of the peptides of interest, whilst reducing matrix interferences and suppression, and 
ensuring robustness. 
1.6.3  Solid Phase Extraction  
Solid phase extraction consists of an adsorbent solid material packed into a cartridge. The 
sample (usually diluted) is loaded into the top of the cartridge, and as it flows through 
solutes either adsorb to the solid material, or remains dissolved. The adsorption is 
dependent on the physicochemical properties of the solute, and that of the loading solvent 
and SPE adsorbent. The loading solvent and solid phase material are analogous to the 
mobile phase and stationary phases in UHPLC. The adsorbent solid material, loading 
solvents, and subsequent wash solvents can be optimised for increased retention of the 
analyte of interest and/or selective retention. Similarly the elution solvent can be optimised 
for high recovery and/or selective elution of the analyte.  
There is no general consensus as to the group that first performed a SPE, or produced an 
SPE cartridge [138]. Attribution is further complicated due to the term SPE becoming 
adopted only several years after the products became available [138]. Although it is 
commonly agreed that a patent in 1980 by McDonald et al [139] provided the basis for the 
first commercially successful product [138].  
These initial SPE products consisted of silica particles as the solid phase [140]. Polymer 
based sorbents were later developed, including hypercrosslinked polymers incorporating 
polar moieties, which result in higher specific surface areas and improved absorption of 
polar compounds [141]. Such a phase is used in Waters Oasis Hydrophilic-Lipophilic 
Balance (HLB) SPE products, specifically a macroporous copolymer of the lipophilic 
divinylbenzene and the hydrophilic N-vinylpyrrolidone [140]. Additional functionality can 
be added enabling adsorption of charged (or chargeable) analytes via ion exchange 
mechanisms (Figure 1.18). 
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Figure 1.18 Waters non-ion exchange (HLB) retentive SPE phase and four phases with 
additional ion exchange functionality. 
MCX- Mixed-mode strong cation exchange, MAX- Mixed-mode strong anion exchange. 
MCX- Mixed -mode weak cation exchange, WAX- Mixed-mode weak anion exchange.  
 
Analytes are retained using lipophillic or hydrophilic interactions using the HLB-only SPE phase. 
Following washing, analytes can be eluted using organic solvents at a neutral pH. 
 
MCX phases are effectively permanently negatively charged. They are suitable for weak base 
analytes that obtain a positive charge at low pH, adsorbing onto the phase via ionic attraction. 
Following washing, the pH is raised neutralising and eluting the analyte. Conversely MAX phases 
are effectively permanently positively charged. These are suitable for weak acid analytes that 
obtain a negative charge when pH is raised, and are eluted by lowering the pH. 
 
WCX or WAX phases are suitable for strong base or strong acid analytes that have permanent 
positive or negative charges respectively. Instead of manipulating the charge of the analyte, that of 
the phase is manipulated. This allows the adsorption (high/low pH for WCX/WAX) and elution 
(low/high pH for WCX/WAX) of the analyte.  
 
Figure reproduced from reference [140]. 
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SPE approaches can show superior peptide recovery compared to protein precipitation 
approaches, both in terms of the total number of peptides extracted and the diversity of 
mass range [134]. This is because the average peptide will contain many hydrophobic 
amino acids, which will strongly adsorb to hydrophobic phases, as well as polar amino 
acids that increase adsorption to phases also containing a polar moiety, such as HLB. 
Whilst high recovery of the peptide of interest is desirable, for targeted bioanalytical 
methods high recovery of other peptides is not. Phases with weak cation exchange or 
strong anion exchange functionality are recommended by some manufacturers for more 
selective extractions in terms of high recovery and low matrix effects [142]. Although one 
study demonstrated LC column fouling following the injection of strong anion exchange 
extracts originating from a relatively small amount (100 µL) of plasma [86], so it is 
prudent to screen a variety of phases.  
Peptides usually have multiple chargeable functional groups and are, therefore, present in 
zwitterionic forms, making their retentive properties hard to predict. As a consequence 
method development is often more empirical than that with simple small molecules, where 
acid dissociation constants (pKa) of a limited number of chargeable groups can be readily 
used to inform the choice of solvent pH. However, the peptide’s isoelectric point, at which 
pH it has not net charge, can be used as a guide to select initial conditions for development. 
Alternative SPE phases amenable to peptide bioanalysis include those with size exclusion 
functionality. For example, the particles in Bond Elut Plexa SPE plates have a non-
retentive surface, with a hydrophobic core of limited pore size that is designed to minimise 
protein and lipid adsorption. Comparison of such size exclusion hydrophobic (SEH) SPE 
with a diluted protein precipitation based approach (75% ACN (aq)) demonstrated that the 
SPE was less efficient at removing large proteins, however, it demonstrated similar, or 
superior, enrichment for many smaller proteins [137]. The SPE loading conditions (acid, 
neutral, basic) were found to dramatically alter the enrichment of particular proteins. There 
was no correlation between a protein’s isoelectric point and optimal preloading conditions, 
which may be related to the role of loading conditions in primarily disrupting binding to 
larger proteins. 
The SPE phases described above were investigated as part of this project for the specific 
extraction of peptides of interest, in terms of high recovery and low matrix effect  
(Section 2.3.1.2.2). SPE is amenable to high throughput analysis as it is available in  
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96-well plate formats, and although more costly (approx. £200/SPE plate) than protein 
precipitation it is still significantly cheaper than immunoenrichment approaches. 
1.6.4 2D Extractions  
Whilst the techniques above have been described separately, several protocols use more 
than one technique to enhance analyte enrichment. Combining extraction techniques can 
also lead to the detection of peptides that are not observed in each method individually as 
demonstrated when ACN (2:1) protein precipitation was performed before HLB SPE 
[134]. This may be due to the removal of species that would otherwise compete for the 
adsorption on the SPE phase, changes in conformation following the addition of the 
precipitation solvent affecting SPE binding, and/or the removal of matrix suppressants. 
Aside from combining extraction techniques off-line, a trapping column can be introduced 
into the LC system to clean up extracts prior to analysis with the analytical column. For 
example, a C8 trapping column was used to avoid fouling of the C18 analytical column 
caused by direct injection of MAX SPE extracts [86]. However, this requires a more 
complicated LC setup, and may increase run times, therefore off-line 2D extractions are 
preferable and were investigated as part of this project. 
1.6.5 Non-Specific Binding 
Non-specific binding (NSB) of peptides to laboratory materials (e.g tubes, 
extraction/collection plates, columns, and injection valves) can occur affecting analyte 
signal and/or quantitation. NSB occurs in the absence of other species in the matrix that 
preferentially adsorb to binding sites, and, therefore, most commonly occurs when peptides 
are present in pure solvent or in extracts following relatively specific (“clean”) extractions. 
The prevalence of hydrophobic amino acids in many peptides leads to the strong 
adsorption to plastics, in an analogous fashion to the strong absorption to hydrophobic SPE 
phases. Similarly, the presence of polar and ionisable groups enables strong adsorption to 
glass via interaction with silanol groups. 
The extent of NSB varies considerably between different peptides and containers, as 
demonstrated in one study investigating six different tubes for a variety of peptides [143]. 
Here it was noted that ghrelin solutions gave minimal recovery (20%) in glass and 
maximum recovery (90%) in plastic containers, whereas the trend was reversed for GLP-1 
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(40% vs 4%). The type of plastic can also have a large effect, as demonstrated by insulin 
where recovery from polypropylene and polyallomer containers were 11% and 68% 
respectively. Attempts to correlate preferred binding to plastic or glass to peptide 
hydrophobicity, size, net charge, or regional charge distribution were not fruitful, and, 
therefore, NSB needs to be investigated experimentally. 
NSB is most significant at low concentrations, as a larger proportion of the total peptide 
amount will be adsorbed before binding site saturation. Although one study [144] noted 
peptide NSB to plastic in a mixture containing 46 synthetic peptides up to 1 mg/mL. The 
study investigated a chaotropic agent to attempt to disrupt binding, and an amino acid 
mixture, a peptide mixture and a protein solution to attempt to saturate binding sites. Only 
the latter two strategies were effective at reducing NSB. However, the peptide mixture 
caused ion suppression during LC-MS/MS, and hence the protein solution (0.1% bovine 
serum albumin (BSA)) was considered optimal. The addition of BSA is commonly used 
strategy to minimise NSB [78][143][144], and was among those investigated in this project 
(Section 2.3.2). 
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1.7 QUANTITATION STRATEGIES 
1.7.1 Absolute Quantitation  
LC-MS/MS response is not inherently quantitative, as response depends on analyte 
ionizability, and for tandem MS the fragmentation of compounds. Therefore, to provide 
analyte concentrations (i.e absolute quantitation), comparisons to standards of known 
concentrations are required. 
SIL internal standards (IS) may be used as standards for absolute quantitation. These 
incorporate alternative isotopes to those primarily abundant in the analyte (e.g. deuterium 
rather than hydrogen or 
13
C rather than 
12
C), which leads to a m/z shift which distinguishes 
it from the analyte upon analysis. Aside from the m/z shift the SIL IS behaves almost 
identically to the analyte in extraction and subsequent LC-MS/MS. However due to the m/z 
difference co-eluting interferences can affect the IS differently to the analyte, and up to 20 
fold differences to the expected response have been observed [145]. This may be solved by 
altering MS resolution or selecting alternative transitions.  
To enable absolute quantitation, SIL IS can be directly spiked into samples at a known 
concentration, and the observed response ratio of SIL to unlabelled peptide used to 
determine analyte concentration [146]. However, such single point calibration is dependent 
on the linear extrapolation of peptide response, although the need to extrapolate can be 
reduced if levels of internal standard are closely matched to expected analyte levels [146]. 
Alternatively, multipoint external calibration lines can be constructed using unlabelled 
peptides. To improve robustness IS can be added to all samples to correct for inter-sample 
extraction and ionisation variability. In such cases analyte/internal standard ratios are used 
to construct calibration curves, and for analyte interpolation [147]. Ideally SIL IS should 
be used, however if these are not available, acceptable performance may be achieved using 
other structurally similar compounds (analogues) to the analyte. The use of external 
calibration lines with (ideally SIL) internal standards offers the most robust and reliable 
quantitation and was, therefore, used in this project. 
The FDA Bioanalytical Method Validation guidelines [148], describe the limit of detection 
(LOD) as the lowest concentration of analyte that can be reliably distinguished from 
background noise. Whereas the lower limit of quantification (LLOQ) is described as the 
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lowest concentration of analyte that can be quantitatively determined with suitable 
precision and accuracy. Due to the quantitative nature of the methodologies developed in 
this project, the LLOQ, rather than the LOD, was characterised in Chapter 2 and Chapter 4. 
Suitable acceptance criteria for precision and accuracy at the LLOQ was based on 
recommendations in the latest FDA [1] and EMA [2] bioanalytical validation guidelines, as 
described further in these chapters. 
1.7.2 Endogenous Quantitation  
Endogenous compounds present additional experimental challenges as an authentic 
analyte-free matrix cannot be obtained to construct calibration standards. Either a standard 
addition, surrogate analyte, or a surrogate matrix approach must therefore be used 
[149][150]. 
In the standard addition approach, analyte is spiked into the matrix containing the 
endogenous compounds to create a calibration line, which is extrapolated to measure 
concentrations below the matrix’s endogenous value. However, the USA FDA Guidance 
for Bioanalytical Method Validation [148] actively discourages the extrapolation of 
calibration curves beyond their range.  
 
The surrogate analyte based approach uses an analogue of the analyte, which may be a 
heavy labelled version, in place of the analyte itself in calibration samples. As this will 
have a SRM transition unique from the authentic analyte, these can be prepared in 
authentic biological matrix [149]. However, as this approach requires the relationship 
between the authentic and surrogate analyte to be thoroughly investigated, this approach is 
not commonly used, and is not considered in the FDA [148] or EMA bioanalytical 
guidelines [151]. 
 
Alternatively, the surrogate matrix approach may be used for endogenous quantitation. 
Here calibration lines are constructed by spiking analyte into a surrogate matrix. QCs can 
be prepared in actual sample matrix, and the accuracy calculated to demonstrate the 
absence of a matrix effect. Surrogate matrices may be the authentic matrix stripped of 
analyte (e.g. by charcoal [150] or immuno-afffinity methods [2]) or an alternative matrix 
(e.g. protein buffers, dialysed serum [2]). Although not ideal, the EMA Guideline on 
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bioanalytical method validation [151] concedes that such an approach may be necessary 
for endogenous analyte quantitation, and this was the approach adopted for this project. 
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1.8 PEPTIDE MODIFICATIONS AND DEGRADATION  
1.8.1 Post-translational Modifications 
As described in Section 1.1.2, many proteins (and resulting peptides) experience PTMs, 
from the translated form. Over 200 different PTMs have been reported [152], and greater 
than 5% of the human genome encodes enzymes that form such modifications, including 
hundreds of protein kinases and opposing phosphatases, ubiquitinyl ligases, 
acetyltransferases and deacetylases, methyl transferases and glycosyl transferases [153]. 
Due to PTMs each protein species generates in the order of 8-10 modified forms [18]. 
PTMs result in mass variations, and can therefore by readily distinguished by mass 
spectrometry [18][154], except in rare cases where they are isobaric with respect to the 
resolution of the mass spectrometer. This is in contrast to immunoassay based approaches, 
where antibodies specific to each modification are required, which may not be available 
[154]. Otherwise all modifications which do not affect the immunoassay epitope, will be 
detected. 
Table 1.3 Examples of post translational modifications and corresponding average mass 
variations. 
Selection of data reproduced from reference [79], with permission. 
Post-translational Modification Mass Difference (Da) 
Methylation 14.03 
Propylation 42.08 
Sulfation 80.06 
Phosphorylation 79.98 
Glycosylations by: 
Deoxyhexoses 
Hexoses 
Pentoses 
 
146.14 
162.14 
132.12 
Reduction of a disulfide bridge 2.02 
Carbamidomethylation 57.03 
Carboxymethylation 58.04 
Acetylation 42.04 
Palmitoylation 238.41 
Deamidation of Asn or Gln 0.98 
Hydroxylation 16.00 
Methionine oxidation 16.00 
Deamination of Gln to pyroglutamic acid -17.03 
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Whether it is desirable to detect just one PTM of a species, a subset, or all PTMs, will 
depend on the application, and needs to be considered during experimental design. 
Selection may, for example, depend on which forms show biological activity for the 
system of interest. Similar modifications can occur in vitro, as a result of sample handling 
(e.g. oxidation), or due to the action of endogenous enzymes in samples. These can be 
minimised by appropriate sample stabilisation. Examples of some of the most frequent 
modifications and their corresponding mass variations are shown in Table 1.3. 
Chapter 3 describes plasma protease-derived metabolites formed under typical laboratory 
sample handling conditions. 
1.8.2 Protein and Peptide Degradation  
Proteins and peptides may be degraded by the action of protease (also peptidase or 
proteinase) enzymes, which often hydrolyse peptide bonds via attack from a specific 
nucleophilic amino acid from the enzyme. The amino acid involved gives rise to one 
system of classifying such enzymes. For example, the digestive enzyme tryspsin is 
classified as a serine protease. Degradation can lead to the formation of “peptide ladders” 
as a result of sequential proteolytic cleavage at the N or C terminal ends [155]. 
Proteases cleave at specific residues, for example trypsin cleaves exclusively at the 
carboxyl side of lysine or arginine (except when there is an adjacent proline) [156]. As 
these residues are present in many proteins and peptides, trypsin is regarded as a 
promiscuous protease. This is exploited for LC-MS/MS protein analysis, as trypsin can be 
added to protein samples to digest them to (tryptic) peptides. These may be more amenable 
for analysis, for example by mass spectrometers of limited m/z range. Other proteases are 
capable of significantly greater specificity, for example a protease from the tobacco etch 
virus cleaves at a seven amino acid motif, although there is some flexibility of the amino 
acids at some positions within this sequence [157]. Other proteases cleave at terminal 
positions of peptides, for example dipeptidyl-peptidase IV (DPP IV) removes the N-
terminal dipeptide where proline or alanine is in the second position [158]. 
Ex vivo protease activity can affect protein or peptide levels in plasma or serum samples 
[159], and sample stabilisation approaches may need to be considered for the analyte(s) of 
interest. Serum has particularly high enzyme activity due to the large number of enzymes 
which are formed by the onset of the clotting cascade. The activity of certain proteases can 
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be reduced by the selection of particular anticoagulants, addition of protease inhibitors, or 
by generating platelet depleted plasma [160]. Reducing sample handling and storage 
temperatures and times, and minimising freeze-thaw cycles can also improve analyte 
stability [160]. The stability of the analyte was considered during the development of the 
methods described in this project. 
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1.9  GLUCAGON AND GLP-1 
The peptide hormones glucagon and glucagon-like peptide-1 (GLP-1) were chosen as 
model peptides for this project. Both peptides help to regulate blood glucose levels, and are 
consequently of interest as biomarkers, as well as in development of therapeutics for 
diseases such as diabetes. Quantitative immunoassays, traditionally used for PD or PK 
characterisation, often perform particularly poorly for these peptides. Therefore, the 
development of LC-MS/MS based approaches could help circumvent these problems. 
There are, however, several analytical challenges associated with their quantitation, which 
makes them particularly well suited for this research, and will be introduced in Sections 
1.9.6 and 1.9.7. 
1.9.1 Glucose Utilisation by the Body  
To appreciate the biochemical importance of glucagon and GLP-1, the use of glucose 
within the body and the importance of its regulation are introduced below. 
1.9.1.1 Glucose as a Fuel 
Glucose is an important fuel in the body. It is the sole fuel used by the brain, except during 
prolonged starvation during which ketone bodies are utilised, and is the only fuel of red 
blood cells. Although in the resting state fatty acids are the main fuel for muscles, glucose 
is used for bursts of activity, with fatty acids and ketone bodies additionally utilised during 
periods of prolonged activity. [161] 
The release of energy from glucose begins with glycolysis, which occurs in the cytosol. 
Glucose entering a cell is rapidly phosphorylated to glucose-6-phosphate. From the 
breakdown of one molecule of glucose-6-phosphate, two molecules of pyruvate and two 
molecules of the universal energy carrier adenosine triphosphate (ATP) are produced. 
Under aerobic conditions pyruvate undergoes oxidative decarboxylation and acetylates 
coenzyme A (CoA) to form acetyl CoA, which enters the citric acid cycle, alongside acetyl 
CoA derived from other fuel molecules (e.g. amino acids, fats and carbohydrates). The 
citric acid cycle, which occurs inside the mitochondria, releases high energy electrons from 
acetyl CoA, reducing the oxidised forms of three molecules of nicotinamide adenine 
dinucleotide (NAD+) and one molecule of flavin adenine dinucleotide (FAD) to their 
reduced forms (NADH and FADH2 respectively). These then enter the oxidiative 
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phosphorylation pathway, alongside these molecules produced elsewhere during glycolysis 
and fatty acid oxidation. Here, they are re-oxidised, and the subsequent flow of electrons 
through a series of membrane proteins (known as the electron transport chain) to O2 leads 
to the generation of ATP from adenosine diphosphate (ADP) and inorganic phosphate. 
Oxidative phosphorylation is key for releasing energy from fuels; it releases 26 out of the 
30 molecules of ATP generated when glucose is completely oxidised to CO2 and H2O. 
[161] 
1.9.1.2 Glucose Storage and Anabolism  
Under conditions of high ATP, where glucose is not immediately required as a fuel, it can 
be stored as glycogen by some tissues, such as the muscles (which stores 75% of the 
body’s glycogen) and liver. It can then be converted back to glucose-6-phosphate and enter 
glycolysis when ATP is required. [161] 
Precursors for biosynthesis can also be generated from glucose. For example, acetyl CoA 
from glycolysis can be used as a precursor for fatty acids, cholesterol, or ketone bodies. 
Alternatively, glucose-6-phosphate can enter the pentose phosphate pathway forming 
nicotinamide adenine dinucleotide phosphate (NADPH) needed for the reductive 
biosynthesis of fatty acids, cholesterol, neurotransmitters and nucleotides. [161] 
1.9.1.3 Glucose Homeostasis 
Blood glucose levels must be maintained at a stable concentration (known as glucose 
homeostasis). Blood glucose must be sufficiently high, so that the brain (which cannot 
store glucose as glycogen) and muscle can extract sufficient glucose to meet their 
metabolic requirements.  
In contrast, excess glucose should be removed from the blood, both for storage as glycogen 
and for biosynthesis (Section 1.9.1.2). High blood glucose levels are also associated with 
numerous symptoms, which occur in untreated diabetics. Early symptoms include, thirst, 
headaches, trouble concentrating, blurred vision, frequent urination, fatigue, and weight 
loss. Chronically high glucose levels may lead to skin infections, slow-healing cuts and 
sores, nerve damage, stomach and intestinal problems, and damage to eyes, blood vessels 
or kidneys. [162] 
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1.9.1.4 The Central Role of the Liver in Glucose Homeostasis  
When blood glucose levels are low, glucose can be formed by breakdown of liver glycogen 
(glycogenolysis). Although the muscles contain about ¾ of the bodies store of glycogen, 
they cannot release glucose into the blood for use by other organs as they lack the glucose-
6-phosphatase possessed by the liver needed to convert glucose-6-phosphate to glucose. 
The ability of the liver to export glucose is key for the maintenance blood glucose levels. 
[161] 
Glucose can also be formed in the liver via gluconeogenesis. This uses lactate and alanine 
from muscle, glycerol from adipose tissue, and glucogenic amino acids from the diet to 
synthesise glucose. The use of lactate and alaline from the muscles also removes part of the 
metabolic burden from the muscles of converting these anaerobic respiration products 
produced during vigorous exercise back to pyruvate; this interchange between the muscle 
and liver is known as the Cori Cycle. A small amount of gluconeogenesis also occurs in 
the kidney (although this is increased during starvation), and very little occurs in the brain 
or muscle. [161] 
When blood glucose levels are high, the liver replenishes its glycogen stores and then uses 
glucose to generate precursors for biosynthesis (Section 1.9.1.2). 
1.9.2 Role of Glucagon and GLP-1 in Maintaining Glucose Homeostasis 
Glucagon and GLP-1 help to regulate glucose homeostasis. Glucagon is released from 
pancreatic α cells as blood glucose levels fall (e.g. several hours after a meal) and directly 
affects glucose homeostasis. Glucagon stimulates gluconeogenesis and glycogenolysis, 
whilst inhibiting glycogen synthesis and glycolysis. In place of glycolysis, glucagon 
promotes fatty acid β-oxidation and ketogenesis as alternative energy pathways. Fatty acid 
β-oxidation occurs in most of the cells of the body, although not the brain due to the 
inability of fatty acids to cross the blood-brain barrier. Ketogenesis primarily occurs in the 
liver. Glucagon also reduces fatty acid synthesis in the liver and adipose tissue. [161] 
Insulin, a counter regulatory hormone to glucagon released from pancreatic β-cells, 
accelerates glucose uptake and glycogen synthesis by the liver and muscles. It also 
accelerates glycolysis and fatty acid synthesis in the liver, whilst suppressing 
gluconeogenesis. Furthermore it promotes glucose uptake into the adipose tissue, forming 
triacylglycerols, and stimulates protein synthesis building up muscle protein. [161] 
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GLP-1, which is released from intestinal L cells in response to eating, indirectly affects 
glucose homeostasis. It enhances the pancreatic β-cells insulin-releasing response to high 
blood sugar levels (e.g. shortly after meal), as well as improving β-cell survival, further 
increasing insulin release.[8][163]  
GLP-1 also inhibits gastric emptying, inhibits glucagon secretion, and suppresses appetite 
[8][163][164]. Such hormones that stimulate a decrease in blood sugar levels are known as 
incretins and also include GIP [16]. 
As a consequence of their biochemical roles, both glucagon and GLP-1 are of interest as 
biomarkers. For example, glucagon can be used as a biomarker for diabetes [8] and 
neuroendocrine tumours [5], whereas GLP-1 can be used to indicate for satiation [165]. In 
addition they are both therapeutic targets are detailed in Section 1.9.4. 
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1.9.3 Glucagon and GLP-1 Biosynthesis and Receptor Action 
Glucagon and GLP-1 are both peptide hormones encoded by the preproglucagon (GCG) 
gene. Following cleavage of the preproglucagon gene product to proglucagon these 
peptides are released via tissue-specific post-translational processing in the pancreas and 
gut/brain respectively (Figure 1.19) [8]. The amino acid sequences of proglucagon and its 
major processing products are shown in Figure 1.20. 
 
 
Figure 1.19 Preproglucagon cleavage to form proglucagon, and its processing products in 
the pancreas and gut/brain. 
Preproglucagon is cleaved to form proglucagon. Various peptides products, including glucagon, are 
then released in the pancreas, whereas other peptide products, including GLP-1, are released in the 
gut/brain. 
 
Figure reproduced from reference [8], with permission. 
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Gut/ 
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 GLP-2 
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69 
70- 
71 
72-
77 
78-107 108-125 126- 158 159-
160 
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KR 
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KR 
NR 
NN 
IA 
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EF 
ER 
HAEGTFTSDV 
SSYLEGQAAKE 
FIAWLVKGR 
GRRDFPE 
EVAIVEEL 
GRR 
HADGSFSDEM 
NTILDNLAARD 
FINWLIQTKITD 
RK 
Pancreas  Glucagon 
(3480.6 Da) 
  Major pro-glucagon fragment 
(9151.6 Da) 
 
 
Figure 1.20 Amino acid sequence of proglucagon and its major processing products in the 
pancreas and gut/brain.  
Peptide sequences from [166] Theoretical average mass values calculated from peptide sequences 
using [167]. 
 
All known actions of glucagon are a result of binding to the glucagon receptor at the target 
tissues. This activates a G-protein leading to the generation of cyclic adenosine 
monophosphate (cAMP) promoting the activities of protein kinase A (PKA), activating 
other downstream mediators [8][168]. GLP-1 similarly acts at GLP-1 receptors, but the 
cAMP generated also activates exchange protein directly activated by cAMP 2 (EPAC2) 
[8][16]. 
1.9.4 Glucagon and GLP-1 Based Therapeutics 
There is increasing focus on the development of therapeutics for metabolic disorders, as 
the prevalence of these increases. In 2013, nearly 1/3 of peptides in phase I trials were 
focused on metabolic disorders, compared to just 11% and 8% at phase II and phase III 
respectively [41]. 
The vast majority of therapeutics for metabolic disorders (85%) are either mono or dual 
agonists of the GLP-1 receptor. For example, RO6811135 (Hoffmann-La Roche), 
developed to treat diabetes, is an agonist for GLP-1 and GIP receptors. Whereas ZP2929 
(Boehringer Ingelheim/Zealand Pharmaceuticals), developed for the treatment of diabetes 
and obesity, is a dual agonist for the GLP-1 and glucagon receptors [41]. Despite 
glucagon’s hyperglycaemic action, relative potencies can be tuned to ensure the 
hypoglycaemic action of GLP-1 dominates, whilst maintaining increased energy 
expenditure associated with glucagon antagonism [8][169]. Glucagon antagonism also 
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suppresses appetite [8][168][169][170], complementing the effect from GLP-1 
[8][163][164].  
GLP-1 receptor agonists also have application in cardiovascular diseases and 
neurodegenerative disorders [41]. Native GLP-1 is not ideal as a therapeutic due to its very 
short half-life in blood, in the order of minutes, whereas approved GLP-1 agonists 
(including exenatide, liraglutide, and lixisenatide) have half-lives of several hours [41]. 
Glucagon antagonists have been investigated as potential diabetes therapeutics, although 
none have entered clinical trials due to undesirable side effects observed in animal models 
with interrupted glucagon signalling. These include -cell hyperplasia, profound elevation 
of circulating pro-glucagon related peptides, reduced lipid oxidation, and increased 
susceptibility of hepatocytes to toxic injury. [8] 
Native glucagon can be used as part of a rescue kit for the treatment of unconscious 
hypoglycaemic patients. However, administration is cumbersome, as it requires the 
reconstitution and agitation of lyophilized peptide powder prior to injection. Glucagon 
analogues agonists  are being developed with more amenable routes of administration, for 
example, as a stable liquid form injected via a pen [40]. 
Glucagon and GLP-1 receptor agonists are often analogues of the native peptides sharing 
significant homology with them. Therefore, a LC-MS/MS method for the native peptides 
would be a good starting point for the development of a method for such therapeutics. 
Some physiological studies involve infusions of native glucagon and/or GLP-1, for 
example those investigating their potential to increase energy expenditure [169] or 
suppress appetite [170]. A LC-MS/MS method for native peptides would be immediately 
applicable for such studies, in addition to those where they are of interest as biomarkers. 
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1.9.5  Glucagon and GLP-1 Immunoassays  
The precision and accuracy of many glucagon and GLP-1 immunoassays can be poor, as 
can be the correlation between assays [51][66][67][68][69]. Even when the correlation is 
good (R=0.97), absolute concentrations can differ greatly (3 fold) between immunoassays 
[171]. This is often attributed to the potential for antibodies to cross-react with similar 
compounds, including inactive degradation fragments and metabolites. Cross-reaction with 
alternative proglucagon products glicentin and oxyntomodulin has been reported [67]. 
Specificity is particularly challenging for GLP-1 assays due to the large number of 
isoforms present that may cross-react. GLP-1 1-37, 7-37, and 9-37 are produced from 
differential cleavage of the proglucagon precursor [51]. In humans these primarily exist in 
C-terminal amidated isoforms (GLP 1-36NH2, 7-36NH2, and 9-36NH2) [51][163][172]. 
GLP-1 7-36NH2 is the biologically active form and is referred to by the unqualified GLP-1 
nomenclature. Similarly glucagon metabolites [173] may also cross-react with glucagon 
immunoassays. 
These concerns cast doubt on the integrity of some of the data in the literature. Cross-
validations to help assess the performance of different kits and laboratories can be 
impractical, as kits can be expensive, resources may not be available for training, and assay 
specific equipment may be required. For example, only one of seven glucagon 
immunoassays recently evaluated used a standard microplate reader [67]. In addition RIA 
necessitate additional health and safety precautions during set-up and require specialised 
disposal of radioisotopes, and due to isotope degradation the kits have limited life times 
(e.g. 2 months).  
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1.9.6 Glucagon and GLP-1 LC-MS/MS Analysis  
LC-MS/MS based methodologies can help to overcome some of the challenges seen with 
existing immunoassays [174]. Specificity can be improved by monitoring SRM transitions 
that incorporate the full length peptide and a related fragment ion, which will exclude 
many structurally similar compounds, and extraction methodologies and chromatographic 
separations can be tailored to the peptides of interest. Furthermore, qualifier SRM 
transitions can be monitored, provided sufficiently sensitive transitions can be determined, 
to ensure results are consistent with those achieved from the quantitation SRM 
[175][176][177][178]. Inter-lab cross validations are also easier as methods can be 
transferred between LC-MS/MS systems with limited re-optimisation. 
However, the application of LC-MS/MS to glucagon and GLP-1 quantitation has been 
limited, primarily due to sensitivity challenges, even using SRM analysis. Typical human 
plasma glucagon concentrations are in the region of 30 pg/mL, which can increase to  
30-100 pg/mL as a result of hypoglycemia, but decrease to 3-7 pg/mL during 
hyperglycaemia [67]. GLP-1 is typically present at lower plasma concentrations, at approx. 
13 pg/mL for fed and 2 pg/mL for fasted subjects [147]. 
At the start of this research, published LC-MS/MS methods [78][179] were not sensitive 
enough to detect endogenous glucagon levels, with the lowest reported lower limit of 
quantitation (LLOQ) in the peer reviewed literature being 250 pg/mL [179], although 
LLOQs of 100 pg/mL [180] and 10 pg/mL [181] had been reported at some conferences. 
Lee et al. recently described a LC-MS/MS method capable of quantifying endogenous 
GLP-1 to 2.6 pg/mL using 500 µL plasma [147], which was a refinement of their previous 
method using 1000 µL [130]. However, these methods used immunoaffinity enrichment 
with magnetic beads coated with anti-analyte antibodies, adding expense and complexity to 
the method. The methods also had long LC run times (ca. 15 minutes) due to the use of 
microflow LC to obtain the required sensitivity. Methods for GLP-1 quantitation avoiding 
immunochemistry have much higher LLOQs, for example 66 pg/mL in a recent paper 
[182]. Furthermore, as glucagon and GLP-1 are endogenous, this presents additional 
experimental challenges for the development of a endogenous level assays, as an authentic 
analyte free matrix cannot be obtained to construct calibration standards. Either a standard 
addition, surrogate analyte, or a surrogate matrix approach must therefore be used (Section 
1.7.2). 
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1.9.7 Sample Stability  
Both glucagon and GLP-1 are reported to be unstable in plasma, and sample handling 
conditions should be chosen to minimise any degradation.  
Glucagon samples are often handled on ice and/or enzyme inhibitors are added to reduce 
enzymatic degradation, which is commonly attributed to the circulating serine protease 
DPP IV [183][184]. PTMs, such as pyroglutamation, may also be formed following initial 
degradation [173]. However, reports vary as to the extent of glucagon degradation, with 
one investigation describing a half-life of <6 hours at room temperature (RT) [185] in non-
stabilised plasma, whilst another demonstrated stability for up to 72 hours [186]. Similarly 
the reported effectiveness of these measures varies. For example, one study described 65% 
of glucagon remaining in plasma after 17 hours [50] on ice, whilst another demonstrated 
little effect in reducing the temperature, with glucagon degrading to approx. 50% and 60% 
after 24 hr on either ice or at RT [171]. 
Furthermore, the effectiveness of enzyme inhibitors at stabilising glucagon in plasma is 
controversial. For example, whilst the serine protease inhibitor aprotinin is often added, 
several studies have shown that it does not offer any advantage for over non-stabilised 
plasma [186][187]. Other inhibitors used include DPP IV inhibitors [184] or cocktail 
inhibitors (e.g. P800 [147], aprotinin & leupeptin & 4-(2-aminoethyl) benzenesulfonyl 
fluoride [50], DPP IV & neutral endopeptidase (NEP) 24-11 inhibitors [184], or 
unspecified cocktails [184][188][189]). However, the reported effectiveness of these also 
varies between studies. Some investigations demonstrate that P800 cocktail inhibitors 
stabilise samples [185][190], whereas others demonstrate they are ineffective [171]. 
There are several possible reasons for these discrepancies. They may be due to 
inappropriate analysis methods compromising the integrity of the data. The precision and 
accuracy of some glucagon immunoassays is known to be poor, which is often attributed to 
the potential for antibodies to cross react with similar compounds, including metabolites 
(Section 1.9.5). For example, poor specificity likely led to a C-terminal immunoassay 
demonstrating stability for samples incubated for 3 hr at RT, whereas an N-terminal 
immunoassay demonstrated degradation of the same samples [184].  
Unlike glucagon, the instability of GLP-1 in plasma is not widely disputed. GLP-1, is 
known to be rapidly degraded by DPP IV and other enzymes such as NEP-24.11[191]. It 
has a reported half-life of 20 minutes at 37C in plasma [192]. Studies have investigated 
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the use of various inhibitors, including ethylenediaminetetraacetic acid (EDTA), aprotinin, 
NEP-24.11 inhibitor, and/or cocktail inhibitors, to reduce degradation but are consistent in 
finding only DPP IV inhibitors (or cocktails containing them) improve stability [192] 
[184]. Thereby suggesting that in vitro plasma degradation is mainly due to DPP IV, at 
least in the short term. Many protocols therefore use DPP IV inhibitors [51][68], or 
cocktails containing them (e.g. P800, P700) [147] [130], with sample handling performed 
at room temperature [147][51] or on ice [68][130]. Although some studies have shown that 
handling on ice without stabilisers is sufficient [192]. 
As part of this project glucagon and GLP-1 stability was assessed using well characterised 
LC-MS/MS methods so that the results were not influenced by poorly performing 
immunoassays. 
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1.10 PROJECT OVERVIEW 
The aim of this research was to develop mass spectrometry-based methodologies for the 
high throughput quantitation of peptides in biological matrices. Glucagon was initially 
used as a model peptide, before GLP-1 was added as a secondary analyte. 
Chapter 2 describes the development and qualification of the first LC-MS/MS method in 
the peer reviewed literature for the quantitation of endogenous glucagon from human 
plasma. A novel 2D extraction procedure was developed to ensure robustness and 
sensitivity along with a novel surrogate matrix calibration strategy. Clinical samples from a 
physiological study using glucagon infusions were used to cross-validate the method 
against a conventional RIA. 
Instability of glucagon in plasma was noted in Chapter 2 using the well characterised  
LC-MS/MS method, even in the presence of the stabiliser aprotinin. Chapter 3 therefore 
describes the use of high resolution MS to identify plasma protease derived metabolites 
formed under typical laboratory sample handling conditions to help characterise 
degradation. Novel glucagon metabolites were identified, some of which may be of 
biological significance, may result in non-specific immunoassay interferences, and/or 
inform the development of stabilisation strategies. 
Chapter 4 describes a refinement of the method developed in Chapter 2 to improve 
sensitivity, robustness and throughput and to add GLP-1 as a secondary analyte. It also 
describes the novel use of a supercharging mobile phase additive, m-NBA to obtain a 
sensitive qualifier SRM transition to ensure specificity of endogenous glucagon 
quantitation. The method was cross-validated against two established immunoassays for 
each analyte using the same physiological study sample set. 
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2.1 INTRODUCTION 
The physiological role of glucagon was described in Section 1.9.2, and glucagon-based 
therapeutics detailed in Section 1.9.4. Existing immunoassay and LC-MS/MS quantitation 
techniques were described in Section 1.9.5 and Section 1.9.6 respectively. This chapter 
outlines the development, qualification and cross-validation of the first peer-reviewed  
LC-MS/MS method capable of quantifying endogenous levels of glucagon from human 
plasma. This method can help to overcome some of the challenges associated with existing 
immunoassays (Section 1.9.5). 
A calibration range of 25-1000 pg/mL was selected for development to maximise the 
applicability of the method. This range encompasses endogenous glucagon concentrations 
from healthy volunteers, those from diabetic patients, and those from volunteers 
undergoing glucagon infusions as part of physiological investigations. These ranges have 
been reported as 25-80 pg/mL [1], up to 160 pg/mL [1], and up to 906 pg/mL [2] 
respectively. The method reported in this chapter is, therefore, suitable for both biomarker 
(PD) and PK applications. 
The method utilised a novel 2D extraction procedure that is relatively quick, simple, and 
cheap in comparison to many immunochemistry-based approaches [3], and which can 
analyse large numbers of samples (60) within an analytical batch. Along with the use of 
UHPLC to minimise sample run times, this makes the method amenable to high throughput 
analysis. 
High sensitivity was achieved by the use of a sensitive SRM transition, a 2D extraction 
procedure (which reduced matrix suppression, background noise and interferences) and 
UHPLC (to obtain sharp chromatographic peaks). A novel surrogate matrix calibration 
approach was used to account for the endogenous nature of the analyte. The method’s 
performance was evaluated based on experiments described in EMA [4] and FDA [5] 
guidelines, and in accordance to the principles of GCP [6]. 
This chapter also presents the first comparison of glucagon concentrations determined by 
LC-MS/MS and RIA. This used a large number of clinical samples (n=88) derived from 
patients undergoing glucagon infusions as part of physiological investigations. 
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2.2 EXPERIMENTAL 
2.2.1 Chemicals and Materials 
Certified human glucagon (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) was obtained 
from the European Directorate for the Quality of Medicines and HealthCare (EDQM) 
(Strasbourg, France) and the analogue internal standard (IS) (des-thr
7
-glucagon) 
(HSQGTFSDYSKYLDSRRAQDFVQWLMNT) from Bachem (Bubendorf, Switzerland). 
This internal standard has given suitable performance in LC-MS/MS glucagon assays [7] 
[8], and it avoids the expense of synthesising a heavy labelled internal standard.  
Water was purified by a Triple Red water purifier (Long Crendon, U.K.). When required, 
sample extracts were evaporated using a Porvair MiniVap (Norfolk, U.K.) with nitrogen at 
60 litres per minute and 40 C, or by overnight rotary evaporation. A MiVac Quattro 
concentrator operated at 40C and 250 x g, attached to MiVac Duo vacuum pump (10 
mbar) and a SpeedTrap, all from Genevac (Ipswich, U.K.), were used for rotary 
evaporation. 
Glass blood collection tubes (5 mL) containing K3 EDTA anticoagulant and 250 Kallikrein 
Inhibitor Units (KIU) of aprotinin were obtained from Becton Dickinson (BD) (Oxford, 
UK). Following collection, tubes were placed on ice, then centrifuged at 2300 x g for 10 
min to obtain plasma, which was stored at -80 C when not in use.  
All chemicals and solvents were HPLC or analytical reagent grade and purchased from 
commercial vendors. 
2.2.2 Instrumentation: LC-MS/MS 
The LC-MS/MS system consisted of a Waters Acquity UPLC system (Waters Corporation, 
Massachusetts, USA) coupled to an AB SCIEX 5500 QTRAP (Applied Biosystems / MDS 
SCIEX, Ontario, Canada) with an electrospray ion source. Data acquisition and processing 
were performed using Analyst 1.5.2 (Applied Biosystems/ MDS SCIEX). The majority of 
the chromatograms were integrated using fully automated settings. A minority had their 
integration settings (peak selection, peak splitting factor, noise percentage) altered to 
ensure appropriate and consistent integration. No samples were integrated using manual 
integration mode. 
91 
Glucagon was separated on a Waters UPLC BEH C18 1.7 µm (2.1 x 100 mm) column 
maintained at 60 C. The mobile phase consisted of (A) 0.2% FA in ACN and (B) 0.2% 
FA (aq). The gradient for separation was 22–32% A over 2 minutes. The column was then 
washed with 95% A for approximately 1 min then 22% A for approximately 4 min. The 
flow rate was 0.8 mL/min and the total run time 7.1 min. 
The mass spectrometer was operated in positive ion mode with an electrospray voltage of 
5500 V, an entrance potential (EP) of 10 V, and a declustering potential (DP) of 70 V. The 
source temperature was 600 C, the curtain gas 40 psi, and the desolvation gases (GS), 
GS1 and GS2, were set at 60 psi and 40 psi respectively. Quantitation was performed using 
the SRM transitions 697.5 (5+)693.8 (5+) and 677.2 (5+)673.8 (5+) for glucagon and 
the internal standard respectively. The N2 collision gas was set to medium and both 
transitions used collision energies (CE) of 15 V, collision exit cell potentials (CXP) of  
13 V, and dwell times of 100 ms. The Q1 and Q3 quadrupoles were both operated at unit 
resolution. 
2.2.3 Preparation of Stock, Standards and QC MED and HIGH Plasma 
Samples 
Stock solutions (1 mg/mL) of glucagon and glucagon internal standard were prepared in 
borosilicate vials using surrogate matrix [MeOH:H2O:FA:BSA, (20:80:0.1:0.1, v/v/v/w); 
typically 200 mL MeOH, 800 mL H2O, 1 mL FA and 1 g BSA]. Glucagon working 
solutions were prepared by dilution with this solvent to create nine calibration standard 
spiking solutions (125, 225, 375, 500, 1000, 2000, 3000, 4500, 5000 pg/mL), and four 
quality control spiking solutions (125, 250, 10000, 75000 pg/mL). Additional calibration 
standard and QC spiking solutions at 50 and 75 pg/mL were also prepared for the 
assessment of assay performance at the 10 and 15 pg/mL levels respectively. Internal 
standard working solution (ISWS) was similarly prepared at 20 ng/mL. The stock and 
working solutions were prepared to a volume of 10 mL and were stored at -20 C when not 
in use.  
QC MED and QC HIGH plasma samples were prepared by diluting the appropriate spiking 
solution 100-fold with a plasma pool. As no endogenous glucagon was detected in the 
pool, final QC concentrations were 100 and 750 pg/mL respectively. Plasma samples were 
handled on wet ice (ca. 4 C), and either used immediately, or stored at -80 C prior to use.  
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2.2.4 Extraction Optimisation  
2.2.4.1 Protein Precipitation 
Plasma samples were prepared by the ten-fold dilution of a 10 µg/mL surrogate matrix 
glucagon solution with human plasma (K2 EDTA), and were handled on wet ice  
(ca. 4 C). 400 µL samples (n=3 replicates) were transferred to a 2 mL 96-well 
polypropylene plate, precipitated with 1.2 mL of precipitation solvent, vortex mixed, and 
then centrifuged for 10 min at 2300 x g. The supernatant was then transferred to a 1 mL 
96-well LoBind plate from Eppendorf (Stevenage, U.K.), evaporated to dryness at 40 C, 
and then reconstituted in 100 µL 0.2% FA (aq). Extracts were then injected onto the LC-
MS/MS system using a method based on that described in Section 2.2.2. The following 
precipitation solvents were investigated: ACN, ACN:H2O (50:50, v/v), and ACN:H2O 
(75:25, v/v). Each solvent was investigated with and without 0.1% FA. Further 
investigations increased the solvent volume to 2 mL and investigated the effect of adding 
0.1% ammonium hydroxide.  
2.2.4.2 Solid Phase Extraction 
Extraction efficiencies from the MAX, MCX and WCX SPE phases from a 96-well Oasis 
sorbent selection plate (10 mg) (Waters Corporation) were evaluated. Generic SPE 
protocols provided by the manufacturer, as well as conditions recommended for two 
specific applications (extraction of tryptic peptides from herceptin and extraction of Aβ 
peptides) were followed as summarised below. The protocols describe solvents for 
conditioning and equilibrating the SPE plate, loading samples onto the plate, washing the 
plate and eluting the extracts. In each case n=3 replicates from plasma samples (prepared 
as described in Section 2.2.4.1) were extracted. Extracts were eluted into a 1 mL 96-well 
LoBind plate, evaporated to dryness at 40 C, and then reconstituted in 100 µL 0.2% FA 
(aq). Extracts were then analysed by LC-MS/MS based on the method described in Section 
2.2.2. 
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1) WCX & MAX (Generic Protocol 1) - Condition: 1 mL MeOH, Equilibrate: 1 mL 
water, Load: Samples diluted 1:1 with 2% NH4OH (aq), Wash 1: 1 mL 5% NH4OH 
(aq), Wash 2: 20% ACN (aq), Elute: 2 x 400 µL ACN:H2O:FA (75:25:1, v/v/v). 
 
2) WCX & MAX (Generic Protocol 2) - As 1), except plasma diluted 1:1 with 4% 
H3PO4 (aq) instead of 2% NH4OH
 
(aq), during the load step. The protocol explains 
that this may help to disrupt the binding of peptides to plasma proteins. 
 
3) MCX (Application 1  herceptin tryptic digest) - Condition: 1 mL MeOH, 
Equilibrate: 1 mL water, Load: Samples diluted 1:1 with 4% H3PO4 (aq), Wash 1: 1 
mL 2% FA (aq), Wash 2: 1 mL 5% MeOH (aq), Elute: 2 x 400 µL  
ACN:NH4OH:H2O (40:5:55, v/v/v). 
 
4) MCX (Application 2  Aβ peptides) - Condition: 1 mL MeOH, Equilibrate:  
1 mL 4% H3PO4 (aq), Load: Samples diluted 1:1 with 4% H3PO4 (aq), Wash 1: 4% 
H3PO4 (aq), Wash 2: 1 mL 10% ACN (aq), Elute: 2 x 400 µL ACN:NH4OH:H2O 
(75:10:15, v/v/v). 
Similarly, extraction efficiencies from a SEH phase of a Bond Elut Plexa SEH SPE Plate  
(96-round-well, 30 mg) (Agilent technologies, California, USA) were evaluated using an 
in-house generic protocol described below. 
1) SEH (in-house generic protocol): Condition: 1 mL MeOH, Equilibrate: 1 mL water, 
Load: samples diluted 1:1 with 2% NH4OH (aq), Wash: 1 mL 5% MeOH (aq), 
Elute: 2 x 450µL ACN:H2O:FA (75:25:0.1, v/v/v). 
In addition 2% FA (aq) and 50 mM ammonium bicarbonate (AMBIC) (aq) were 
investigated as alternative loading solvents, and 10% ACN (aq), 20% ACN (aq), 10% 
MeOH (aq), and 20% MeOH (aq) were investigated as alternative wash solvents. Finally, 
ACN:H2O:FA (75:25:1, v/v/v) was investigated as an alternative elution solvent. After 
elution extracts were processed as for the other phases above.  
Control samples, extracted using a protein precipitation based approach, were extracted 
alongside the SPE samples for comparison. For these 400 µL plasma samples were 
precipitated in 5 mL polypropylene tubes with 2 mL ACN:H2O (75:25, v/v). Samples were 
vortex mixed, centrifuged for 10 min at 2300 x g and the supernatant transferred to another 
tube of the same type. This was then evaporated to dryness at 40 C, the extracts 
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reconstituted in 100 µL 0.2% FA (aq) and then transferred to a 1 mL 96-well LoBind plate. 
Extracts were then analysed by LC-MS/MS based on the method described in Section 
2.2.2. 
2.2.4.3 2D Extraction (Protein Precipitation then SPE) 
Plasma samples (400 µL) were prepared according to Section 2.2.4.1. They were then 
precipitated using 2 mL ACN:H2O:NH4OH (75:25:0.1, v/v/v), according to the protocol 
described in Section 2.2.4.1, except that after evaporation to dryness the extracts were 
reconstituted in 800 µL SPE loading buffer before being subjected to SEH SPE. A 
selection of the protocols described in Section 2.2.4.2 were evaluated for the SPE 
extraction, with n=3 replicates extracted in each case. 
2.2.4.4 Surrogate Matrix Extraction  
The calibration standard spiking solutions described in Section 2.2.3 were diluted five-fold 
with various potential surrogate matrices. Aliquots (400 µL) were then extracted according 
to the procedure described in Section 2.2.5. The matrices investigated were H2O,  
MeOH: H2O:FA:BSA (20:80:0.1:0.1, v/v/v/w), 6% BSA (aq) and 6% rat plasma (aq). 
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2.2.5 Extraction Method for Validation 
Plasma samples (aprotinin stabilised, K3 EDTA) (400 µL) were placed into 5 mL 
polypropylene tubes handled on wet ice (ca. 4 C) and 20 µL ISWS was added to all 
nonblank samples. The samples were briefly vortex mixed, precipitated using 3.2 mL 
ACN:H2O:NH4OH (72:25:0.1,v/v/v), vortex mixed again, and then centrifuged for 10 min 
at 2300 x g. The supernatant was transferred to a new tube and evaporated to dryness 
overnight under vacuum. Samples were reconstituted in 800 µL 2% NH4OH (aq) and then 
vortex mixed. A Bond Elut Plexa SEH SPE Plate (96-round-well, 30 mg) was conditioned 
using 1 mL MeOH, then equilibrated with 1 mL H2O. The samples were loaded, washed 
with 1 mL 5% MeOH (aq), eluted with 2 x 225 µL ACN:H2O:FA (75:25:0.1, v/v/v) into a 
1 mL 96-well LoBind plate, and then evaporated under nitrogen at 40C, before being 
reconstituted in 200 µL 0.2% FA (aq). 
Calibration standards, QC LLOQs and QC LOWs were then prepared freshly for each 
batch by spiking 80 µL of the appropriate spiking solution into the plate, along with 20 µL 
ISWS and 100 µL surrogate matrix. Taking into account the two-fold concentration 
experienced by plasma samples (400 µL plasma sample is reconstituted into 200 µL 
solvent) this gives final calibration levels of 25, 45, 75, 100, 200, 400, 600, 900, and 1000 
pg/mL, and final QC levels of 25 and 50 pg/mL. The plate was centrifuged for 10 min at 
2300 x g, and 50 µL sample was injected onto the LC-MS/MS system for analysis. 
2.2.6 Validation Experiments 
The validation experiments chosen were based on those described in the latest EMA 
guidance [4]. Calibration standards were analysed in duplicate with each batch. Data was 
imported into Watson LIMS v7.2 (Thermo Fisher Scientific Inc, Massachusetts, USA) and 
linear regression with 1/x
2
 weighting was applied to the peak area ratios-concentration plot 
for the construction of calibration lines. The precision and accuracy of the method was 
determined by analysis of replicate (n=6) QC samples at four different concentrations 
within a batch (intra-batch) and between batches (inter-batch, three batches). The 
concentrations selected at the LLOQ, low, medium (med), and high QC levels were 25, 50, 
100, and 750 pg/mL respectively. The LLOQ QC was at the same concentration as the 
lowest calibration standard, as required [4]. It was decided to limit the low QC 
concentration to 2 x LLOQ (rather than the 3x LLOQ typically used [4]), and to select the 
96 
medium QC concentration lower than the geometric mean of the calibration standards  
(193 pg/mL), so that the QCs better represented endogenous glucagon concentrations. The 
high QC concentration was selected as 75% of the highest calibration standard (the upper 
limit of quantitation, ULOQ), in accordance with guidelines (75% ULOQ [4]). 
Physiological study samples (Section 2.2.8) were anticipated to give concentrations in this 
region. 
The ability to dilute was assessed by diluting an over-range dilution sample (7500 pg/mL) 
ten-fold with blank plasma. Carryover effects were evaluated by injection of blank samples 
immediately after injection of the highest point in the calibration range.  
Selectivity was assessed by qualitatively examining chromatograms from six independent 
control matrix samples for the presence of potentially interfering peaks. It was not feasible 
to monitor multiple charge states or SRM transitions to further ensure selectivity as only 
the selected transition demonstrated sufficient sensitivity at the endogenous concentration. 
The modification of analyte and internal standard responses to the presence of matrix 
(plasma) was also determined in such samples. These were extracted and either their 
endogenous response was determined, or they were post spiked at either the medium or 
high level along with internal standard at the working concentration. The mean response 
from analogously prepared surrogate matrix samples (minimum n=6) was also determined. 
The ratio (Matrix Factor (MF)) of the response from the post-spiked plasma samples 
(corrected for the endogenous contribution) to post-spiked surrogate matrix samples was 
determined at each concentration for the analyte and internal standard. The IS-normalised 
MF (MF Analyte / MF IS) was calculated to determine whether the internal standard 
compensated for analyte modification.  
 
The effect of haemolysed plasma (plasma spiked with 3% whole blood) and 
hyperlipidaemic plasma (~4 mmol/L triglycerides) upon quantitation was investigated by 
preparing QCs in these matrices at the medium and high level (n=6 replicates). Recovery 
of the analyte was evaluated by comparing the analytical results for extracted analyte 
samples at the medium and high level with post spiked (unextracted) analyte samples that 
represent 100% recovery. IS was spiked into extracted and unextracted samples 
immediately prior to LC-MS/MS analysis, to account for variations in instrument response.  
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The stability of glucagon in aprotinin stabilised human plasma was evaluated at the 
medium and high concentrations in replicate (n=6). Stability was assessed after 6 hr 20 min 
on ice (ca. 4 C), after storage for 11 and 75 days at -20 °C, and for 7, 11, 51, and 64 days 
at -80 °C. Similarly stability was assessed after 4 freeze-thaw cycles from -20 C to 4 C 
and also 4 freeze cycles from -80 C to 4 C. Stability was also assessed in whole blood 
following storage on ice for 1 hr. The ability to re-inject sample extracts at medium and 
high concentrations was assessed after storage at 4 °C for 6 days. The stability of the stock 
solution was assessed after storage at -20 C for 66 days and that of LLOQ and ULOQ 
working solutions after 163 days at -20 C. 
 
All results are quoted from batches where the standards and QCs passed the prospectively 
defined acceptance criteria, which were based on the EMA and FDA guidelines. These 
required that at least 75% of standards in each batch had back-calculated accuracy within 
15% (20% at the LLOQ) of the nominal concentration, with standards outside these criteria 
excluded from the regression. QCs in precision and accuracy batches needed to have mean 
intra-batch accuracy within 20% of the nominal concentration, and intra-batch precision 
that did not exceed 20%. In other batches at least 2/3 of the individual QCs had accuracy 
within 20% of the nominal concentration, with at least one QC passing criteria at each 
level. Although the guidelines suggest a 15% criteria (20% at the LLOQ) should be applied 
to QC performance, they state it can be widened prospectively in special cases. It was felt 
justified to raise the QC acceptance criteria to 20% (CV and RE) due to challenges 
associated with the surrogate matrix nature of the assay. The 20% (RE) acceptance criteria 
was also applied to plasma, blood and extract stability experiments, as well as for the effect 
of haemolysed or hyperlipidaemic plasma. For matrix effects in independent control 
matrices, an acceptance criterion of CV20% for the IS-normalised matrix factors across 
the individuals was applied. 
2.2.7 Collection of Samples from Healthy Volunteers 
Plasma was collected from 12 healthy males and 12 healthy females using glass collection 
tubes containing K3 EDTA and aprotinin, as described in Section 2.2.1. Glucagon levels 
were determined using the LC-MS/MS method assessed during the validation. Plasma was 
collected at the start of the working day and volunteers were not asked to change their 
usual eating regime. 
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2.2.8 Collection of Physiological Study Samples 
Physiological study samples were collected by Imperial College London. Blood was 
collected at various time points in 5 mL lithium heparin collection tubes containing 1000 
KIU aprotinin, spun down in a cold centrifuge within 5 to 10 min of collection, and the 
resulting plasma stored at -20 C. 
The samples originated from a dose range finding study in humans, which supported a 
further study investigating the effect of glucagon infusions on energy expenditure, similar 
to that described by Salem et al [9].  
The samples originated from seven different volunteers, who were each infused 
subcutaneously with various combinations of saline solution (for 6 hours on each occasion) 
and glucagon solutions at either 16 or 20 pmol/kg/min (for 12 hours on each occasion). 
The total infusion time for each individual was up to 60 hours. Volunteer 1 and 2 returned 
for a second visit.  
A selection of physiological study samples, taken at various time points throughout the 
infusions, were provided to LGC (n=117). Their collection times and the infusion 
conditions upon their collection are described in Figure 2.12. 
Appropriate institutional review board approval (West London Research Ethics 
Committee: No.11/LO/1782) and informed consent were obtained and the principles 
outlined in the Declaration of Helsinki were followed for this study. 
2.2.9 Analysis of Physiological Study Samples  
A selection of the physiological study samples (n=100) were analysed using the  
LC-MS/MS method assessed during the validation. Additional QCs prepared in aprotinin-
stabilised plasma with lithium heparin anticoagulant were analysed to ensure assay 
performance in the sample matrix. A subset of the study samples (n=38) were analysed 
over the calibration range 25-1000 pg/mL, whilst the remainder were analysed over the 
calibration range 10-1000 pg/mL. For these latter samples additional calibration points and 
QCs were included at the 10 and 15 pg/mL levels to evaluate assay performance. Samples 
(n=105) were also analysed by Imperial College using their established RIA method over 
the calibration range 5-1000 pg/mL, which is directed against the C-terminal region of 
glucagon [10][11]. Samples were analysed upon their first freeze-thaw.  
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2.3 RESULTS AND DISCUSSION 
2.3.1 Method Development 
Analysis of endogenous levels of glucagon by LC-MS/MS poses a significant technical 
challenge. Not only are the low endogenous concentrations difficult to measure, an 
endogenous analyte quantitation strategy must be used, and stability issues must be 
addressed. Extensive assay optimisation was therefore performed to obtain the low 25 
pg/mL LLOQ, as described below. 
2.3.1.1 LC-MS/MS 
A QTRAP mass spectrometer (Section 1.4.2.4) was used in SRM mode (Section 1.4.2.3) to 
maximise sensitivity, and parameters were optimised. UHPLC was chosen for 
chromatographic separation because it results in greater efficiencies [12] and/or shorter 
runtimes [13] than the HPLC commonly used for such separations. The greater efficiency 
can lead to lower matrix effects due to improved separation from matrix suppressants and 
to higher sensitivities due to sharper peak shapes [14]. The advantages of UHPLC were 
discussed in Section 1.5.4 
The [M+5H]
 5+
 ion (m/z 697.5) was found to give the highest intensity during MS method 
development (Figure 2.1a), although other studies have found the [M+4H]
4+
 ion  
(m/z 871.5) to be optimal [15][16]. MS2 experiments showed that the ionic species 
generated by ESI of glucagon were able to absorb substantial collision energy (CE) 
without undergoing major fragmentations (Figure 2.1b), as demonstrated previously [16]. 
As also reported [7][17], an SRM transition corresponding to the loss of ammonia 
([M+5H]
5+
[M+5H-NH3]
5+
) was found to be optimal. Although this is not a particularly 
specific transition, the intensity was significantly greater than other transitions and was 
therefore chosen; selectivity was fully investigated during the validation. Resolution 
settings for Q1 and Q3 were optimal at unit-unit, rather than high-high as reported by 
others [15]. The optimal ion pairs of the transitions were 697.5693.8, which corresponds 
to a 18.5 Da loss. The small difference between the optimal pair, and that previously 
reported (697.6694.2) [7][17] is attributed to the resolution limitations of the mass 
spectrometer used [18], as is the difference between the theoretical mass loss of ammonia 
(17 Da) and that observed (18.5 Da). 
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Figure 2.1 Glucagon full scan and product ion scan spectra. 
a) Glucagon full scan MS spectrum. A mass window of m/z 400-1250 was isolated (m/z 550-1200 
shown).The [M+5H]
5+
 ion (m/z 697.5) was found to give the highest intensity. 
 
b) Glucagon product ion (MS/MS) spectrum. (Parent=697.5, CE=25 V). 
The [M+5H]
5+
 glucagon ion absorbs substantial collision energy without undergoing major 
fragmentation. The most intense peak (m/z 693.8) corresponds to the loss of ammonia, and 
provided the optimal SRM transition ([M+5H]
5+[M+5H-NH3]
5+
). 
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[M+4H]
4+ 
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 3+ 
m/z 1161.8 
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5+ 
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2.3.1.2 Extraction Method Optimisation 
2.3.1.2.1 Protein Precipitation  
A relatively large plasma volume (400 µL) was chosen for extraction to enable 
concentration of extracts to achieve higher sensitivities. The volume does, however, 
compare well to the 2 x 200 µL that is typically required for RIA methods. Initially, 
protein precipitation based extraction techniques were investigated, as they are quick and 
cheap, and are amenable to automation and high throughput analysis. Additionally, pure 
ACN precipitation has been previously selected for glucagon extractions [15][16]. It has 
been shown that diluting ACN with various proportions of water can lead to more specific 
peptide extractions [19], as can the addition of acids or bases due to the differences 
between the isoelectric points (pI) of the proteins or peptides of interest and the 
background proteins [20] (Section 1.6.2). Precipitation solvents containing various 
proportions of acetonitrile, water, and acid were therefore investigated, with ACN:H2O 
(75:25,v/v) initially giving the best response. Further investigations, showed that the 
addition of 0.1% ammonium hydroxide to the ACN:H2O (75:25,v/v) precipitation solvent 
slightly increased response, and therefore this solvent was selected for future work   
(Figure 2.2). However, in all cases background noise and interferences were relatively 
high, as was matrix suppression. It was, therefore, decided to investigate SPE-based 
approaches, as these should lead to cleaner samples with reduced background noise and 
interferences.  
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Figure 2.2 Comparison of the performance of various protein precipitation solvents to 
extract glucagon from human plasma. 
The ACN:H2O (75:25, v/v) solvent gave good performance. This was slightly improved by the 
addition of 0.1% NH4OH, but was significantly reduced by the addition of 0.1% FA. The optimal 
0.1% ammonium hydroxide in ACN:H2O (75:25,v/v) solvent was selected for future work.  
Error bars show one standard deviation from the mean (n=3 replicates). The figure is a combination 
of two experiments. Exp 1) Contained all solvents except 0.1% ammonium hydroxide in ACN:H2O 
(75:25,v/v). Exp 2) Contained 0.1% ammonium hydroxide in ACN:H2O (75:25,v/v) and ACN:H2O 
(75:25,v/v) solvents only. The ACN:H2O (75:25,v/v) response in the two experiments was used to 
appropriately scale the 0.1% ammonium hydroxide in ACN:H2O (75:25,v/v) response. 
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2.3.1.2.2 Solid Phase Extraction  
Three mixed mode SPE phases were investigated using peptide extraction protocols 
suggested by the manufacturer. The ion exchange component of the phases were: MAX, 
MCX and WCX. No peaks were observed following the WCX extraction demonstrating 
inefficient extraction, whilst the MCX phase gave the best response (Figure 2.3). However, 
whilst the chromatograms were cleaner, peak areas were not significantly enhanced 
compared to protein precipitation alone, as would be expected due to the reduced matrix 
effect associated with SPE, therefore suggesting poor recovery.  
 
Figure 2.3 Comparison of ion exchange SPE and protein precipitation extraction 
methodologies to extract glucagon from human plasma. 
The WCX SPE phase gave poor performance using the protocols investigated, with no analyte 
peaks detected. MCX was the best performing phase; however peak areas were not significantly 
enhanced compared to protein precipitation, suggesting poor recovery overcame any reductions in 
matrix suppression. 
 
Error bars show one standard deviation from the mean (n=3 replicates). 
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SEH SPE, was therefore investigated as its dual mode of action, combining size exclusion 
functionality with hydrophobic pores, is reported to lead to a high degree of selectivity for 
peptides, and good recoveries [21]. In contrast to the ion exchange SPE methodologies 
described above, the SEH SPE phase gave significantly better signal than that obtained 
with protein precipitation extractions (Figure 2.4), although it is possible that similar 
performance could be achieved using alternative SPE phases following further 
optimisation. Altering the SEH SPE wash and elution solvents from those in the generic 
method did not lead to significant improvements in signal (Figure 2.4). 
 
Figure 2.4 Comparison of SEH SPE and protein precipitation extraction methodologies 
to extract glucagon from human plasma. 
In contrast to ion exchange SPE (Figure 2.3), SEH SPE extractions significantly enhanced analyte 
peak areas compared to protein precipitation. Altering SEH SPE wash and elution solvent did not 
lead to significant improvements, and therefore the generic conditions were retained for future 
work.  
The SPE methods were based on the in-house generic protocol, with modified wash/elution steps as 
shown. See Section 2.2.4.1-2.2.4.2 for full method details. 
Error bars show one standard deviation from the mean (n=3 replicates). 
 
Unfortunately, SEH SPE led to large on-column matrix effects, such that subsequent 
samples experienced large matrix suppression and the UHPLC pressure increased with 
each injection. Clearly, this extraction method did not provide the required degree of 
robustness. 
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2.3.1.2.3 2D Extraction (Protein Precipitation then SPE) 
2D extractions, combining SPE and protein precipitation, have been shown to improve 
signal to noise [22], through reduced matrix effects, and these were therefore investigated 
to improve the robustness of the extraction. Combining protein precipitation with SEH 
SPE was found to reduce the on-column matrix effects, whilst providing adequate 
recovery, which was significantly greater than that obtained using protein precipitation, 
although less than SPE alone (Figure 2.5). The 2D extraction with the in-house generic 
SEH SPE conditions performed well and was therefore selected for the validation. 
To my knowledge this is the first time protein precipitation has been combined with SEH 
SPE for quantitative peptide analysis, although protein precipitation has been combined 
with other SPE phases for this purpose [23]. Due to the satisfactory performance of this 
extraction methodology, alternatives such as immunoaffinity enrichment were not 
investigated [24]. 
Various UHPLC gradients were investigated to further reduce matrix build-up on the 
column and it was found that an approximately 1 min flush at 95% organic mobile phase, 
followed by a 4 minute flush at the LC starting conditions gave the best performance. This 
gradient, combined with the 2D extraction methodology, significantly increased the 
robustness of the assay. 
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Figure 2.5 Comparison of SEH SPE and protein precipitation extraction methodologies, 
with and without an initial protein precipitation clean-up, to extract glucagon from human 
plasma. 
Combining SPE with protein precipitation (2D extraction, red bars) significantly improved analyte 
peak areas compared to protein precipitation alone (green bar). Although peak areas were not as 
large as for the SPE alone extraction (blue bars), the reduction of on-column matrix effects using 
the 2D approach, significantly improved assay robustness. Altering SEH SPE wash or elution 
solvents did not significantly improve performance compared to the generic method. The generic 
2D method was therefore retained for future work. 
The SPE methods were based on the in-house generic protocol, with modified wash/elution steps as 
shown. See Section 2.2.4.1-2.2.4.3 for full method details. This Figure is as per Figure 2.4, but with 
the addition of the 2D extraction results. 
Error bars show one standard deviation from the mean (n=3 replicates). 
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2.3.1.2.4 Use of Stabilisers 
Glucagon is known to be degraded by enzymes in the blood and consequently sample 
stabilisation is required [25]. The enzyme inhibitor aprotinin was used and samples were 
extracted on ice to reduce degradation. As there have been reports of enzyme inhibitors 
interfering with peptide quantitation [26] assay performance was closely monitored during 
the validation for any such issues. There were no issues observed during the validation 
(Section 2.3.3) that could be attributed to interference from aprotinin. 
2.3.2 Surrogate Matrix Quantitation 
Several mixtures were screened for their suitability as surrogate matrices. A dilute buffer 
matrix (MeOH:H2O:FA:BSA (20:80:0.1:0.1, v/v/v/w)) was evaluated, as such matrices 
have been shown to be suitable for some assays [27][28]. A buffer solution containing a 
relatively high percentage of BSA was also evaluated to minimise any non-specific analyte 
binding that may occur. In addition, a diluted rat plasma matrix was chosen to investigate 
whether biological matrices improved assay performance.  
Water and the dilute buffer matrix resulted in low signals following extraction, which is 
attributed to non-specific binding of glucagon to plastic consumables used during the 
extraction procedure, as has been described previously for glucagon [16] and is generally 
observed for peptides (Section 1.6.5). The 6% BSA (aq) matrix, selected to minimise 
nonspecific binding in solvent, led to a very high background noise, whilst the 6% rat 
plasma (aq) led to poor calibration line accuracy against prepared concentrations. It was 
therefore decided to use the dilute buffer matrix as the surrogate matrix, but not to extract 
samples prepared in this, in order to prevent large losses by nonspecific binding. Whilst 
plasma samples require extraction, their high protein content prevents binding and the use 
of an IS was expected to take into account recovery differences between the surrogate 
matrix calibrants (which will necessarily have recovery of 100% for the analyte and IS) 
and the extracted plasma samples. The IS was also expected to take into account the 
differences in matrix effect between the two matrices, as well as any small losses due to 
non-specific binding that occurred in the injection plate. Whilst the buffer solution selected 
as the surrogate matrix is of quite a different nature to the plasma samples, assays for small 
[27] and large molecules [28] have been successfully validated using such an approach, 
and the validation experiments described later in Section 2.3.3 fully assess the assay’s 
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performance. It was decided to proceed with this approach rather than investigate 
alternative matrices such as charcoal-stripped plasma. 
It has been suggested that when a surrogate matrix approach is used that aliquots of the 
authentic matrix containing the endogenous analyte should be used as QC MED samples 
and QC HIGH samples should be prepared by spiking analyte in addition to this 
endogenous level [27]. QC LOW samples are then made by diluting authentic matrix with 
surrogate matrix, and QC LLOQ samples prepared in pure surrogate matrix. Unfortunately, 
this strategy cannot be used for glucagon quantitation due to its relatively low endogenous 
levels (LLOQ to 3x LLOQ). It was therefore decided to construct QC LOW using 
surrogate matrix, and QC MED and QC HIGH samples were prepared by spiking analyte 
on top of the endogenous level in authentic matrix.  
Human plasma (K3 EDTA) from a commercial supplier was analysed using the assay to 
determine its suitability as an authentic matrix. Such plasma was found to have a 
significantly raised background (Figure 2.6a) compared to plasma collected from 
volunteers in-house (Figure 2.6b). This may be a result of the lack of stabiliser upon 
collection, the age of the plasma and/or storage conditions. The raised background makes it 
unsuitable for the construction of QC samples, and, therefore, it was decided to use plasma 
collected in-house as the integrity of these samples could be ensured. Similarly, sample 
collection and storage regimes for any clinical samples should be carefully controlled to 
ensure their integrity. It is recommended that blood samples are collected on wet ice, 
plasma generated as soon as possible (ideally <30 minute from sample collection), and that 
samples are stored at -80 C until use. 
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Figure 2.6 Background noise in the analyte and internal standard transitions from 
extracted human plasma (K3 EDTA) samples containing endogenous levels of glucagon and 
spiked with internal standard to 1 ng/mL. 
Plasma sourced from a) a commercial supplier, stabilised with aprotinin post collection and b) an 
in-house volunteer, collected in blood tubes containing aprotinin. 
Plasma sourced from a commercial supplier had significantly raised background compared to that 
collected in-house, which may explain the lack of detectable endogenous glucagon. The raised 
background may be due to the lack of stabiliser upon collection, the age of the plasma and/or 
storage conditions. In-house collected plasma was therefore selected as the matrix for QC 
preparation, as its integrity could be ensured.  
A dual x axis is shown on the chromatograms. The upper part displays the time (e.g. 0.7 – 2.6 min 
for panel a)) and the lower part displays the scan number (e.g. 201 – 744 for panel a)). 
Analyte transition, 697.5693.8. Internal standard transition, 677.2 673.8. 
  
Analyte transition 
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Analyte transition 
 
 
Internal standard 
transition 
 
 
a) 
 
b) 
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2.3.3 Validation  
The assay was linear over the 25-1000 pg/mL calibration range assessed (Figure 2.7). No 
carryover after high calibration standards was observed and no potentially interfering 
peaks were observed during the selectivity assessment.  
 
Figure 2.7 Representative surrogate matrix glucagon calibration line (25-1000 pg/mL)  
The calibration line was linear, with back calculated concentrations of all calibration standards 
within 15% (20% for LLOQ) of their nominal concentrations, thereby passing acceptance criteria. 
The y axis, “Instrument Response”, is analyte area/internal standard area (i.e. peak area ratio). 
 
The precision and accuracy of the method was determined by analysis of replicate (n=6) 
QC samples at four different concentrations (25, 50, 100 and 750 pg/mL). Precision and 
accuracy was assessed within a batch (intra-batch, n=6 replicates) and between batches 
(inter-batch, three batches). The intra- and inter-assay CV did not exceed 20%, nor did the 
intra- and inter-assay RE demonstrating the method was performing robustly (Table 2.1). 
 
The ten-fold dilution of an over-range QC sample (7500 pg/mL) with control plasma was 
used to demonstrate the absence of dilution effects (Table 2.2). 
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Table 2.1 Intra- and inter-assay precision and accuracy of the LC-MS/MS method for 
the quantitation of glucagon in human plasma. 
Intra- and inter-assay precision and accuracy were within acceptance criteria at all levels 
(%CV20%, %RE±20%), demonstrating the assay was robust.  
Batch  
Number 
 QC LLOQ  
(25.0 pg/mL) 
QC LOW 
(50.0 pg/mL) 
QC MED 
(100 pg/mL) 
QC HIGH 
(750 pg/mL) 
1 Intra-run Mean 28.0 51.4 107 815 
Intra-run SD 1.84 2.16 9.05 29.0 
Intra-run %CV 6.6 4.2 8.5 3.6 
Intra-run %RE 12.0 2.8 7.0 8.7 
n 6 6 6 6 
2 Intra-run Mean 28.1 52.9 105 668 
Intra-run SD 3.64 3.74 5.14 31.3 
Intra-run %CV 13.0 7.1 4.9 4.7 
Intra-run %RE 12.4 5.8 5.0 -10.9 
n 6 6 6 6 
3 Intra-run Mean 29.0 50.9 97.8 670 
Intra-run SD 2.33 1.79 3.16 24.9 
Intra-run %CV 8.0 3.5 3.2 3.7 
Intra-run %RE 16.0 1.8 -2.2 -10.7 
n 6 6 6 6 
Overall Inter-run mean 28.4 51.7 103 718 
Inter-run SD 2.59 2.67 7.09 75.8 
Inter-run %CV 9.1 5.2 6.9 10.6 
Inter-run %RE 13.6 3.4 3.0 -4.3 
n 18 18 18 18 
SD:Standard deviation; CV:Coefficient of variation; RE: Relative error; n: number of replicates 
 
 
Table 2.2 Precision and accuracy of the method for glucagon in human plasma for a 
ten-fold diluted over-range sample. 
Precision and accuracy were within acceptance criteria (%CV20%, %RE±20%), demonstrating 
over range samples can be analysed following dilution. 
 QC DIL 
(7500 pg/mL) 
Mean 8210 
SD 390 
%CV 4.8 
%RE 9.5 
n 6 
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The analogue IS compensated for differences in suppression observed by the analyte in 
different matrices, with mean IS-normalised matrix factors being 1.08 and 1.05 at the 
medium and high level; a perfect correction would have a ratio of one (Table 2.3). The 
%CVs of the IS-normalised matrix factors were within acceptance criteria (%CV20%) at 
both levels. 
 
Table 2.3 Matrix effects: the modification of analyte and internal standard responses by 
six independent matrices. 
IS-normalised matrix factors were close to 1 at both levels assessed, demonstrating that the internal 
standard compensated for analyte response modification by the independent matrices. The  
IS-normalised ratio %CVs were within acceptance criteria (CV20%), demonstrating that the 
extent of compensation was similar between matrices. 
Control 
Matrix ID 
MED Samples 
 (100 pg/mL) 
HIGH Samples 
 (750 pg/mL) 
MF 
(Analyte 
Peak 
Area 
Only) 
MF 
(IS 
Peak 
Area 
Only) 
IS-Normalised 
MF 
MF 
(Analyte  
Peak  
Area  
Only) 
MF  
(IS  
Peak  
Area  
Only) 
IS-Normalised 
MF 
M1 0.835 0.793 1.05 0.804 0.820 0.981 
M2 0.757 0.731 1.03 0.837 0.789 1.06 
M3 0.616 0.630 0.98 0.797 0.743 1.07 
F1 0.692 0.683 1.01 0.758 0.725 1.05 
F2 0.679 0.578 1.17 0.812 0.752 1.08 
F3 0.670 0.534 1.26 0.689 0.655 1.05 
Mean 0.708 0.658 1.08 0.783 0.747 1.05 
SD 0.0767 0.097 0.108 0.0526 0.057 0.0359 
%CV 10.8 14.7 9.9 6.7 7.6 3.4 
MF = Corrected peak area in presence of plasma matrix ions* / mean peak area in absence of 
plasma matrix ions 
* Corrected peak area in presence of plasma matrix ions = Peak area in presence of plasma matrix 
ions and spiked analyte - endogenous peak area 
IS-normalised MF = MF Analyte / MF IS  
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Recovery was assessed across three different analytical batches with a minimum of three 
replicates at each level. In order to investigate whether the nature of the matrix affected 
recovery it was assessed from: samples where the analyte was spiked into stored control 
matrix then immediately extracted, samples where the analyte was spiked into 3 freshly 
acquired matrix pools then immediately extracted, and finally samples where the analyte 
was spiked into stored matrix then further stored for a week at -80 C before extraction 
(Table 2.4). No significant difference between these experiments was observed, which 
gave an average analyte recovery of 51.2%. 
Table 2.4 Analyte recovery from matrices of different natures. 
Analyte recovery was similar regardless of whether analyte was spiked into freshly acquired or 
stored matrix, or whether spiked samples were stored prior to extraction. Recovery was also similar 
between analyte levels. 
Experiment Analyte Recovery (%) 
MED HIGH Mean 
Analyte spiked into stored pooled plasma immediately 
before extraction 
50.4 52.6 51.5 
Analyte spiked into freshly 
acquired pooled plasma 
immediately before extraction 
Pool 1 (M7+M8) 50.3 45.6 48.0 
Pool 2 (F8+F9) 50.2 45.4 47.8 
Pool 3 (M9+F7) 56.5 50.0 53.3 
Analyte spiked into stored pooled plasma then further 
stored at -80 C for 1 week 
59.4 51.7 55.6 
Mean 53.4 49.1 51.2 
SD 4.31 3.38 3.37 
%CV 8.1 6.9 6.6 
Analyte Recovery (%) = 100 x Mean peak area ratio extracted samples / Mean peak area ratio unextracted 
samples. 
Peak area ratio = mean analyte response / mean IS response  
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Acceptable sensitivity is usually demonstrated by assessing whether the analyte response at 
the LLOQ level is at least five-times [4] the average response due to background noise 
which was the case for all accepted batches (Figure 2.8). It is then assumed that an 
unknown sample at the LLOQ concentration would also have a similarly acceptable 
response. However, this will not necessarily be the case for surrogate matrix assays, due to 
differences in the recovery and MF between the surrogate and authentic matrices. By 
taking into account the mean analyte recovery (51.2%) and mean matrix factor (0.746) for 
the assay, it was calculated that signal-to-noise ratio (S/N) at the LLOQ should be at least 
13.1 to ensure that S/N for an authentic sample at the LLOQ level 5 (assuming an 
unchanged background level). This criterion was not formally part of the validation, but it 
was met by all accepted batches 
 
 
 
Figure 2.8 Representative LLOQ (25 pg/mL analyte and 2000 pg/mL internal standard) 
surrogate matrix chromatogram. 
a) Analyte response demonstrating S/N ≥ 13.1. b) Internal standard response with S/N 236. 
The representative surrogate matrix LLOQ has a signal-to-noise ratio 13.1, which taking into 
account recovery and matrix effect differences between matrices, should ensure a plasma matrix 
sample has a signal-to-noise ratio 5.0 at the LLOQ. 
A dual x axis is shown on the chromatograms. The upper part displays the time (e.g. 0.7 – 2.6 min 
for panel a)) and the lower part displays the scan number (e.g. 201 – 744 for panel a)). 
Analyte transition, 697.5693.8. Internal standard transition, 677.2 673.8.  
 
  
Analyte transition 
S/N= 19 
Internal standard 
transition 
S/N= 236 
a) 
b) 
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Although aprotinin was used, a degree of glucagon instability within human plasma was 
apparent and most experiments gave results outside the acceptance criteria of 20% of the 
nominal concentration (Table 2.5). Even if 0 hr concentrations were used, to take into 
account any assay bias or preparation differences, many results remained outside 20% of 
this concentration. Glucagon plasma samples were found to be within 23.7% of their 
nominal concentrations following storage at the extraction temperature (+4C) for  
6 hr 20 min. They were within 21.4% of their 0 hr concentration following storage for 75 
days at -20 C, or within 20.2% following storage for 51 days at -80 C. Greater instability 
was observed following multiple freeze-thaw cycles, and these should, therefore, be 
minimised during analysis. The accuracy of the method is therefore limited by the sub-
optimal sample stabilisation procedure. The metabolism of glucagon is investigated in 
Chapter 3, results from which may aid the development of more effective stabilisation 
strategies. 
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Table 2.5 Glucagon stability data: freezer and extraction temperature stability of glucagon in plasma. 
The majority of stability results were outside of the acceptance criteria (20% of the nominal concentration), and many other were just within it. The accuracy 
of the method is therefore limited by the suboptimal sample stabilisation procedure, and is consequently termed a “qualified” method rather than a “validated 
method.” It is however likely to be “fit-for-purpose” for many applications, as the instability was moderate. Freeze-thaw cycling was particularly detrimental 
to stability, so should be minimised. 
Nominal  
Concentration 
 
Stability of glucagon in aprotinin-stabilised human plasma (K3 EDTA)  
+4 C - 20 C 
C 
-80 C 
6 hr 20 min 
 
4 F/T 11 days 75 days 4 F/T 7 days 11days 51 days 64 days  
MED  
(100 pg/mL) 
  
Mean Measured Conc. (pg/mL) 76.9 54.8 83.6 81.8 75.0 89.0 - 81.4 71.4 
SD 4.23 6.48 6.75 5.35 5.23 5.16 - 8.97 4.16 
%CV 5.5 11.8 8.1 6.5 7.0 5.8 - 11 5.8 
% Stability (cf. nominal) 76.9 54.8 83.6 81.8 75.0 89.0 - 81.4 71.4 
% Stability (cf. 0 hr) - 51.6 85.5 83.7 70.6 91.0 - 81.7 71.7 
HIGH 
(750 pg/mL)  
 
  
  
  
Mean Measured Conc. (pg/mL) 572 332 581 526 464 530 615 533 445 
SD 9.50 25.3 21.9 52.8 57.7 11.9 32.7 46 30.6 
%CV 1.7 7.6 3.8 10 12.4 2.2 5.3 8.6 6.9 
% Stability (cf. nominal) 76.3 44.3 77.5 70.1 61.9 70.7 82.0 71.1 59.3 
% Stability (cf. 0 hr) 85.6 41.5 86.8 78.6 58.0 79.2 91.9 79.8 66.7 
% Stability (c.f. nominal) = 100 * mean measured concentration / nominal concentration 
% Stability (c.f. 0 hr) = 100 * mean measured concentration / mean measured 0 hr concentration 
Statistics are means of n=6 replicates, except for 64 days (-80 C), which have n=4 and n=5 replicates at the MED and HIGH level respectively. 
Conc.: Concentration; Cf.: Confer (Compared with); - No data available; F/T: Freeze–thaw cycle  
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As stability in human K3 EDTA plasma with aprotinin stabilisation did not pass the 
acceptance criteria, the method is described as a qualified method, rather than a validated 
assay. The method is also likely to be a “fit-for-purpose” assay for many applications, as the 
instability was moderate. 
 
The ability to re-inject extracts was demonstrated after storage at +4 °C for 6 days 
 (Table 2.6). The stability of stock and working solutions of glucagon, which were stored at  
-20 C when not in use, was demonstrated for 67 and 163 days respectively (Table 2.7). 
These results demonstrate that glucagon instability is a plasma-related event. 
 
Table 2.6 Ability to inject extracts after storage for six days at 4 C. 
Extracts could be analysed after 6 days storage at 4C (stability was 20% of the nominal 
concentration) 
 
MED 
(100 pg/mL) 
HIGH 
(750 pg/mL) 
Mean Conc. (pg/mL)  110 738 
SD 7.14 43.9 
%CV 6.5 5.9 
%Stability 110.0 98.4 
 
% Stability = 100 * mean measured concentration (n=6 replicates) / nominal concentration. 
 
Table 2.7 Stability of glucagon in solution. 
Solution stability was demonstrated after storage at -20 C for all glucagon concentrations and storage 
periods tested (stability was 20% of the nominal concentration) 
Solution Days stored  
at -20 C 
% Stability 
Stock (1 mg/mL) 67 98.1 
LLOQ (125 pg/mL) 163 102.0 
ULOQ (5000 pg/mL) 163 97.2 
% Stability =100 * Stored solution (mean peak area ratio)/ Freshly prepared solution (mean peak area ratio) 
Statistics are from n=6 replicates. 
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The stability of glucagon in aprotinin-stabilised whole blood following storage on ice for 1 hr 
was found to be within acceptance criteria (Table 2.8). 
The presence of hyperlipidaemic plasma did not significantly affect the quantitation of 
glucagon (Table 2.9). 
 
Table 2.8 Stability of glucagon in aprotinin-stabilised human whole blood (K3 EDTA) 
stored on ice. 
Glucagon was found stable in whole blood stored on ice for 1 hour (stability was 20% of the 0 hr 
concentration) 
 
0 hr 
(B11) 
1hr 
(B11) 
Mean Concentration (pg/mL) 72.4 61.4 
SD 4.67 3.93 
%CV 6.5 6.4 
%Stability 84.8 
% Stability = 100 * mean measured concentration / nominal concentration. 
Statistics are from n=6 replicates. 
 
Table 2.9 Effect of hyperlipidaemic plasma on quantitation. 
Hyperlipidaemic plasma did not significantly affect glucagon quantitation (%RE±20%). 
 
100 pg/mL 750 pg/mL 
Mean Concentration (pg/mL) 82.9 670 
SD 6.15 101 
%CV 7.4 15.1 
%Nominal 82.9 89.3 
%RE -17.1 -10.7 
 
Statistics are from n=6 replicates. 
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Haemolysed samples contained a large neighbouring peak, and did not pass acceptance 
criteria, demonstrating haemolysed samples cannot be accurately quantified using the method 
(Figure 2.9). 
 
 
 
Figure 2.9 Effect of haemolysed plasma on analyte and internal standard chromatograms. 
Haemolysed samples (plasma spiked with 3% whole blood) spiked with glucagon at a) 100 pg/mL 
and b) 750 pg/mL. 
 
Hameolysed samples led to large increases in background noise in both the analyte and internal 
standard transitions, compared to non-haemolysed samples (e.g. Figure 2.6b and Figure 2.10). 
Partially resolved interference peaks were also present in the analyte and internal standard transitions.  
 
Quantitative accuracy at the both the 100 pg/mL and 750 pg/mL level (73.9% and 68.7% nominal 
respectively), was outside of acceptance criteria, demonstrating that the method was not suitable for 
the analysis of haemolysed samples.  
 
A dual x axis is shown on the chromatograms. The upper part displays the time (e.g. 0.6 – 2.5 min for 
panel a)) and the lower part displays the scan number (e.g. 172 – 715 for panel a)). 
 
Analyte transition, 697.5693.8. Internal standard transition, 677.2 673.8. 
  
Analyte transition 
 
Analyte transition 
 
Internal standard 
transition 
 
 
Internal standard 
transition 
 
 
a) 
b) 
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2.3.4 Endogenous Glucagon Concentrations from Healthy Volunteers 
Plasma was collected from 12 healthy males and 12 healthy females and glucagon levels 
determined using the qualified LC-MS/MS method. The majority of levels agreed well with 
the 25-80 pg/mL range determined by RIA [1] (Table 2.10). Chromatograms from samples 
which gave glucagon concentrations above the qualified LLOQ (25 pg/mL) showed good 
S/Ns (Figure 2.10). Some samples which gave glucagon concentrations below the LLOQ 
showed integratable peaks (Figure 2.10) and their approximate concentrations were 
determined by extrapolation (Table 2.10). 
Table 2.10 Glucagon concentrations from healthy volunteers. 
The majority samples from healthy volunteers gave glucagon concentrations within the range 
expected by RIA (25-80 pg/mL) 
Male 
Volunteer 
ID 
Measured 
glucagon 
concentration 
(pg/mL) 
Female 
Volunteer 
ID 
Measured 
glucagon 
concentration 
(pg/mL) 
M1 34.2 F1 BLQ (10.4) 
M2 27.4 F2 BLQ (16.5) 
M3 BLQ (16.0) F3 BLQ (12.1) 
M4 31.2 F4 41.6 
M5 50.2 F5 BLQ (17.7) 
M6 63.0 F6 44.4 
M7 BLQ (21.3) F7 29.6 
M8 53.7 F8 59.5 
M9 40.4 F9 31.7 
M10 39.4 F10 BLQ 
M11 BLQ (20.0) F11 BLQ 
M12 153 F12 BLQ 
BLQ – Below limit of quantitation (25 pg/mL).   Extrapolated values are in parenthesis.  
No integratable peaks were observed for  F10, F11, F12.  No haemolysis was observed in the samples. 
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Figure 2.10 Chromatograms showing endogenous levels of glucagon in plasma samples from 
healthy volunteers. 
Volunteer a) M3, b) M8, c) F8, d) F9.  
Chromatograms from volunteers M8, F8 and F9 showed peaks of good intensity corresponding to 
endogenous glucagon above the LLOQ (25 pg/mL). Even though the sample from volunteer M3 gave 
endogenous glucagon below the LLOQ, the peak was integratable enabling an indicative 
concentration to be determined by extrapolation. 
 
A dual x axis is shown on the chromatograms. The upper part displays the time (e.g. 0.7 – 2.6 min for 
panel a)) and the lower part displays the scan number (e.g. 201 – 744 for panel a)). 
 
The majority of samples (58%) gave glucagon concentrations above the 25 pg/mL qualified 
LLOQ, demonstrating the assay’s utility for endogenous level analysis. However, as 
glucagon concentrations in some individual plasmas were very close to, or below, this level, 
for subsequent analysis it was decided to include additional surrogate matrix standards and 
QCs at the 10 and 15 pg/mL concentrations. QCs consistently performed within 20% (RE and 
CV) at the 15 pg/mL level in each of the three batches analysed, and were within 20% (RE 
and CV) at the 10 pg/mL level in two out of the three batches analysed demonstrating good 
performance (Table 2.11). The use of surrogate matrix LLOQs at the 10 or 15 pg/mL level 
a) M3 (BLQ (16.0 pg/mL)) 
 
b) M8 (53.7 pg/mL) 
 
d) F9 (31.7 pg/mL) 
 
c) F8 (59.5 pg/mL) 
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for the construction of calibration lines (determined by ensuring S/N >5, and CV and RE 
<20%) enabled plasma concentrations to be determined below the qualified LLOQ without 
the need to extrapolate calibration lines. However, as explained in Section 2.3.3, acceptable 
performance in surrogate matrix does not necessarily translate to that in plasma samples at 
the same concentration, due to differences in recovery and matrix effect reducing signal-to-
noise in plasma samples. Therefore, glucagon concentrations determined below the qualified 
LLOQ should be treated with caution, and as indicative only.  
 
Table 2.11 Surrogate matrix QC performance at 10, 15 and 50 pg/mL. 
To allow plasma glucagon concentrations to be determined below the qualified 25 pg/mL LLOQ 
without extrapolation, additional surrogate standards and QCs at 10 and 15 pg/mL were introduced. 
QCs at 15 pg/mL performed within standard acceptance criteria 20% (RE and CV) in each of the three 
batches analysed, whilst those at 10 pg/mL performed within this for 2/3 of the batches demonstrating 
reasonable performance. However, due to differences between surrogate and plasma matrices 
explained in Section 2.3.3, acceptable performance in the surrogate matrix does not necessary 
correspond to that in plasma. Therefore, plasma glucagon concentrations determined below the 
qualified 25 pg/mL LLOQ should be treated with caution and as indicative only.  
  
QC Level 
(pg/mL) 
Replicates 
(n) 
Measured 
Mean 
(pg/mL) 
SD CV %Nominal 
Batch 1 
10 6 10.5 1.2 11.2 104.8 
15 6 16.6 2.0 12.0 110.8 
50 6 50.1 1.8 3.6 100.1 
Batch 2 
10 6 10.9 1.8 16.6 109.1 
15 6 15.5 1.0 6.7 103.5 
50 2 47.9 3.6 7.5 95.9 
Batch 3 
10 6 6.2 1.5 24.3 62.2 
15 6 13.3 1.3 10.0 88.5 
50 2 47.0 2.2 4.6 94.0 
These batches included assessment of the pooled sample described in Table 2.12. 
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To assess whether quantitation was reproducible at the endogenous level, samples containing 
endogenous glucagon were pooled together, and analysed multiple times in 3 different 
batches (n=6 replicates in each batch) using the approach above. An overall mean of  
26.5 pg/mL was observed with an overall CV of 19.8%, demonstrating reproducible 
quantification at the endogenous level (Table 2.12).  
 
Table 2.12 Repeat analysis of a pooled sample at the endogenous glucagon level. 
Repeat analysis of a pooled endogenous level sample showed good intra- and inter-batch precision 
(CV20 %), demonstrating reproducible quantitation at the endogenous level. 
Replicate Measured glucagon concentration (pg/mL) 
Batch 1 Batch 2 Batch 3 
1 19.9 30.2 23.6 
2 24.7 24.8 31.4 
3 19.9 19.6 34.8 
4 22.3 26.6 33.9 
5 23.7 25.8 36.1 
6 26.0 22.8 31.5 
Mean 22.8 25.0 31.9 
SD 2.5 3.6 4.5 
%CV 11.1 14.4 14.1 
    Inter-batch mean 26.5 
 Inter-batch SD 5.3 
 Inter-batch CV 19.8 
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2.3.5 LC-MS/MS vs. RIA for Physiological Study Samples 
Plasma samples (n = 117) were collected from a physiological study involving the infusion of 
glucagon. A subset of these samples (n = 100) were analysed using LC-MS/MS and another 
subset (n= 105) using the established RIA. Both assays contained QC samples, which 
performed within their established acceptance criteria.  
Bland-Altman analysis of the 88 common samples shows that the mean bias of the  
LC-MS/MS assay versus the RIA is +45.06 pg/mL with 95% bias confidence intervals of 
-358.5 to 448.6 pg/mL. Inspection of the plot (Figure 2.11a) shows that there is a 
concentration-dependent positive bias, particularly at values above 600 pg/mL, which is also 
evident in the scatter plot (Figure 2.11b). This would be expected if the RIA was suffering 
from the “hook effect” at higher concentrations, which has been reported for other 
biomarkers such as calcitonin [29]. 
 
 
Figure 2.11 Analysis of physiological study samples by LC-MS/MS and RIA. 
a) Bland-Altman and b) scatter plot comparing performance of LC-MS/MS and RIA methods for 
glucagon.  
Bland-Altman analysis showed mean bias of the LC-MS/MS assay versus the RIA of +45.06 pg/mL 
The bias was concentration dependent, with stronger positive bias at higher concentrations (above  
600 pg/mL). This may be due to the RIA suffering from the “hook effect” at such levels.  
This figure was created by Imperial College. 
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RIA and LC-MS/MS assays produced PK profiles of similar shapes, which fitted with 
expectations from the nature of the study (Figure 2.12). The drop in glucagon concentrations 
during the 12 hour infusions was attributed to physical and chemical degradation of glucagon 
in the infusion solutions, as noted by others [30]. As both assays agreed with the nature of the 
study, it is not possible to determine which assay gives the “right” answer, and the 
approaches should be regarded as complementary. 
.
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Figure 2.12 Pharmacokinetic profiles from RIA (red squares) and LC-MS/MS (blue diamonds) assays. 
Y axis units are pg/mL. 
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
Nominal Time (hr) 
Volunteer 1 Visit 1: 12 hr glucagon 
infusions begun after 0 & 24 hr  
(20 pmol/kg/min) 
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
Nominal Time (hr) 
Volunteer 1 Visit 2: 12 hr  glucagon 
infusions begun after 6 hr  
(20 pmol/kg/min) and  30 & 48 hr  
(16 pmol/kg/min) 
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
Nominal Time (hr) 
Volunteer 2 Visit 1: 12 hr  glucagon 
infusions begun after 30 & 48 hr  
(20 pmol/kg/min) 
 
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
Nominal Time (hr) 
Volunteer 2 Visit 2: 12 hr glucagon 
infusions begun after 6 hr  
(20 pmol/kg/min) and  48 hr  
(16 pmol/kg/min) 
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
Nominal Time (hr) 
Volunteer 3: 12 hr glucagon infusions 
begun after 6, 24 & 48 hr  
(20 pmol/kg/min) 
 
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
Nominal Time (hr) 
Volunteer 4: 12 hr glucagon infusions 
begun after 0, 24, & 48 hr  
(16 pmol/kg/min) 
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
Nominal Time (hr) 
Volunteer  5: 12 hr infusions begun after 
6, 24 & 48 hr (20 pmol/kg/min) 
 
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
Nominal Time (hr) 
Volunteer 6: 12 hr infusions begun after 
 0 & 24 hr (20 pmol/kg/min) 
 
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
Nominal Time (hr) 
Volunteer 7: 12 hr infusions begun after  
0 & 24 hr (20 pmol/kg/min) 
 
127 
Seven different volunteers were each infused subcutaneously with various combinations of saline solution (for 6 hours on each occasion) and glucagon 
solutions at either 16 or 20 pmol/kg/min (for 12 hours on each occasion). The total infusion time for each individual was up to 60 hours. Volunteer 1 and 2 
returned for a second visit. A selection of physiological study samples, taken at various time points throughout the infusions, were analysed by LC-MS/MS 
and/or RIA for glucagon. The collection times and the infusion conditions upon their collection are shown in the figure. 
The resulting PK profiles fitted with the nature of the study. The drops in glucagon concentrations during the 12 hour glucagon infusions were attributed to 
glucagon degradation in the infusion solution. Due to the similar PK profiles, the RIA and LC-MS/MS assays are considered complementary. 
 
128 
 
2.4 CONCLUSION 
The developed procedure is the first peer reviewed LC-MS/MS method capable of 
quantifying endogenous levels of glucagon in human plasma. The majority of glucagon levels 
from healthy volunteers were within the range expected from RIA. The method avoids the 
radioactivity (and precautions this requires) associated with RIA, has a shorter extraction 
time and good precision and accuracy. 
The 25 pg/mL LLOQ in the qualified assay is a considerable improvement over the lowest 
LC-MS/MS LLOQ previously reported (250 pg/mL) in the peer reviewed literature [15]. A 
10 pg/mL LLOQ has been reported in a conference presentation [8], using a highly sensitive 
QTRAP mass spectrometer. By extrapolation of the calibration line, or by the inclusion of 
additional surrogate matrix calibrants below the established LLOQ, it was possible to indicate 
samples with glucagon levels in this region. Transferring this assay onto a more modern 
instrument may enable the qualification of plasma LLOQ of 10 pg/mL. The 2D extraction 
procedure was key to achieving high sensitivity, by reducing matrix suppression, background 
noise, and interferences. To my knowledge this is the first time protein precipitation and size 
exclusion SPE have been combined for such a purpose for high-throughput peptide analysis. 
The surrogate matrix approach, using a mixture of non-extracted surrogate matrix STDs and 
QCs and extracted authentic matrix QCs, is also a novel strategy for endogenous peptide 
analysis.  
Bland-Altman analysis shows a mean positive bias of the LC/MS-MS method versus the RIA 
that appears to be a concentration-dependent, as would be expected if the RIA was suffering 
from the “hook effect” at higher concentrations. The PK profiles from both assays were 
similar shapes, and both profiles fitted with the nature of the physiological study suggesting 
the methods are complementary. 
The performance of the method reported in this chapter has been qualified using experiments 
described in the latest EMA [4] and FDA [5] guidance and in accordance to the principles of 
GCP [6]. The method is termed “qualified” rather than “validated”, due to the moderate 
instability of glucagon noted in human plasma, which was outside of acceptance criteria 
under many sample handling conditions. The effect of this should be considered when 
interpreting results from study samples. Glucagon degradation is further characterised in 
Chapter 3, which may help inform future stabilisation strategies.  
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The LC-MS/MS method is refined in Chapter 4 to improve sensitivity, as several endogenous 
level samples gave glucagon concentrations below the qualified LLOQ using the current 
method. Robustness and throughput were also improved, and the method expanded to include 
GLP-1 as a secondary analyte, increasing its applicability. 
 
  
130 
2.5 APPENDIX: DEFINITIVE METHOD FOR GLUCAGON 
QUANTITATION 
2.5.1 Solution Preparation  
Stock solutions (1 mg/mL) of glucagon (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) 
and glucagon internal standard (HSQGTFSDYSKYLDSRRAQDFVQWLMNT) (des-thr
7
-
glucagon) should be prepared in borosilicate vials using surrogate matrix 
[MeOH:H2O:FA:BSA, (20:80:0.1:0.1, v/v/v/w); typically 200 mL MeOH, 800 mL H2O, 
1 mL FA and 1 g BSA]. 
Glucagon working solutions are prepared by dilution with this solvent to create nine 
calibration standard spiking solutions (125, 225, 375, 500, 1000, 2000, 3000, 4500, 5000 
pg/mL), and four quality control spiking solutions (125, 250, 10000, 75000 pg/mL). Internal 
standard working solution (ISWS) should be prepared in this solvent at 20 ng/mL.  
Stock and working solutions should be prepared to a volume of 10 mL and stored at -20 C 
when not in use.  
2.5.2 Plasma Preparation  
Plasma should be generated in-house, as commercially sourced plasma has high background 
noise levels masking endogenous glucagon. 
Blood should be collected in glass collection tubes (5 mL) containing K3 EDTA 
anticoagulant and 250 Kallikrein Inhibitor Units (KIU) of aprotinin Following collection, 
tubes should be placed on ice, then centrifuged at 2300 x g for 10 min to obtain plasma, 
which should be stored at -80 C when not in use. 
2.5.3 Plasma QC Preparation  
QC MED and QC HIGH samples are prepared by diluting the appropriate spiking solution 
100-fold with plasma to create samples at 100 and 750 pg/mL respectively, plus the 
endogenous glucagon concentration of the plasma, if quantifiable. Samples can be used 
immediately, or stored at -80 C prior to use. They are extracted according to procedure 
detailed in Section 2.5.5. 
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2.5.4 Preparation of Surrogate Matrix Calibration Standards and QC Samples 
Calibration standards, QC LLOQs and QC LOWs should be prepared freshly for each batch 
after plasma sample extraction (i.e. at step 17 of the procedure in 2.5.5). 80 µL of the 
appropriate spiking solution should be added into the plate, along with 20 µL ISWS and  
100 µL surrogate matrix. Taking into account the two-fold concentration experienced by 
plasma samples (400 µL of plasma sample is reconstituted into 200 µL of solvent) this gives 
final calibration levels of 25, 45, 75, 100, 200, 400, 600, 900, and 1000 pg/mL, and final QC 
levels of 25 and 50 pg/mL. 
2.5.5 Sample Extraction Procedure 
Steps 1-4 should be performed on wet ice (ca. 4 C) (except during the brief vortex mix).  
Step Process 
1 Aliquot 400 µL plasma sample into a 5 mL polypropylene tube 
2 Add 20 µL internal standard working solution (20 ng/mL) 
3 Cap tubes and vortex mix briefly 
4 Add 3.2 mL of ACN:H2O:NH4OH (72:25:0.1,v/v/v)  to the tubes 
5 Cap tubes and vortex mix briefly 
6 Centrifuge the tubes for 10 min at approximately 2300 x g. 
7 Transfer supernatant to a new tube 
8 Evaporate to dryness overnight under vacuum  
9 Reconstitute in 800 µL 2% NH4OH (aq), cap tubes and vortex mix briefly. 
10 Condition a Bond Elut Plexa SEH SPE Plate (96-round-well, 30 mg) plate, with 1 mL 
MeOH 
11 Equilibrate with 1 mL H2O  
12 Load the samples onto the plate 
13 Wash with 1 mL 5% MeOH (aq)  
14 Elute with 2 x 225 µL ACN:H2O:FA (75:25:0.1, v/v/v), into a 1 mL 96-well LoBind plate  
15 Evaporate to dryness at 40 C under N2 
16 Reconstitute sample in 200 µL 0.2% FA (aq)  
17 Prepare surrogate matrix calibration and QC samples as described in Section 2.5.4 
18 Cap the plate and vortex mix briefly 
19 Centrifuge the plate for 10 min at approximately 2300 x g 
20 Inject onto LC-MS/MS system for analysis or transfer to storage at nominally 4C  
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2.5.6 HPLC Conditions  
Autosampler Waters Acquity Sample Manager  
Strong wash Acetonitrile (advised volume = 1000 µL) 
Weak wash Acetonitrile: water (10:90, v/v) (advised volume = 1000 µL) 
Injection mode Full loop (50 µL injection) 
Autosampler temperature 4 ºC  
LC system Waters Acquity Binary Solvent Manager  
Flow rate 0.800 mL/min 
Analytical Column Waters UPLC BEH C18 1.7 µm (2.1 x 100 mm) 
Column temperature Nominally 60 C 
Run Time 7.1 minutes 
Mobile phase A 0.2% FA in ACN 
Mobile phase B 0.2% FA (aq) 
 
Gradient Profile  
Time (min) %A %B Gradient Profile 
1
 
Initial 22 78 - 
2.00 32 68 6 
2.05 95 5 11 
3.00  95 5 11 
3.10  22 78 11 
7.10  22 78 11 
1
 A gradient profile of 6 describes that the gradient was altered at a constant rate from the gradient 
conditions at the preceding time point. A profile of 11 describes that the gradient changes only when 
the time point is reached; at this point it changes immediately to the new conditions. 
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2.5.7 MS/MS Conditions  
Mass Spectrometer AB SCIEX 5500 QTRAP 
Ionisation Mode (polarity) Electrospray (Positive) 
Electrospray Voltage 5500 V 
Source Temperature 600 ºC 
GS1 /GS2 60 / 40 psi 
Curtain gas setting 40 psi 
Collision gas setting Medium 
Q1/Q3 Resolution Unit/Unit 
 
ID 
Precursor 
ion 
(m/z) 
Product  
ion 
(m/z) 
Dwell 
time 
(ms) 
EP 
(V) 
DP 
(V) 
CE 
(V) 
CXP 
(V) 
Typical  
Retention 
Time (min) 
Glucagon  
(analyte) 
697.5 693.8 100 10 70 15 13 1.5 
Des-thr
7
-glucagon 
(internal standard) 
677.2 673.8 100 10 70 15 13 1.5 
 
  
134 
2.6 REFERENCES  
[1]  Kolb A, Rieder S, Born D, et al. Glucagon/insulin ratio as a potential biomarker for 
pancreatic cancer in patients with new-onset diabetes mellitus. Cancer Biol. Ther. 
8(16), 1527–1533 (2009). 
[2]  Tan TM, Field BCT, McCullough K a, et al. Coadministration of glucagon-like 
peptide-1 during glucagon infusion in humans results in increased energy expenditure 
and amelioration of hyperglycemia. Diabetes. 62(4), 1131–8 (2013). 
[3]  Polaskova V, Kapur A, Khan A, Molloy MP, Baker MS. High-abundance protein 
depletion: comparison of methods for human plasma biomarker discovery. 
Electrophoresis. 31(3), 471–82 (2010). 
[4] Guideline on bioanalytical method validation, EMA(2012). 
[5] Guidance for industry: Bioanalytical method validation. U.S. Department of Health 
and Human Services, Food and Drug Administration, Center for Drug Evaluation and 
Research (CDER), Center for Veterinary Medicine (CVM), May 2001, (2001). 
[6] International committee on harmonisation (ICH) guideline E6: Triparite guidelines for 
GCP, EMEA(1996). 
[7]  Lapko V, Brown P, Nachi R, et al. Exploring quantification of peptides: measurement 
of glucagon in human plasma by LC–MS/MS, in EBF 3rd Annual Open Symposium: 
From Challenges to Solutions, (2010). 
[8]  Garofolo F, Mess JN, Morin LP, et al. Glucagon bioanalysis by LC–MS: 
unprecedented level of sensitivity (10 pg/ml) for a novel formulation, in 2013 
American Association of Pharmaceutical Scientists National Biotechnology 
Conference, (2013). 
[9]  Salem V, Coello C, Thomas DB, et al. Glucagon increases energy expenditure 
independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 
18(1), 72–81 (2016). 
[10]  Kreymann B, Williams G, Ghatei MA BS. Glucagon-like peptide-1 7-36: a 
physiological incretin in man. Lancet. 2(8571), 1300–1304 (1987). 
[11]  Ghatei MA, Uttenthal LO, Bryant MG, Christofides ND, Moody AJ BS. Molecular 
Forms of Glucagon-Like Immunoreactivity in Porcine Intestine and Pancreas. 
Endocrinology. (112), 917–923. (1983). 
[12]  Fekete S, Ganzler K, Fekete J. Facts and myths about columns packed with sub-3 
microm and sub-2 microm particles. J. Pharm. Biomed. Anal. 51(1), 56–64 (2010). 
[13]  Ruta J, Guillarme D, Rudaz S, Veuthey J-L. Comparison of columns packed with 
porous sub-2 microm particles and superficially porous sub-3 microm particles for 
peptide analysis at ambient and high temperature. J. Sep. Sci. 33(16), 2465–2477 
(2010). 
  
135 
[14]  Ismaiel OA, Zhang T, Jenkins R, Karnes HT. Determination of octreotide and 
assessment of matrix effects in human plasma using ultra high performance liquid 
chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. 
Biomed. Life Sci. 879(22), 2081–2088 (2011). 
[15]  Li YX, Hackman M, Wang CY. Quantitation of polypeptides (glucagon and salmon 
calcitonin) in plasma samples by ‘high resolution’ on a triple quadrupole mass 
spectrometer. Bioanalysis. 4(6), 685–691 (2012). 
[16]  Delinsky DC, Hill KT, White CA, Bartlett MG. Quantitation of the large polypeptide 
glucagon by protein precipitation and LC/MS. Biomed. Chromatogr. 18(9), 700–5 
(2004). 
[17]  Lapko VN, Miller PS, Brown GP, et al. Sensitive glucagon quantification by 
immunochemical and LC – MS / MS methods. Bioanalysis. 5(23), 2957–2972 (2013). 
[18]  Holčapek M, Jirásko R, Lísa M. Recent developments in liquid chromatography-mass 
spectrometry and related techniques. J. Chromatogr. A. 1259, 3–15 (2012). 
[19]  Kay R, Barton C, Ratcliffe L, et al. Enrichment of low molecular weight serum 
proteins using acetonitrile precipitation for mass spectrometry based proteomic 
analysis. Rapid Commun. Mass Spectrom. 22(20), 3255–60 (2008). 
[20]  Halquist MS, Karnes HT. Quantification of Alefacept, an immunosuppressive fusion 
protein in human plasma using a protein analogue internal standard, trypsin cleaved 
signature peptides and liquid chromatography tandem mass spectrometry. J. 
Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 879(11–12), 789–98 (2011). 
[21]  Barton C, Kay RG, Gentzer W, Vitzthum F, Pleasance S. Development of high-
throughput chemical extraction techniques and quantitative HPLC-MS/MS (SRM) 
assays for clinically relevant plasma proteins. J. Proteome Res. 9(1), 333–340 (2010). 
[22]  Bailly-Chouriberry L, Pinel G, Garcia P, Popot M-A, Le Bizec B, Bonnaire Y. 
Identification of recombinant equine growth hormone in horse plasma by LC-MS/MS: 
a confirmatory analysis in doping control. Anal. Chem. 80(21), 8340–7 (2008). 
[23]  Wang Y, Qu Y, Bellows CL, Ahn J, Burkey JL, Taylor SW. Simultaneous 
quantification of davalintide, a novel amylin-mimetic peptide, and its active metabolite 
in beagle and rat plasma by online SPE and LC–MS/MS. Bioanalysis. 4, 2141–2152 
(2012). 
[24]  Chappell D, Lee A, Castro-Perez J, et al. An ultrasensitive method for the quantitation 
of active and inactive GLP-1 in human plasma via immunoaffinity LC-MS/MS. 
Bioanalysis. 6(1), 33–42 (2014). 
[25]  Hinke SA, Pospisilik JA, Demuth HU, et al. Dipeptidyl peptidase IV (DPIV/CD26) 
degradation of glucagon. Characterization of glucagon degradation products and 
DPIV-resistant analogs. J. Biol. Chem. 275(6), 3827–34 (2000). 
[26]  Omenn GS. THE HUPO Human Plasma Proteome Project. PROTEOMICS – Clin. 
Appl. 1(8), 769–779 (2007). 
[27]  Houghton R, Horro Pita C, Ward I, Macarthur R. Generic approach to validation of 
small-molecule LC-MS/MS biomarker assays. Bioanalysis. 1(8), 1365–74 (2009). 
136 
[28]  Lee JW. Method validation and application of protein biomarkers: basic similarities 
and differences from biotherapeutics. Bioanalysis. 1(8), 1461–74 (2009). 
[29]  Leboeuf R, Langlois M-F, Martin M, Ahnadi CE, Fink GD. “Hook effect” in 
calcitonin immunoradiometric assay in patients with metastatic medullary thyroid 
carcinoma: case report and review of the literature. J. Clin. Endocrinol. Metab. 91(2), 
361–4 (2006). 
[30]  Matilainen L, Larsen KL, Wimmer R, et al. The effect of cyclodextrins on chemical 
and physical stability of glucagon and characterization of glucagon/gamma-CD 
inclusion complexes. J. Pharm. Sci. 97(7), 2720–9 (2008). 
137 
 
Chapter 3 Identification of Plasma Protease-
Derived Metabolites of Glucagon and their 
Formation under Typical Laboratory Sample 
Handling Conditions 
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3.1 INTRODUCTION 
In vitro instability of glucagon in human plasma was noted during the validation of the  
LC-MS/MS method described in Chapter 2, despite the presence of the stabiliser aprotinin 
(Section 2.3.3). For example, after storage for 6 hr 20 min on ice, 11 days at -20 C, or 
after 4 freeze-thaw cycles (-20 C to +4 C), stability was 76.9%, 83.6%, and 54.8% 
respectively, when referenced against the nominal concentration (100 pg/mL). Samples 
prepared at a higher concentration (800 pg/mL), showed similar instability (76.3%, 77.5%, 
44.3% respectively), and instability remained even when samples were stored at -80 C. 
Clearly aprotinin did not sufficiently stabilise glucagon in human plasma. However, this 
was not wholly unexpected, as its effectiveness is controversial, with some studies 
demonstrating that it does not lead to any improvements in stability [1][2]. The 
effectiveness of other stabilisers is similarly disputed (Section 1.9.7). Therefore, the 
development of more effective stabilisation approaches is required. The identification of in 
vitro plasma protease metabolites of glucagon could help to inform this. For example, the 
subsequent identification of enzymatic pathways could suggest inhibitors to stabilise 
samples. Alternatively metabolite formation could be monitored to help characterise 
stabilisation approaches, and suggest further refinement. 
Identification of plasma protease metabolites may also help to explain the poor precision 
and accuracy [3][4][5] experienced by many glucagon immunoassays due to their cross 
reactivity with antibodies. Cross reactivity with peptides related to glucagon 
(oxyntomodulin and/or glicentin) was reported in four out of seven immunoassay kits [4] 
and in one out of three sandwich ELISA kits [5] evaluated. It could also help to explain the 
seven-fold difference in endogenous glucagon concentrations reported by immunoassays 
directed against the middle or C-terminal regions of glucagon [6]. 
The metabolism of glucagon (glucagon1-29) in vivo is well documented. It is rapidly 
metabolised in humans, with a half-life of approx. 5 min in healthy subjects, which is 
raised to approx. 6 min in diabetic subjects [7]. The liver and kidney are primarily 
responsible for glucagon metabolism, although some also occurs in the blood 
compartment, and a wide range of metabolites have been identified [8]. For example, 
glucagon4-29, glucagon7-29, and glucagon1-13 are formed by hepatocytes in the liver [9][10]. 
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Glucagon1-13 and glucagon14-29, and the minor metabolites glucagon1-10, glucagon14-25 and 
glucagon23-29, are similarly formed by a glucagon receptor-linked protease in the hepatic 
plasma membrane [8][9]. The metabolite known as miniglucagon, glucagon19-29, is 
produced after processing of glucagon by liver plasma membranes [11] and pancreatic 
cells [12]. Miniglucagon has a unique biological activity as a modulator of glucagon1-29 
[13]. Furthermore, glucagon is hydrolysed at the proximal tubule’s brush border in the 
kidneys [14] by the serine protease DPP IV [15][16]. This is also present in the liver, 
pancreatic duct, the endothelial cells of the blood vessels, and as a soluble enzyme in blood 
plasma and, therefore, similar metabolism is suspected to occur here [16]. 
Many of the in vivo metabolites have the potential for biological activity. For example, 
although the C-terminal region of glucagon improves receptor binding, peptides lacking 
this region, such as glucagon1–21 and glucagon1–6, are essentially fully active glucagon 
derivatives, but with lower potency [17]. In contrast, modifications at the amino-terminus 
of glucagon, including removal of the initial residue (His), have a greater effect on receptor 
binding affinity and biological activity [18]. 
Despite the range of metabolites identified in vivo there have not been any studies to 
identify in vitro plasma protease derived metabolites. However, in serum diluted to 20% 
with Tris buffer (0.1 mM, pH 7.6), it has been reported that DPP IV hydrolyses  
glucagon1-29 to glucagon3–29, which then undergoes immediate conversion to exclusively 
form pyroglutamyl glucagon3–29 ([pGlu]
3
glucagon3–29) [15]. A similar process may occur 
in vitro in plasma, and help to account for the instability of glucagon or the poor 
performance of some immunoassays. However, in view of the range of metabolites formed 
in vivo, many other alternatives are possible, which need to be experimentally determined. 
This chapter describes the identification of novel metabolites formed in vitro by human 
plasma protease metabolism of glucagon, and characterises their formation. Metabolite 
formation under typical laboratory sample handling conditions is assessed, and the 
effectiveness of aprotinin stabilisation is investigated. 
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3.2 EXPERIMENTAL 
3.2.1 Chemicals and Materials 
Certified human glucagon (glucagon1-29)(HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) 
was obtained from EDQM (Strasbourg, France). Water was purified by a Triple Red water 
purifier (Long Crendon, UK). When required, sample extracts were evaporated using a 
Porvair MiniVap (Norfolk, U.K.) with nitrogen at 60 litres per minute. Human plasma was 
obtained from CTLS (London, UK). Aprotinin from BioUltra was obtained from Sigma-
Aldrich (Poole, UK). Plasma was stabilised using aprotinin at 100 KIU/mL as appropriate. 
All chemicals and solvents were HPLC or analytical reagent grade and purchased from 
commercial vendors.  
3.2.2 Preparation of Glucagon Stock Solutions 
Glucagon stock solutions (1 mg/mL) were prepared in borosilicate vials using MeOH:H2O: 
FA:BSA (20:80:0.1:0.1, v/v/v/w)( typically 200 mL MeOH, 800 mL H2O, 1 mL FA and  
1 g BSA) as a solvent and stored at -20C when not in use. 
3.2.3 Preparation of Metabolite Samples 
Glucagon samples were prepared by diluting the stock solution 100-fold with human 
plasma to create samples at 10 µg/mL. Plasma was unstabilised unless stated otherwise. 
Samples were extracted either immediately, or after storage at set time points under 
specific conditions. Samples were extracted on wet ice (ca. +4 C) using a protein 
precipitation methodology. Briefly samples (100 µL) were placed into a 1 mL 96-well 
polypropylene plate, precipitated using 500 µL ACN:H2O (75:25, v/v), vortex mixed, and 
then centrifuged for 10 min at 2300 x g. The supernatant was transferred to a 1 mL 96-well 
LoBind plate from Eppendorf (Stevenage, U.K.), and evaporated to dryness under nitrogen 
at 40 C. The samples were reconstituted in 700 µL 0.2% formic acid (aq) to form 
“concentrated extracts”, vortex mixed and centrifuged again, before being analysed by LC-
MS as described below. To avoid the most abundant metabolites leading to detector 
saturation the extracts were also diluted to form “diluted extracts” and re-analysed by LC-
MS/MS. For this dilution, 100 µL of the “concentrated extracts” was added to 250 µL 
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0.2% FA (aq) and 350 µL MeOH:H2O:FA:BSA, (20:80:0.1:0.1, v/v/v/w) in a 1 mL 96-
well LoBind plate, before being vortex mixed and centrifuged. 
3.2.4 Initial Metabolite ID Experiments 
The LC-MS/MS system consisted of a Waters Acquity UPLC system (Waters Corporation, 
Milford, MA, USA) coupled to an AB SCIEX 5500 QTRAP (triple quadrupole-linear ion 
trap mass spectrometer) (Applied Biosystems/MDS SCIEX, Concord, Ontario, Canada) 
with an ESI source. Data acquisition and processing were performed using Analyst 1.5.2 
software (Applied Biosystems/MDS SCIEX). 
The mass spectrometer was operated in positive ion mode with an electrospray voltage of 
5500 V, an entrance potential of 10 V, and a declustering potential of 70 V. The source 
temperature was 600 C, the curtain gas 40 psi, and the nitrogen desolvation gases, GS1 
and GS2, were set at pressures of 60 psi and 40 psi respectively. Full scan spectra were 
acquired using quadrupole mode over the range m/z 450-1250 with a scan rate of 2000 m/z 
units/s and with unit resolution. 
Glucagon was separated on a Waters UPLC BEH C18 column (2.1 x 100 mm, 1.7 µm) 
maintained at 60 C. The mobile phase consisted of (A) 0.2% FA (ACN) and (B) 0.2% FA 
(aq). The gradient for separation was 10-50% A over 7.9 min. The column was then 
cleaned with 95% A for approx. 1 min followed by 10% A for approx. 4 min. The flow 
rate was 0.8 mL/min and the total run time 13 min. 10 µL of the “concentrated extracts” 
from plasma samples incubated at 0 hr and 25 hr at room temperature was injected, and the 
total ion chromatograms were compared to putatively identify metabolites.  
An enhanced resolution (ER) spectrum of the 25 hr sample was similarly acquired using 
linear ion trap mode with a scan rate of 250 m/z units/s over the mass range m/z 800–830. 
An enhanced product ion (EPI) spectrum of the m/z 815.6 ion from the 25 hr sample was 
similarly acquired using Q1 at unit resolution to select the precursor, and using the linear 
ion trap at a scan rate of 10,000 m/z units/s over the range m/z 100-1000 to monitor the 
product ions.  
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3.2.5 Metabolite ID Confirmation 
The LC-MS/MS system consisted of a Dionex LC system (Thermo Scientific, Waltham 
MA, USA) coupled to a Q Exactive Orbitrap system (Thermo Scientific) with an ESI 
source operating in positive ion mode. A scan range of m/z 233.4–3500 was selected with a 
resolution of 140,000 (FWHM) with centroid data acquisition. Data acquisition and 
processing were performed using Xcalibur v2.2 (Thermo Scientific). The LC conditions 
were based on those described in Section 3.2.4. A “concentrated extract” of a sample 
incubated for 75 hr at room temperature was injected (10 µL), and peaks corresponding to 
those observed during the analysis with the QTRAP were observed. 
3.2.6 Time-course Studies  
Samples were prepared and extracted as described in Section 3.2.3 after 0, 0.5, 1.5, 3, 25, 
49, and 75 hr storage at room temperature. Quantitation was performed using the  
AB SCIEX 5500 QTRAP LC-MS/MS system used for the initial metabolite identity (ID) 
experiments, but using SRM transitions; 697.5693.8, 815.6811.0, 676.9478.2, 
641.3632.3, 577.3478.2, and 811.1807.0. These transitions corresponded to the 
most sensitive SRM transitions for glucagon1-29, glucagon3-29, glucagon19-29, glucagon20-29, 
glucagon21-29 and [pGlu]
3
glucagon3–29 respectively. The nitrogen collision gas pressure was 
set to medium and all transitions used collision energies of 15-20 V and collision exit cell 
potentials of 13 V. Excel 2010 (Microsoft, Redmond, WA, USA) was used to fit 
glucagon1-29 degradation to an exponential equation. 
3.2.7 Metabolite Formation in Solution 
Glucagon stock solutions (1 mg/mL) were stored at -20 C for 310 days or under ambient 
conditions for 50 hr, and diluted to 204 ng/mL with MeOH:H2O:FA:BSA (20:80:0.1:0.1, 
v/v/v/w) prior to analysis with the SRM method described in Section 3.2.6. 
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3.2.8 Metabolite Formation in Unstablised and Aprotinin-stabilised 
Human Plasma  
 
Aprotinin-stabilised (100 KIU/mL) or unstabilised human plasma glucagon samples were 
prepared and extracted as described in Section 3.2.3. Samples were extracted after: storage 
for 0 hr, storage at room temperature or 4 C for 6 hr 20 min and 26 hr, after 4 freeze-thaw 
cycles (-20 C to +4 C) and (-80 C to +4 C), and after 1 month and 5 months storage at  
-20 C or -80 C. In all cases n=6 replicates were extracted. “Concentrated extracts” and 
“diluted extracts” were analysed using the SRM method described in Section 3.2.6. 
3.2.9 Metabolite Formation in Physiological Study Samples 
Physiological study samples were obtained from Imperial College London. The samples 
were from the set described in Section 2.2.8. In brief, they originated from seven different 
volunteers, who were each infused subcutaneously with various combinations of saline 
solution (for 6 hours on each occasion) and glucagon solutions at either 16 or 20 
pmol/kg/min (for 12 hours on each occasion). Blood samples were collected at various 
time points throughout the infusions, and plasma samples containing lithium heparin and 
stabilised with aprotinin were generated. 
The study was approved by the West London Research Ethics Committee (Reference 
No.11/LO/1782). All volunteers gave written informed consent, and the study was planned 
and performed in accordance with the Declaration of Helsinki [19]. 
A selection of the samples (n=87) were extracted using the 2D extraction procedure 
described in Chapter 2 (Section 2.2.5) and the SRM method described in Section 3.2.6. 
They were also analysed using the qualified glucagon quantitation SRM method described 
in Chapter 2 (Section 2.2.2). 
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3.3 RESULTS AND DISCUSSION  
3.3.1 Initial Metabolite ID Experiments (LRMS) 
Initial metabolite ID experiments were performed using low-resolution mass spectrometry 
(LRMS) in full scan mode (m/z 450-1250). Overlaying spectra from spiked glucagon 
human plasma samples stored at room temperature for 0 hr and 25 hr revealed several 
potential plasma metabolite peaks (Figure 3.1). 
 
 
Figure 3.1 Overlay of MS full scan total ion chromatograms (TICs) from a spiked 
glucagon human plasma sample (10 µg/mL) stored at room temperature for 0 hr (red) and  
25 hr (blue). 
Peak 1 corresponds to the parent glucagon1-29 molecule, which degrades after plasma samples are 
stored at room temperature forming metabolites associated with peaks 2-6. Peaks 2a-2c all 
contained ions similar to those expected from glucagon3-29.The peak at approx 4.7 minutes 
contained ions similar to those expected from glucagon19-29, glucagon20-29, and glucagon21-29,  these 
were found to elute at slightly different retention times (peaks labelled 3, 4, 5 respectively). Peak 6 
contained ions expected from [pGlu]
3
glucagon3–29. The low-resolution mass spectrometer used did 
not allow unambiguous metabolite identification. 
A dual x axis is shown on the chromatograms. The upper part displays the time (i.e. 4.00 – 5.10 
min for panel a)) and the lower part displays the scan number (e.g. 593 – 756 for panel a)).  
2a 
1 (Glucagon) 
2b 
3, 4, 5 
4 2c 
6 
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The mass spectrum from peak 1 contained ions corresponding to the parent glucagon1-29 
molecule, whilst peak 6 contained ions corresponding to the 3+ and 4+ charge state of the 
metabolite [pGlu]
3
glucagon3–29 observed in 20% serum (buffer) (Table 3.1). The peak at 
approximately 4.7 min was found to have several ions with m/z values consistent with 
glucagon19-29, glucagon20-29, and glucagon21-29. It was determined that these eluted at 
slightly different retention times (Peaks 3, 4, and 5 respectively).  
Peaks 2a, 2b and 2c, contained similar ions that corresponded approximately to those 
expected by the 3+ and 4+ charge state of glucagon3-29 (Table 3.1). Glucagon3-29 was not 
reported in the related matrix 20% serum (buffer) in the literature [15], as it was suggested 
that the cyclisation to form [pGlu]
3
glucagon3–29 occurred immediately (Figure 3.2). Such 
cyclisation may be performed by a transglutaminase serum enzyme such as glutaminyl 
cyclase [20]. It is possible that such enzymes are less active in plasma than in buffered 
serum, thereby allowing significant levels of glucagon3-29 to remain. The enzymatic nature 
of the cyclisation may also explain why it does not occur for position-2-modified glucagon 
analogs [18], as these may introduce steric hindrance. 
 
Table 3.1 Potential metabolites formed by glucagon in human plasma identified using 
LRMS. 
Metabolites associated with peaks 2-6 were putatively identified using LRMS, however mass 
accuracy was poor and metabolites associated with peaks 2a- 2c could not be distinguished from 
one another. 
Peak Observed 
(m/z) 
Putative 
charge 
state 
Putative 
mass 
(Da) 
Putative ID Average 
theoretical 
mass (Da) 
Mass 
accuracy 
(ppm) 
1 697.5 +5 3482.5 
glucagon1-29 3482.7473 
a 
-82 
1 871.5 +4 3482.0 -224 
2a 815.1 +4 3256.4 
glucagon3-29 (?) 3258.53072 
a 
-663 
2a 1086.5 +3 3256.5 -630 
2b 815.3 +4 3257.2 
glucagon3-29 (?) 3258.53072 
a 
-418 
2b 1086.4 +3 3256.2 -722 
2c 815.1 +4 3256.4 
glucagon3-29 (?) 3258.53072 
a 
-663 
2c 1087.4 +3 3259.2 198 
3 577.3 +2 1152.6 glucagon21-29 1153.30694 
a -627 
4 641.3 +2 1280.6 glucagon20-29 1281.43616 
a -665 
5 676.8 +2 1351.6 glucagon19-29 1352.51406 
a -687 
6 811.1 +4 3240.4 
[pGlu]3glucagon3–29 3241.5002 
b 
-349 
6 1081.2 +3 3240.6 -285 
a
Theoretical average mass value calculated from peptide sequence [21] 
b
Calculated by subtracting NH3 average molecular mass from glucagon3-29 mass.  
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Figure 3.2 Metabolism of glucagon by DPP IV in solution and in 20% human serum 
(buffer) reported in the literature. 
Glucagon3-29 was not reported in 20 % serum (buffer) in the literature [15], as it was suggested to 
cyclise immediately to form [pGlu]
3
glucagon3–29. [pGlu]
3
glucagon3–29 was however detected in 
plasma in the work described in this chapter (Table 3.1 and Table 3.2). 
 
Previously, double peaks were observed for glucagon3-29 in solution, and these were 
attributed to cis/trans isoforms of the truncated molecules[15]. To investigate whether this 
could be the origin of the multiple peaks observed in human plasma, a higher resolution 
scan was acquired using the ion trap functionality of the mass spectrometer (Figure 3.3). 
The first peak of the isotope cluster detected for 2a was m/z 814.8, whilst for 2c it was  
m/z 815.1. Taking into account the 4+ charge state, this corresponds to approximately one 
mass unit difference, demonstrating that the species are not isomers. The spectrum for 2b 
was not of a high enough quality for a similar comparison to be made. Often when a 
peptide is one mass unit higher than expected it is indicative that a deamidation has 
occurred; however, this is not thought to be the case here as the deamidated product 
usually elutes earlier than the native form. 
The MS/MS spectra suggested that 2a and 2b were similar, but that 2c was markedly 
different showing less overall fragmentation as evidenced by the high intensity of the 
precursor ion (Figure 3.3). Assuming neutral losses (i.e. no loss of charge) metabolites 2a 
and 2b show single losses of 17.6 Da and 19.2 Da respectively; the loss of 17.6 Da may 
correspond to water. Whereas metabolite 2c shows two product ions, which may be due to 
sequential losses of 17.2 Da and 17.6 Da, potentially corresponding to water and ammonia. 
Despite this putative structural information, it was not possible to confirm the identity of 
metabolites 2a, 2b or 2c at the resolution and mass accuracy offered by LRMS. 
Glucagon
3-29
 pyroglutamyl 
glucagon3–29 
Glucagon
1-29
 
Glucagon
5-29
 
DPP IV 
(Pathway in solution) 
DPP IV 
(Pathway in 20% serum (buffer) & solution) 
Unknown transglutaminase enzyme 
(Pathway in 20% serum (buffer)) 
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Figure 3.3 Ion trap LRMS data of a spiked glucagon human plasma sample (10 μg/mL) 
stored at room temperature for 25 hr. 
Left: MS Spectra. Right: Product ion (MS/MS) data of m/z 815.6, from a spiked glucagon human 
plasma sample 
 
Peaks 2a-2c all contained MS ion masses similar to those expected for glucagon3-29. The first peak 
of the MS isotope cluster for 2a was m/z 814.8, whilst for 2c it was m/z 815.1. The 1 Da 
difference (considering the 4+ charge state) demonstrates that these species are not isomers. The 
MS spectrum in 2b was not of high enough quality for a similar comparison to be made.  
2c also gave markedly different MS/MS spectra to those of 2a or 2b, corroborating its distinct 
identity. Despite this putatively structural information, it was not possible to confirm the identity of 
these metabolites at the resolution and mass accuracy offered by LRMS. 
 
In summary, LRMS allowed 7 putative metabolites to be detected and putatively identified 
(Table 3.1). However due to the low mass accuracy and resolution of the technique, it was 
not possible to distinguish between metabolites corresponding to peaks 2a, 2b, and 2c, all 
of which were assigned the putative identity of glucagon3-29. Therefore further studies were 
performed using high-resolution mass spectrometry (HRMS).  
  
2a 
2b 
2c 
2a 
2b 
2c 
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3.3.2 Metabolite ID Confirmation (HRMS) 
High-resolution mass spectrometry (HRMS) at a resolving power (FWHM) of 140,000 at 
m/z 200, allowed peaks separated by m/z 0.001 units to be resolved [22], as exemplified in 
Figure 3.4. This enabled <5 ppm mass accuracies to be achieved, rather than the several 
hundred ppm offered by the LRMS method, and therefore provided sufficient mass 
accuracy for the unequivocal identification of novel species. In addition, the HRMS 
instrument has a higher m/z limit than the LRMS (m/z 4000 vs. m/z 1250) allowing a 
greater number of charge states to be observed for additional confirmation.  
 
Figure 3.4 HRMS data observed for peaks 2a (top), 2b (middle), and 2c (bottom). 
Much higher resolution was obtained than with the ion trap LRMS instrument (Figure 3.3). The 
lowest m/z with significant peak height in each spectra (814.87933, 814.87933 and 815.13751 for 
2a, b and c respectively) is attributed to the monoisotopic mass of the underlying species. The 
regular spacing between isotopic peaks is due to increasing incorporation of 
13
C atoms; the m/z 
differences between these peaks confirm that 2a), b) and c) all originate from 4+ charged species.  
Observed m/z suggest 2a and 2b correspond to isomers of oxidised [pGlu]
3
glucagon3–29, whereas 2c 
corresponds to glucagon 3-29, all with 1.5 ppm mass accuracy. 
2a) 
2b) 
2c) 
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A spiked glucagon human plasma sample (10 µg/mL) stored at room temperature for 75 hr 
was analysed using HRMS. Peaks corresponding to those observed during the analysis 
with the QTRAP were identified and metabolite IDs determined (Table 3.2). Peak 6 was 
confirmed as [pGlu]
3
glucagon3–29  (2.5 ppm) and peak 2c was assigned as glucagon3-29 
(2.0 ppm). Peaks 2a and 2b were assigned as oxidised [pGlu]3glucagon3–29 (1.5 ppm). 
The assignments of peaks 2a, 2b and 2c are corroborated by the MS/MS data acquired by 
LRMS (Figure 3.3), as only glucagon3-29 can form a product ion corresponding to the loss 
of the terminal ammonia, as this has already occurred from the oxidised [pGlu]
3
glucagon3–
29 forms due to pyroglutamisation. 
Table 3.2 Glucagon metabolites in human plasma confirmed using HRMS. 
Glucagon metabolites were confirmed within 2.5 ppm mass accuracy using HRMS, except for the 
minor metabolites associated with peaks 3-5, which, likely due to the lower MS signal, were 
confirmed within 3.8 ppm. Mass accuracies are considerably better than those obtained using 
LRMS, which are in the region of several hundred ppm (Table 3.1). 
Peak Observed 
(m/z) 
Charge 
state 
Metabolite ID Theoretical 
(m/z) 
Mass accuracy 
(ppm) 
1 697.12921 +5 
glucagon1-29 
697.13042 
a
 -1.7 
1 871.15967 +4 871.16120 
a
 -1.8 
2a 814.87933 +4 
oxidised [pGlu]
3
glucagon3–29 
814.88056 
b
 -1.5 
2a 1086.17004 +3 1086.17165 
b
 -1.5 
2b 814.87933 +4 
oxidised [pGlu]
3
glucagon3–29 
814.88056 
b
 -1.5 
2b 1086.17029 +3 1086.17165 
b
 -1.3 
2c 815.13751 +4 
glucagon 3-29 
815.13847 
a
 -1.2 
2c 1086.51331 +3 1086.51553 
a
 -2.0 
3 577.26898 +2 
glucagon 21-29 
577.27097 
a
 -3.4 
3 1153.53027 +1 1153.53466 
a
 -3.8 
4 641.29828 +2 
glucagon 20-29 
641.30026 
a
 -3.1 
4 1281.58899 +1 1281.59324 
a
 -3.3 
5 676.81628 +2 
glucagon19-29 
676.81881 
a
 -3.7 
5 1352.62651 +1 1352.63035 
a
 -2.8 
6 810.87982 +4 
[pGlu]
3
glucagon3–29 
810.88183 
b
 -2.5 
6 1080.8374 +3 1080.84001 
b
 -2.4 
a 
Theoretical monoisotopic value calculated from peptide sequence [21] 
b
 Value calculated from other masses in table and the masses of the modifications [23] 
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The oxidised forms of [pGlu]
3
glucagon3–29 are likely to be two diastereomeric methionine 
sulfoxide (Met(O)) peptides formed by methionine oxidation (Figure 3.5). Met(O) peptides 
are the only stable peptide oxidation products, unlike for example reversible cysteine 
sulfenic acid formation, which only act as transient intermediates [24]. The S and R forms 
of Met(O) peptides can, however, be reduced back to Met by methionine sulfloxide 
reductases MsrA and MsrB respectively, in roles associated with protection of peptides 
against oxidative stress and regulation of the aging process [25]. 
It is not possible to assign each peak to a particular methionine sulfoxide diastereoisomer, 
as no robust method exists [26]. The partially resolved nature of peaks 2a and 2b 
corroborates their assignment, as peptides containing diastereomers of Met(O) are known 
to be challenging to separate by reversed-phase liquid chromatography [26]. 
 
Figure 3.5 Diastereomeric structure of methionine sulfoxide, Met-S-(O) and Met-R-(O). 
Met-S-(O) denotes the diastereomer with the (S) configuration at the alpha carbon and (S) 
configuration at the sulphur, whereas Met-R-(O) indicates the (S) configuration at the alpha carbon 
and (R) configuration at the sulphur. 
 
The isomeric oxidised [pGlu]
3
glucagon3–29 metabolites at peaks 2a and 2b were assigned as the 
diastereomeric methionine sulfoxide (Met(O)) peptides. The partially resolved nature of peaks 2a 
and 2b corroborates this assignment, as such peptides are known to be challenging to separate by 
reversed-phase liquid chromatography. 
 
Peaks 3, 4, and 5 were confirmed as glucagon21-29, glucagon20-29 and glucagon19-29 to within 
3.8 ppm. These peaks showed lower mass accuracies than the other metabolites, probably 
due to their lower abundances limiting the mass spectrometer signal.  
Glucagon19-29, or miniglucagon, has previously only been identified in liver plasma 
membranes [11] and pancreatic cells [12], whereas glucagon20-29 and glucagon21-29
 
 have 
not been previously reported. Miniglucagon has its own unique biological activity, which 
is opposite to that of gluagon1-29, and thus acts as a modulator [12]. Further studies are 
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needed to determine whether glucagon20-29 and glucagon21-29
 
might have similar roles. It 
has been suggested that glucagon19-29, is formed by insulin degrading enzyme (IDE), a 
neutral thiol-metalloendopeptidase, also called insulysin, in liver cells by the cleavage of 
Arg
18
-Ala
19 
bonds [27]. However, other studies have suggested that IDE cleaves at  
Arg
17
-Arg
18
 bonds with the formation of glucagon18-29, which may then be converted into 
glucagon19-29 by an unidentified aminopeptidase-like enzyme [28]. It is possible that such 
residual hepatocyte enzymes are present in plasma, leading to the formation of  
glucagon19-29, and perhaps to the formation of glucagon20-29 and glucagon21-29 by similar 
unidentified aminopeptidase-like enzymes. 
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3.3.3  Time-course Studies  
Incubation of glucagon in human plasma at room temperature for various times (0, 0.5, 1.5, 
3, 25, 49 and 75 hr) showed the rate of glucagon degradation and metabolite formation 
(Figure 3.6). Due to the differences in abundances of the species it was not possible to 
accurately analyse all species in the same run, as an extract concentration that ensured 
sufficient signal for lower abundant species led to detector saturation for higher abundant 
species. Therefore the extracts were analysed twice: once “concentrated” and once 
“diluted”. 
LC-MS/MS peak areas were used to create the metabolite profiles. Whilst these are not 
expected to be absolutely related to molar metabolite abundances, due to differences in the 
ionisation efficiency of the metabolites, there is expected to be a loose correlation.  
Glucagon1-29 decayed with an observed half-life (t1/2) of 12.5 hr. This is considerably less 
than the calculated t1/2 of 19.2 hr from the fitted exponential curve, demonstrating that the 
decay is only approximately exponential. Glucagon3-29 was the metabolite that gave the 
most intense signal between 0.5 and 3 hr, whilst the previously reported 20% serum 
(buffer) metabolite [pGlu]
3
glucagon3–29
 
was the most intense at later time points. This was 
expected due to the reported irreversible cyclisation of the N-terminal of glucagon3-29
 
to 
form [pGlu]
3
glucagon3–29 [15]. 
The [pGlu]
3
glucagon3–29 signal maximises at approximately 32 hr before decreasing, 
indicating that it is itself metabolised. Oxidised metabolites are first detected at 1.5 hr, 
compared to 0.5 hr for the [pGlu]
3
glucagon3–29 metabolite. The oxidised a and b forms 
show similar profiles and maximise at approximately 30 hr, a similar time to the parent 
metabolite. However the b form starts to increase again at 75 hr, whereas the a form 
continues to decrease. In addition, the a form gives a lower signal than the b form. Whilst 
the oxidation of the free amino acid Met by hydrogen peroxide in aqueous solution yields a 
racemic diastereomeric mixture of methionine sulfoxides [29], this will not necessary be 
the case when Met is part of a larger peptide and undergoing oxidation. Therefore, it is not 
unexpected that different signals were measured, or that the profiles for the two oxidised 
metabolites are slightly different. 
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Figure 3.6 Degradation of glucagon and formation of metabolites, by human plasma 
incubated at room temperature, monitored by SRM mass spectrometry. 
Top (injection of the “diluted extract”); Middle+Bottom (injection of the “concentrated extract”). 
 
Top- Glucagon decayed with an observed t1/2 of 12.5 hr, considerably less than the calculated t1/2 
from the fitted exponential curve (19.2 hr), demonstrating that the decay was only approximately 
exponential. The major metabolite [pGlu]
3
glucagon3–29 peaked at approximately 32 hr. 
 
Middle- The glucagon3-29 metabolite gave the most intense signal between 0.5 and 3 hr, whilst 
[pGlu]
3
glucagon3–29  was most abundant at later time points. This was attributed to irreversible 
cyclisation of the N-terminal of glucagon3-29
 
to form [pGlu]
3
glucagon3–29. Glucagon20-29 was overall 
the most abundant of the minor metabolites, and its abundance did not appear to have peaked. 
Bottom- 5 minor metabolises were detected. Oxidised metabolites were first detected after 1.5 hr,  
1 hr after detection of their parent metabolite, with the different isomers forming at different rates. 
The profiles of glucagon19-29, glucagon20-29 and glucagon21-29 suggest they are not formed 
sequentially by a simple mechanism. 
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The novel metabolite glucagon21-29 initially had the fastest rate of formation of the minor 
metabolites; however, this slowed with time and abundance peaked at approximately 49 hr 
before decreasing. In contrast glucagon19-29, or miniglucagon, and the novel metabolite 
glucagon20-29 showed relatively linear rates of formation, and abundance of these 
metabolites does not appear to have peaked. It might be expected that these small peptides 
are formed sequentially, however the kinetics plots do not corroborate a simple model for 
this, as the larger peptides (glucagon19-29
 
and glucagon20-29)
 
continue to increase in 
abundance with time, whereas the smallest peptide (glucagon21-29) plateaus and starts to 
decrease. Longer time course studies may allow the metabolism of these small peptides to 
be better understood, but for a more complete understanding synthetic peptides of these 
metabolites could be acquired and incubated.  
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3.3.4 Glucagon Degradation and Metabolite Formation in Human 
Plasma Samples Subjected to Typical Laboratory Handling Conditions  
 
No metabolites were observed when glucagon solutions at 1 mg/mL were stored at -20 C 
for 310 days or under ambient conditions for 50 hr, hence confirming that the metabolites 
did not arise from impurities in the reference material, nor are they formed in solution 
under normal experimental conditions. This corroborates the high stability of glucagon 
previously noted in stored solutions (Section 2.3.3). 
In order to assess the formation of metabolites under typical laboratory handling 
conditions, samples were prepared in unstabilised human plasma at 10 µg/mL. Due to the 
controversy of the ability of aprotinin to prevent glucagon degradation [1][2], further 
samples were also prepared in plasma containing 100 KIU/mL aprotinin to investigate this. 
Figure 3.7 and Figure 3.8 shows metabolite formation under the applied conditions. 
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Figure 3.7 Degradation of glucagon and formation of metabolites, in human plasma 
samples placed under various conditions monitored by SRM mass spectrometry.  
Glucagon1-29 was spiked at 10 µg/mL into either unstabilised or aprotinin stabilised human plasma 
and samples were subjected to various stress conditions as shown in the Figure.  
 
The Figure was created from data acquired by injecting the “concentrated extract” and 
consequently underestimates glucagon1-29 degradation due to mass spectrometer detector saturation. 
A “diluted extract” was injected to assess glucagon1-29 degradation. 
 
Glucagon1-29 degradation was noted in all stress conditions shown. As expected, glucagon1-29 
degradation was greater in samples stored for longer periods or time and/or at higher temperatures. 
F/T cycling led to higher degradation than expected from the time samples spent at the processing 
temperature alone, suggesting the F/T process itself leads to additional degradation. 
 
Glucagon3-29 was the most intense metabolite at low levels of glucagon1-29 degradation, whilst 
[pGlu]
3
glucagon3–29 was the most intense at higher levels of degradation, in agreement with the 
order of formation noted in time course studies described in Section 3.3.3. The minor metabolites 
(glucagon19-29, glucagon20-29 and glucagon21-29) were detected in all samples with increasing 
abundance at greater glucagon1-29 degradation, reflecting their formation during the time course 
studies. Interestingly, oxidised [pGlu]
3
glucagon3–29  was not observed in the F/T -80C samples, 
despite similar levels of [pGlu]
3
glucagon3–29  being present to that in the F/T -20 C samples. 
 
0
1
2
3
4
5
6
7
8
L
o
g
1
0
 p
ea
k
 A
re
a
 (
co
u
n
ts
) 
glucagon 1-29 oxidised [pGlu]3 glucagon 3–29 a 
oxidised [pGlu]3 glucagon 3–29 b glucagon 3-29
glucagon 19-29 glucagon 20-29
glucagon 21-29 [pGlu]3 glucagon 3–29 
157 
 
Figure 3.8 Degradation of glucagon and formation of metabolites, in human plasma 
samples following storage in a freezer at -20 C or -80 C for 5 months, and monitored by 
SRM mass spectrometry. 
Glucagon1-29 was spiked at 10 µg/mL into either unstabilised or aprotinin stabilised human plasma 
and samples were stored under various conditions as shown the Figure. 
Glucagon1-29 degradation was noted in all stress conditions shown. Similar to Figure 3.7,  
glucagon1-29 degradation is under represented in Figure 3.8 due to mass spectrometer detector 
saturation, resulting from injection of the “concentrated extract”.  
Glucagon3–29 was the most abundant metabolite formed in all storage conditions, reflecting the 
relatively low extent of glucagon1-29 degradation, and its early formation during time course studies 
(Section 3.3.3). [pGlu]
3
glucagon3–29  was the  second most abundant metabolite. The minor 
metabolites (glucagon19-29, glucagon20-29 and glucagon21-29) were detected in all samples. 
Interestingly, oxidised [pGlu]
3
glucagon3–29  was not observed in samples stored at -80C, despite 
similar levels of [pGlu]
3
glucagon3–29  being present to that in the -20 C samples. 
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Glucagon1-29 degradation was observed across all of the stress conditions investigated, 
except for the aprotinin-stabilised samples frozen for 1 month (Table 3.3). Apart from 
these samples the use of aprotinin had a negligible effect, for example after 6 hr 20 min at 
room temperature, glucagon1-29 in unstabilised samples had degraded to 58.3% of the 0 hr 
level, whereas in aprotinin-stabilised samples it had degraded to 60.7%. Whilst aprotinin’s 
lack of stabilisation ability has been reported previously [2], this study used C-terminal 
directed antibodies and antibodies directed against the 6-15 region of glucagon, and 
therefore was not able to assess the impact of aprotinin in preventing N-terminal 
degradations. In contrast, the LC-MS/MS assay assessed degradation across the entire 
molecule. It appears that aprotinin only has a minimal stabilising effect, which requires 
slow metabolism kinetics, such as those experienced in frozen samples, to be observed.  
Table 3.3 Glucagon stability in plasma after 1 month and 5 months storage in a freezer. 
Glucagon1-29 showed degradation in aprotinin and unstabilised plasma to similar extents following 
5 months storage at either -20 C or -80 C. However, aprotinin prevented degradation when 
samples were stored for 1 month at either temperature, suggesting it had limited stabilisation effect.  
 Sample 
(stabiliser/ storage conditions) 
% stability 
1 Month 5 Months 
Aprotinin stabilised (-20 C) 103.4 86.6 
Unstabilised (-20 C) 88.1 85.5 
Aprotinin stabilised (-80 C) 98.8 91.6 
Unstabilised (-80 C) 89.6 91.9 
 
As expected, lowering the temperature reduced glucagon degradation. For example, after  
6 hr 20 min at 4 C, glucagon had degraded to approximately 86% of 0 hr levels; similar to 
that observed in Chapter 2 (Section 2.3.3). Conversely increasing the storage time 
increased degradation. For example, after 26 hr at room temperature glucagon had 
degraded to approximately 11% of 0 hr levels. Subjecting samples to 4 freeze-thaw cycles 
(cycling at -80 C / +4 C, or -20 C / +4 C) led to degradation to approximately 84% of  
0 hr levels, with no significant difference between the different storage temperatures. The 
total amount of time these samples spent at 4 C before extraction was 4 hr 10 min, 
although the degradation is similar to that of non-freeze-thaw samples left for 6 hr 20 min 
at 4C, suggesting the process of freeze-thawing may lead to additional degradation, which 
is again consistent with the data reported in Chapter 2 (Section 2.3.3). 
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Glucagon3-29 was the most intense metabolite for samples with relatively low levels of 
glucagon degradation, for example those stored for 6 hr 20 min at 4 C, freeze thaw 
samples, and frozen samples. This is in agreement with the time-course studies above, 
which showed that glucagon3-29 levels peak, before further metabolism into 
[pGlu]
3
glucagon3–29. Despite being the most intense metabolite, the response was fairly 
low, for example the 6 hr 20 min at 4 C samples gave glucagon3-29 responses of 
approximately 6% their 0 hr glucagon1-29 response. However, as explained in Section 3.3.3, 
the responses do not necessary correlate with abundances. The formation of such 
metabolites would lead to inaccurate quantitation if C-terminal directed antibodies were 
used as the basis of an immunoassay quantitation method. In fact, all of the metabolites 
detected have intact C-terminals, so all have the potential to cross react with such 
antibodies.  
Samples stored at -80 C showed less glucagon degradation than those at -20 C  
(Table 3.3) and correspondingly metabolite formation was greater at -20 C than -80 C 
(Figure 3.8). Interestingly, oxidised [pGlu]
3
glucagon3–29  was not observed in samples 
stored at -80 C, despite similar levels of [pGlu]3glucagon3–29  being present to those in the 
-20 C samples. 
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3.3.5 Metabolite Formation in Physiological Study Samples 
A subset of plasma samples from a physiological study involving the infusion of glucagon 
(Section 3.2.9) were extracted using the sensitive 2D extraction method developed in 
Chapter 2 (Section 2.2.5) before analysis by SRM to assess metabolite formation. The 
samples were analysed in two sets with the second set being assayed two months after the 
first. The extracts were also analysed using the quantitative SRM method developed in 
Chapter 2 (Section 2.2.2) and found to contain a maximum of 1.3 ng/mL of glucagon, 
which is 7,692 fold less than the 10 µg/mL samples used for the experiments described 
above. Because of the low levels, it was not expected to observe all the metabolites. 
 
Despite the low glucagon concentrations, glucagon3-29 was detected in the majority of 
samples (78%) and was found to approximately track the glucagon1-29 levels (Figure 3.9). 
The first set of samples (n=25) gave mean glucagon3-29 levels of 14.3% (CV=33.4) of the 
glucagon1-29 levels (Figure 3.9a, c, and d), whilst the second set (n=62) gave mean 
glucagon3-29 levels of 9.0% (CV=28.1) (Figure 3.9b). [pGlu]
3
glucagon3–29 was detected in 
10% (n=9) of the samples, all of which were from one subject (volunteer 1, visit 2) and 
analysed as part of the first set of samples (Figure 3.9c and d). The levels were 
approximately half of glucagon3-29 levels (mean= 48.3%, CV=12.9%, 2 outliers excluded). 
The low levels of glucagon probably prevented this metabolite, and others, from being 
detected in other samples. If glucagon is measured by immunoassay techniques that do not 
require an intact N terminus [2], then these metabolites could cause glucagon levels to be 
overestimated. 
Freshly prepared QC samples were extracted alongside the clinical samples, and did not 
contain detectable metabolites, thereby demonstrating that those observed were not an 
artefact of the extraction procedure. Clinical samples were stored at -20 C before analysis, 
and as described previously, metabolites were formed in spiked samples stored under these 
conditions. Specifically, after 5 months storage glucagon3-29 was detected at 3.3% of 
glucagon1-29 levels (CV=8.7%) whilst [pGlu]
3
glucagon3–29 
 
was detected at 23.1% of 
glucagon3-29 levels (CV=11.9%); these values were lower at 2.8% (CV=3.6%) and 11.8% 
(CV=15.1%) after 1 month storage. However, as clinical samples were analysed within 5 
months and their mean detected glucagon3-29 levels are up to 4.3-fold greater, and mean 
[pGlu]
3
glucagon3–29
  
levels are 2.1-fold greater, than those observed in the spiked samples 
stored for 5 months, this suggests that at least some metabolism occurs in vivo.  
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Figure 3.9 Glucagon metabolites detected in clinical samples from three representative 
volunteers. 
a + b) The glucagon3-29 metabolite was detected in samples from Volunteer 7 & 4, and found to 
track glucagon1-29 levels. Panel b) contains glucagon3-29 scaled by a factor of ten to emphasise the 
relationship to the parent (glucagon1-29) response. 
 
c) [pGlu]
3
glucagon3–29, was only detected in Volunteer 1, visit 2, and was at a lower level than 
glucagon3–29. 
 
d) The glucagon1-29 response has been removed from panel c) to create d) to emphasise that 
[pGlu]
3
glucagon3–29 tracks glucagon3–29 formation. 
 
Glucagon metabolites were present at higher levels than expected from the degradation of 
glucagon3-29 during storage, suggesting at least some of the metabolites are formed in vivo. 
 
Glucagon infusions conditions at point of sample collection are described Figure 2.12.  
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3.4 CONCLUSION 
Metabolites formed from the incubation of glucagon1–29 in human plasma have been 
identified using high-resolution mass spectrometry. The presence of the previously 
reported 20% serum (buffer) metabolite [pGlu]
3
glucagon3–29 was confirmed; however 
significant amounts of glucagon3–29 were detected, 
 
which has not been reported in buffered 
serum. In fact, at low levels of glucagon metabolism this was the major metabolite. 
Glucagon19-29, or miniglucagon, was also identified in plasma, whereas it had previously 
only been observed in liver plasma membranes [11] or pancreatic cells [12]. The novel 
metabolites glucagon20-29 and glucagon21-29 were also identified. Further studies are needed 
to determine whether these, like minglucagon, have an important function in vivo. In 
addition, two oxidised forms of [pGlu]
3
glucagon3–29 were identified. All of the metabolites 
detected contain an intact C-terminal and have the potential to cross-react with glucagon1-29 
immunoassays that are directed again this portion of the molecule [2]. This could lead to 
inaccurate glucagon1-29 quantitation and consequently clinical decisions could be made on 
the basis of inaccurate data. 
Despite the low levels of glucagon present in the clinical samples, the glucagon3-29 
metabolite was detected in the majority of them, and was the major metabolite, whilst  
[pGlu]
3
glucagon3–29 was detected in just one subject. However, at least some of the 
metabolites observed are likely to be formed as a result of in vitro plasma protease 
metabolism that occurs during sample handling rather than being formed in vivo.  
Metabolite formation and glucagon degradation was investigated under various stress 
conditions, representative of typical laboratory sample handling conditions. Aprotinin 
stabilisation was found to have negligible effect, demonstrating more effective stabilisation 
approaches should be developed. The initial glucagon3-29 metabolite may be formed 
following the action of DPP IV on glucagon1-29, therefore enzyme inhibitors against this 
should be investigated. However further work is required to confirm all of the enzymes 
responsible for glucagon metabolism.  
The formation of the plasma protease metabolites identified in this chapter could be 
monitored during the development of stabilisation strategies to assess their effectiveness, 
and to suggest further refinement. Once effective strategies are developed, these will 
enable the accurate determination of glucagon1-29 concentrations from clinical samples, as 
well as that of in vivo glucagon metabolites, which may be of biological interest. 
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Chapter 4 Development of a UHPLC-MS/MS 
(SRM) Method for the Quantitation of Endogenous 
Glucagon and Dosed GLP-1 from Human Plasma 
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4.1 INTRODUCTION 
The LC-MS/MS method described in Chapter 2 for the quantitation of glucagon from 
human plasma was a significant improvement over those in the peer-reviewed literature, 
having the lowest qualified LLOQ of 25 pg/mL. This enabled the quantitation of 
endogenous glucagon from the majority of healthy volunteers; however glucagon was not 
present above the LLOQ in 42% (10/24) of the samples limiting the method’s applicability. 
Extrapolation of the calibration line, or the addition of surrogate matrix calibration 
standards below this level, enabled indicative concentrations to be determined for the 
majority (70% (7/10)) of such samples. However these concentrations were treated with 
caution as the satisfactory performance of surrogate matrix STD or QC samples below the 
25 pg/mL LLOQ did not necessarily correspond to that of plasma samples (Section 2.3.4). 
This is due to differences in the recovery and matrix effects between the matrices; the  
25 pg/mL qualified LLOQ was determined taking these differences into account, ensuring 
plasma samples at this concentration had signal-to-noise of at least 5:1. 
Clearly a method with a lower qualified LLOQ is desirable; however this requires 
additional development to improve sensitivity in plasma extracts. This could be achieved 
by further optimisation of the LC-MS/MS system and/or re-optimisation of the extraction 
procedure to improve plasma sample recovery and/or reduce matrix suppression. Such 
developments are described in this chapter. Part of the development included an extensive 
assessment of the use of the mobile phase supercharging reagent m-NBA to improve 
sensitivity, a strategy that is often overlooked for peptide bioanalysis (Section 1.4.1.3).  
The extraction procedure described in Chapter 2 (Section 2.2.5) took two working days to 
complete, which, whilst similar to some immunoassays, is longer than typical LC-MS/MS 
bioanalytical methods. Similarly the UHPLC gradient was relatively long at approx. 7 
min/sample. Therefore, this chapter includes refinements to reduce these times, 
significantly improving throughput. Further refinements include the addition of a SIL 
internal standard to improve robustness. Specificity was assured via the novel use of  
m-NBA, to obtain a sensitive qualifier SRM transition. Reproducibility was assessed by 
reanalysing a selection of samples. 
Instability of glucagon was noted in plasma under typical sample handling conditions 
(Section 2.3.3), therefore the method in Chapter 2 was described as “qualified” rather than 
“validated.” The formation of metabolites under such conditions (Section 3.3.4), 
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demonstrates that instability is at least partly due to metabolism, rather than solely physical 
processes, such as adsorption or aggregation. The addition of protease inhibitors to samples 
should improve stability. However, the commonly used serine protease inhibitor aprotinin 
was shown to be ineffective (Section 3.3.4). 
One simple and effective approach to reduce degradation is to shorten the time that plasma 
samples are handled at the processing temperature (4C). Periods shorter than the 6 hr 20 
min reported (Section 2.3.3 and Section 3.3.4), may reduce its significance. Similarly, the 
effect of instability on freeze-thaw cycling (Section 2.2.3 and Section 3.3.4) could be 
minimised by ensuring that samples are analysed after only one freeze/thaw cycle. Such 
approaches were used for the method described in this chapter, pending the development of 
alternative stabilisation approaches, which may use alternative enzyme inhibitors, such as 
DPP IV inhibitors. 
In order to shorten sample handling times, refinements were made to the extraction method 
to reduce the set-up time and the time prior to protein precipitation. The sample collection 
procedure was also modified to collect multiple sub-aliquots from samples enabling the use 
of unadulterated samples for reanalysis, avoiding multiple freeze-thaw cycles. 
In addition to the refinements described above, the method was expanded to include GLP-1 
as a secondary analyte, which can be of interest alongside glucagon (Section 1.9.4). 
Furthermore, many GLP-1 immunoassays perform poorly, necessitating the development 
of alternative methodologies (Section 1.9.5 and Section 1.9.6). The refined and expanded 
method was qualified using fit-for-purpose criteria based on key experiments from FDA 
[1] and EMA [2] bioanalytical validation guidelines. It was also cross-validated against 
two established immunoassays using the same physiological study sample set.   
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4.2 EXPERIMENTAL 
4.2.1 Chemicals and Materials 
Certified human glucagon (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) was obtained 
from EDQM (Strasbourg, France). The analogue internal standard (IS) (des-thr
7
-glucagon) 
(HSQGTFSDYSKYLDSRRAQDFVQWLMNT) and stable isotope labelled (SIL) internal 
standard (HSQGT-[
13
C9;
15
N]F-TSDYSKYLDSRRAQDFVQW-[
13
C6;
15
N]L-MNT) were 
obtained from Bachem (Bubendorf, Switzerland). GLP-1 (7-36) amide 
(HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR - NH2) was also obtained from Bachem.  
Water was purified by a Triple Red water purifier (Long Crendon, U.K.). When required, 
sample extracts were evaporated using a Porvair MiniVap (Norfolk, U.K.) with nitrogen at 
60 litres per minute. All chemicals and solvents were HPLC or analytical reagent grade 
and purchased from either Fisher Scientific (Loughborough, UK) or Sigma Aldrich (St 
Louis, Missouri, USA). 
4.2.2 Preparation of Stock and Working Solutions 
Stock solutions of glucagon and glucagon internal standards (1 mg/mL), and stocks of  
GLP-1 (0.1 mg/mL), were prepared in borosilicate glass vials using surrogate matrix 
[MeOH:H2O:FA:BSA, (20:80:0.1:0.1, v/v/v/w); typically 200 mL MeOH, 800 mL H2O ,  
1 mL FA and 1 g BSA]. 
For initial method development, working solutions of glucagon were prepared to 1 µg/mL, 
100 ng/mL, 75 ng/mL, and 10 ng/mL by dilution of the stock solution with surrogate 
matrix. These solutions are also referred to as surrogate matrix samples. An analogue 
glucagon ISWS was similarly prepared to 100 ng/mL. 
For later work, combined glucagon and GLP-1 working solutions were prepared by 
dilution with surrogate matrix to create nine calibration standard spiking solutions (300, 
500, 900, 2000, 6000, 12000, 20000, 37000 and 40000 pg/mL), and six quality control 
spiking solutions (300, 500, 900, 1500, 4000 and 35000 pg/mL). A mixed ISWS 
containing both analogue glucagon and SIL glucagon was similarly prepared at 20 ng/mL.  
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All stock and working solutions were prepared to a volume of 10 mL and were stored at  
-20 C when not in use, as glucagon solutions have been shown stable under such 
conditions (Section 2.3.3). 
4.2.3 Method Development: Re-optimisation 
The method described in Chapter 2 was initially refined to increase sensitivity, robustness 
and throughput. When needed, plasma samples were generated by 100-fold dilution of the 
working solutions detailed in Section 4.2.2 with human plasma (EDTA) and were handled 
on wet ice (ca. 4 C). GLP-1 was added later as a secondary analyte (Section 4.2.4.3) 
The LC-MS/MS system consisted of a Waters Acquity UPLC system (Waters Corporation, 
Massachusetts, USA) coupled to an AB SCIEX 5500 triple quadrupole mass spectrometer 
(Applied Biosystems / MDS SCIEX, Ontario, Canada) with an ESI source. The LC-
MS/MS method for method development was based on that described previously in 
Section 2.2.2. Replicates (n=3) were performed for each experiment and mean data are 
presented, unless stated otherwise. 
4.2.3.1 Extraction Optimisation 
4.2.3.1.1 Protein Precipitation: Solvent Composition 
Multiple (n=36) aliquots (100 µL) of glucagon plasma samples (10 ng/mL) were 
transferred to a 1 mL 96-well LoBind plate from Eppendorf (Stevenage, U.K.), 12.5 µL 
analogue glucagon ISWS added to each well, and the plate briefly vortex mixed. The 12 
precipitation solvents detailed in Figure 4.1 were used to precipitate samples, using 300 µL 
solvent for each replicate. The plate was vortex mixed for 5 min, centrifuged for 10 min at 
2300 x g, then 200 µL supernatant was manually transferred to a second 1 mL 96-well 
LoBind plate. The plate was evaporated to dryness at 40 C under nitrogen, and the 
samples reconstituted in 100 µL 0.2% FA (aq) prior to analysis with LC-MS/MS. 
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4.2.3.1.2 Protein Precipitation: Solvent Volume 
Glucagon plasma samples (750 pg/mL) were extracted using the 2D extraction method 
described in Section 2.2.5, which transferred samples to 5 mL polypropylene tubes and 
used 3.2 mL solvent for protein precipitation. Alternatively samples were extracted using a 
modified method, transferring them into a 2 mL 96-well polypropylene plate, using a  
1.1 mL solvent for precipitation, and an automated liquid handling system (Quadra Tower, 
TomTec, Connecticut, USA) to transfer the supernatant. 
4.2.3.1.3 Protein Precipitation: Solvent Evaporation Temperature 
Glucagon plasma samples (750 pg/mL) were extracted according to the modified method 
described in Section 4.2.3.1.2 except that that the supernatant was evaporated at 60C, 
rather than 40 C. 
4.2.3.1.4 Extract Reconstitution Volume 
Glucagon plasma samples (100 & 750 pg/mL) were extracted according to the modified 
method described in Section 4.2.3.1.2, but with reconstitution volumes of 100 and 150 µL, 
in addition to the standard 200 µL volume. 
4.2.3.2 LC Optimisation: Flow Rate, Formic Acid Composition, and Column Wash 
Time 
Lower LC-flow rates (0.25 mL/min and 0.40 mL/min) were investigated in addition to the 
original (0.80 mL/min) flow rate, using glucagon surrogate matrix samples (1 ng/mL). To 
reduce the effect of peak broadening, flow rates were lowered only during analyte elution. 
Formic acid mobile phase compositions of 0.1, 0.5 and 1% were investigated using 
glucagon surrogate matrix samples (1 ng/mL), in addition to the original 0.2% 
composition. 
Plasma samples containing mixed ISWS were extracted according to the original and 
modified methods described in Section 4.2.3.1.2. Both sets of extracts were run with the 
original LC method (5 min column clean) or a method with a reduced column wash time 
(0.8 min). 
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4.2.4 Method Development: Supercharging Mobile Phase Additives  
Supercharging (m-NBA containing) mobile phases were investigated as an attempt to 
improve sensitivity. The LC-MS/MS system was as described in Section 4.2.3. The LC-
MS/MS method was based on that described in Section 2.2.2, expect that the aqueous 
phase contained 5% ACN (i.e. H2O:ACN, 95:5, v/v), to ensure m-NBA solubility. During 
the optimisation described below the aqueous and organic mobile phases were modified to 
the same extent. Plasma samples were extracted using the modified extraction method 
(Section 4.2.3.1.2). Replicates (n=3) were performed for each experiment and mean data is 
presented, unless stated otherwise. 
4.2.4.1 Optimisation of m-NBA Content in Mobile Phases 
Glucagon surrogate matrix samples (1 ng/mL) were analysed using mobile phases 
modified with 0, 0.025, 0.050, or 0.100% m-NBA. The phases also contained 0.1% FA. 
4.2.4.2 Optimisation of Formic Acid Content in Mobile Phases 
Glucagon surrogate matrix samples (1 ng/mL) were analysed using mobile phases 
modified with 0, 0.010, 0.025, 0.050, or 0.100% FA. The mobile phases also contained 
either 0.05 or 0.10% m-NBA, creating 10 variations.  
4.2.4.3 Effect of m-NBA Modified Mobile Phases upon Analysis of Glucagon and 
GLP-1 Solutions and Plasma Extracts  
An SRM method was created with 13 transitions (5 for glucagon or glucagon IS and 8 for 
GLP-1) as detailed in Figure 4.9 and Figure 4.10. The SRM transitions encompassed the 
5+ and 6+ parent ions for glucagon, and the 3+, 4+, 5+ and 6+ parent ions for GLP-1. 
Product ions were identified by fragmentation, followed by collision energy optimisation. 
Multiple transitions were monitored to increase the likelihood of finding those with low 
background noise along with the absence of interferences. A greater number of GLP-1 
transitions were selected, as glucagon transitions had been previously investigated (Section 
2.3.1.1).  
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A 20 ms dwell time was used to ensure sufficient data points across the peaks. Scheduled 
MRM was used to maximise dwell time by only monitoring glucagon and GLP-1 
transitions near their RT (1.6 and 2.5 min respectively), a target scan time of 0.2 s, and 
MRM detection window of 30 s was selected.  
 
Surrogate matrix and plasma samples were spiked to the 1200 pg/mL level with glucagon 
and GLP-1, by dilution of the 12 ng/mL working solution. Plasma samples were extracted 
according to the modified method described in Section 4.2.3.1.2. Samples were analysed 
using mobile phases modified with 0.05% or 0.10% m-NBA. Phases were also modified 
with either 0.1% or 0.01% FA, creating 4 variations. Samples were also analysed using 
0.2% FA without m-NBA modification. 
4.2.5 Quantitation Strategy 
A surrogate matrix based approach was used for glucagon quantitation. Plasma QCs, to 
represent samples, were created by diluting working solutions 20-fold into EDTA plasma 
to 200 (MED) and 1750 (HIGH) pg/mL, and the QC concentration adjusted for the 
endogenous concentration. These were extracted and analysed according to the qualified 
extraction and LC-MS/MS methods described below (Sections 4.2.6-4.2.8). Calibration 
standards, QC LLOQs (precision and accuracy batches only) and QC LOWs were then 
prepared by spiking 20 µL of the appropriate working solution into the collection plate, 
along with 20 µL mixed ISWS and 160 µL surrogate matrix. Taking into account the 2-
fold concentration experienced by plasma samples (400 µL of plasma sample is 
reconstituted into 200 µL solvent) this gave final calibration levels of 15, 25, 45, 100, 300, 
600, 1000, 1850 and 2000 pg/mL, and final QC levels of 15 (QC LLOQ) and 45 (QC 
LOW) pg/mL. 
Endogenous GLP-1 could not be detected, and therefore GLP-1 quantitation was 
performed as per an exogenous compound with calibrants and QCs prepared in the sample 
matrix (EDTA Plasma). Working solutions were diluted 20-fold into plasma to produce 
calibrants at 25, 45, 100, 300, 600, 1000, 1850 and 2000 pg/mL and QC concentrations at 
25 (LLOQ), 75 (LOW), 200 (MED), and 1750 (HIGH) pg/mL. These were extracted 
according to the qualified extraction method described in Section 4.2.6. 
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4.2.6 Qualified Extraction Method  
Plasma sample (EDTA) (400 µL) was placed into a 2 mL 96-well polypropylene plate and 
20 µL mixed ISWS was added to all non-blank samples. This step was performed on wet 
ice (ca. 4C) to maximise analyte stability (Section 3.3.4). The plate was vortex mixed, and 
samples precipitated using 1.1 mL ACN:H2O:NH4OH (72:25:0.1,v/v/v), vortex mixed, 
sonicated for 5 min, and then centrifuged for 10 min at 2300 x g. 1.2 mL supernatant was 
transferred using an automated liquid handling system (Quadra Tower, TomTec) to a 2 mL 
plate and evaporated to dryness at 40C under nitrogen using a Porvair MiniVap blow 
down at 60 litres per minute (ca. 90 min). Samples were reconstituted in 800 µL 2% 
NH4OH (aq) and then vortex mixed, before being extracted using SPE as per Section 2.2.5. 
Namely, a Bond Elut Plexa SEH SPE plate (96-round well, 30 mg; Agilent Technologies, 
California, USA) was conditioned using 1 mL MeOH, then equilibrated with 1 mL H2O. 
The samples were loaded, washed with 1 mL 5% MeOH (aq), eluted with 2 x 225 µL 
ACN:H2O:FA (75:25:0.1, v/v/v) into a 1 mL 96-well LoBind plate, and then evaporated 
under nitrogen at 40 C, before being reconstituted in 200 µL 0.2% FA (aq). The plate was 
centrifuged for 10 min at 2300 x g, and 40 µL sample injected onto the LC-MS/MS system 
for analysis, or the plate stored at 4 C awaiting injection. The entire extraction process 
took 1 working day. 
4.2.7 Qualified LC-MS/MS Method (Formic Acid Phases)  
The LC-MS/MS system was as described in Section 4.2.3. Glucagon was separated on a 
Waters Acquity UPLC BEH C18 1.7 µm (2.1 x 100 mm) column maintained at 60 C. The 
mobile phase consisted of (A) 0.2% FA in ACN and (B) 0.2% FA (aq). The gradient for 
glucagon elution was 22-32% A over 2 min, as in the method described in  
Chapter 2 (Section 2.2.2), followed by a gradient of 32-38% over 0.8 min for GLP-1 
elution. The column was then cleaned with 95% A for 0.75 min then re-equilibrated at the 
starting conditions for 0.05 min. The flow rate was 0.8 mL/min and the total gradient time 
was 3.6 min per sample. 
The mass spectrometer was operated in positive ion mode with an electrospray voltage of 
5500 V. The source temperature was 600 C, the curtain, N2 collision, GS1, and GS2 gases 
were set to 40, 8, 60 and 40 psi respectively. The Q1 and Q3 quadrupoles were both 
operated at unit resolution. Entrance potentials of 10 V and collision exit cell potentials of 
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13 V were used. MS periods were used to maximise dwell times, and therefore sensitivity. 
The SRM transitions 697.5694.0, 677.4673.8 and 702.2698.8 for glucagon, 
analogue glucagon IS, and SIL glucagon IS were monitored between 0-2 min. These 
transitions were attributed to [M+5H]
5+  [M+5H-NH3]
5+
 in each case. Transitions used 
the optimal CE of 20, 18 and 20 V respectively and all used dwell times of 60 ms with DP 
of 80 V. The SRM transitions 660.6656.9 and 660.6752.0, which were attributed to  
[M+5H]
5+  [M+5H-NH3]
5+ 
 and [M+5H]
5+  y20
3+
 respectively,
 
were monitored for 
GLP-1 between 2-3.6 min. These transitions used the optimal CE of 16 and 22 V, and DP 
of 100 and 110 V respectively and all used dwell times of 100 ms. 
4.2.8 Qualified LC-MS/MS Method (m-NBA Mobile Phases) 
The same LC-MS/MS systems were used as above. However the mobile phase consisted of 
(A) 0.01% (FA) in ACN with 0.05% m-NBA and (B) 0.01% FA (95:5 H2O:ACN, v/v) 
with 0.05% m-NBA. The addition of ACN to the aqueous phase enabled solubility of the 
m-NBA. The gradient for glucagon elution was 18-28% A over 2 min, then 28-34% over 
for 0.8 min for GLP-1 elution, before being cleaned and re-equilibrated as above. MS 
settings were as above, unless stated differently below. The SRM transitions 581.5578.5, 
564.7561.8 and 585.5582.4 for glucagon, analogue glucagon IS and SIL glucagon IS 
were monitored between 0-1.75 min. These transitions were attributed to  
[M+6H]
6+ [M+6H-NH3]
6+
 in each case. Transitions used the optimal CE of 13, 12 and 
13 V respectively and all used DP of 80 V and dwell times of 60 ms. The SRM transitions 
550.6601.6 and 550.6639.3 were monitored for GLP-1 between 1.75-3.6 min. These 
transitions were attributed to [M+6H]
6+y16
3+
 and [M+6H]
6+y17
3+ 
respectively. 
Transitions used the optimal DP of 80 and 70 V respectively and both used CE of 19 V and 
dwell times of 100 ms. 
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4.2.9 Qualification Procedure  
The qualification experiments were based on key experiments described in the FDA [1] 
and EMA [2] bioanalytical guidelines. Analyst v1.6.2 (Applied Biosystems / MDS SCIEX, 
Ontario, Canada) was used to process data and to construct calibration lines. Duplicate 
calibration standards were analysed within each batch, and calibration lines were 
constructed using peak area ratio-concentration plots with linear regression and 1/x
2
 
weighting. 
The acceptance criteria for glucagon required that the accuracy of ≥75% of standards in 
each batch was within 15% (20% at the LLOQ) of the nominal concentration, with those 
outside this excluded from the calibration line. For precision and accuracy batches QCs 
needed mean accuracy within 20%, with precision (CV) 20% at each level. In other 
batches ≥2/3 of the individual QCs needed accuracy within 20%, with at least one QC at 
each level. For GLP-1 similar acceptance criteria was used, except that a 25% criteria was 
used for precision and accuracy at all levels. The selection of acceptance criteria is 
discussed in Section 4.3.5. 
Precision and accuracy (P&A) of the method was assessed by analysis of replicate (n=6) 
QC samples at at least four different concentrations within a batch. Selectivity was 
determined by inspecting chromatograms from six independent plasma EDTA samples for 
the presence of potentially interfering peaks. 
The effect of the presence of matrix to the response of the analyte and internal standard 
was determined from six independent plasma EDTA samples. These were extracted and 
post spiked at the 200 pg/mL level, and compared to the mean response from samples in 
surrogate matrix, taking into account endogenous concentrations. In addition QCs were 
fortified at 200 pg/mL in six independent plasma EDTA matrices (1 aliquot of each), and 
in lithium heparin plasma (n=6).  
 
Stability in matrix was determined by spiking a plasma sample at 200 pg/mL and 
incubating it at room temperature or ice for 4 hr 50 min before extraction (n=6 replicates), 
and comparing to a sample immediately extracted. The ability to re-inject extracts was 
assessed at the P&A QC levels after 42 days storage at 4 C. Analyte recovery was 
evaluated by comparing samples (n=6) spiked with 200 pg/mL analyte, with extracts post 
spiked at this level to represent 100% recovery. The ten-fold dilution of a QC HIGH 
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sample (1750 pg/mL)(n=6) with EDTA plasma was used to demonstrate whether low 
samples volumes could be analysed. 
4.2.10 Collection of Samples from Volunteers to Assess Endogenous Glucagon 
Concentrations  
Blood was collected from 11 male and 11 female healthy volunteers using glass blood 
collection tubes (5 mL, EDTA anticoagulant) obtained from BD (Oxford, UK). Tubes were 
placed on ice immediately after sample collection and then centrifuged at 2300 x g for 10 
min to obtain plasma, which was stored in multiple aliquots (500 µL) at – 80 C. Plasma 
was collected at the start of the working day and volunteers were not asked to change their 
usual eating regime. 
Glucagon concentrations were determined using the qualified method with formic acid 
phases (Section 4.2.6 and Section 4.2.7). Concentrations were determined upon the first 
freeze-thaw of the aliquot, as multiple cycles have been shown to affect quantitation 
(Section 2.3.3). The ability to extrapolate below the 15 pg/mL for glucagon limit of 
quantitation was assessed by determining precision and accuracy of surrogate matrix QCs 
(n=6) diluted to 10 and 7.5 pg/mL levels. 
Alternative unadulterated aliquots from samples containing endogenous levels of glucagon 
above the lower limit of quantitation (15 pg/mL) were reanalysed after storage for up to 
249 days at -80 C to assess incurred sample reproducibility (ISR). Similarly, a plasma 
pool from one male and one female individual was created from stored samples and 
analysed immediately after pooling and after additional storage for 42 days at -80 C. 
Finally, extracts from a selection of samples (n=9), and corresponding calibration 
standards and QC samples were reanalysed with the qualified method using m-NBA 
mobile phases to access a sensitive qualifier SRM to assure the method’s selectivity. 
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4.2.11 Collection of Physiological Study Samples 
A 20 mL blood sample was collected from ten fasting healthy volunteers (West London 
National Research Ethics Committee, ref. 11/LO/1782), one volunteer dosed with 
glucagon (15 pmol/kg/min intravenous (IV)) (London Central Ethics and Research 
Committee (13/LO/0925), and two volunteers dosed with GLP-1 (16 pmol/kg/min sc) 
(13/LO/1510). Informed consent was obtained from the volunteers, and the principles 
outlined in the Declaration of Helsinki were followed. Immediately after collection, 2 ml 
samples were decanted into various collection tube types: 1) K3 EDTA anticoagulant (ref 
368860 – BD Vacutainer System, NJ, USA) with the addition of aprotinin (Bayer, 
Newbury, UK; final concentration 250 KIU/ml) and a DPP IV inhibitor (Ile-Pro-Ile, 
Sigma-Aldrich, Dorset, UK; final concentration 10 μg/ml); 2) K3 EDTA anticoagulant 
with the addition of aprotinin; 3) K3 EDTA anticoagulant with the addition of a DPP IV 
inhibitor; 4) K3 EDTA anticoagulant alone; 5) lithium heparin (ref 367883 – BD 
Vacutainer System, NJ, USA) with the addition of aprotinin and a DPPIV inhibitor; 6) 
lithium heparin with the addition of aprotinin; 7) lithium heparin with the addition of a 
DPP IV inhibitor and 8) lithium heparin alone. Following collection, tubes were placed on 
ice and centrifuged at 2300 x g for 10 min to obtain plasma, which was stored at -80 C. 
Two further aliquots, collected in K3 EDTA tubes with aprotinin and DPP IV inhibitor, 
underwent 1 and 2 further freeze/thaw cycles, respectively.  
4.2.12 Analysis of Physiological Study Samples  
Samples of the same stabiliser type and anticoagulant from three of the ten fasting healthy 
volunteers were pooled together. One aliquot was reserved for endogenous level 
determination and a second aliquot was spiked with 200 pg/mL analyte. Samples were 
analysed using the qualified LC-MS/MS method with formic acid mobile phases to assess 
the effect that a change of sample matrix had upon quantitation. 
 
The majority of the samples from five of the remaining seven fasting healthy volunteers 
(endogenous glucagon samples) were analysed by the LC-MS/MS method and by two 
immunoassays (all 50 samples were analysed using the first and second immunoassay, 
whilst 45 were analysed by LC-MS/MS). The first immunoassay was a HTRF sandwich 
immunoassay (Cisbio, Codolet, France) (analytical sensitivity = 12.0 pg/mL) (Section 
1.2.3). The second was a Milliplex MAP Human Metabolic Hormone Magnetic Bead 
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Panel (Merck Millipore, Darmstadt, Germany) (minimum detectable concentration 
(MinDC)=13.0 pg/mL), which involved a sandwich immunoassay with fluorescence 
detection (Section 1.2.4). Samples from the other two fasting healthy volunteers were only 
analysed using one method format, and are therefore not considered further. The same 
formats were also used to analyse samples from the volunteer dosed with glucagon.  
Samples from the two volunteers dosed with GLP-1 were similarly analysed using the LC-
MS/MS method, and by either a Millipore active GLP-1 ELISA (Lowest standard = 6.6 
pg/mL)(Section 1.2.2) or the Milliplex MAP (MinDC=1.2 pg/mL) described above. 
 
The various measures of immunoassay sensitivity quoted by the manufacturers (i.e. 
analytical sensitivity/MinDC/lowest calibration point) were taken as equivalent to the 
lower limit of quantitation (LLOQ) measurement of the LC-MS/MS method for the 
purpose of this study. For all immunoassays, intra-assay CVs were <10% across the 
working range. 
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4.3 RESULTS AND DISCUSSION 
4.3.1 Method Development: Re-optimisation 
Initial development focused on re-optimisation of the glucagon method described in 
Chapter 2 to attempt to improve sensitivity, robustness and throughput. GLP-1 was the 
secondary analyte for the assay, and was not introduced at this stage. A summary of the  
re-optimisation is presented in Table 4.1 
4.3.1.1 Extraction Optimisation 
In the method described in Chapter 2, ACN based protein precipitation solvents diluted to 
various proportions with water (0, 25 and 50 %) were investigated (Section 2.3.1.2.1). The 
solvent ACN:H2O (75:25, v/v) gave the best response, with the addition of 0.1% formic 
acid significantly reducing the response, whilst the addition of 0.1% ammonium hydroxide 
resulted in a small increase. Therefore ACN:H2O:NH4OH (75:25:0.1, v/v/v) was selected 
as the optimal solvent.  
 
In this chapter, additional proportions of ACN in water (5, 10, 15 and 20%) were 
investigated to attempt to further improve performance, alongside MeOH based solvents. 
However, the original solvent composition remained optimal (Figure 4.1). From 
experience with other peptides, solvents containing 25% water in ACN are often optimal. 
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Figure 4.1 Effect on analyte and analogue internal standard (IS) glucagon peak areas 
upon extracting plasma samples with various protein precipitation solvents. 
Of the protein precipitation solvents investigated in Chapter 2, ACN:H2O (75:25, v/v) based 
solvents performed well, with ACN:H2O:NH4OH (75:25:0.1, v/v/v) giving optimal performance 
(Figure 2.2). In this current chapter, additional proportions of ACN in water and the use of MeOH 
in place of ACN were investigated, as shown in the figure above. However ACN:H2O:NH4OH 
(75:25:0.1, v/v/v)  remained optimal. From experience with other peptides, solvents containing 
25% water in ACN are often optimal. 
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Table 4.1 Parameters re-optimised during assay development for glucagon quantitation  
Several parameters from the method described in Chapter 2 were re-optimised to attempt to improve sensitivity, robustness and throughput. If improvements 
resulted, the method was altered to incorporate the re-optimised parameter. 
Parameter re-optimised Aim Result 
Method 
altered? 
Reference 
(Section) 
Protein 
precipitation 
solvent 
 
Composition 
Increase sensitivity by increasing recovery 
and/or reducing matrix effects. 
Original solvent (75:25:0.1, 
ACN:H2O:NH4OH, v/v/v) gave optimal 
performance. 
No 4.3.1.1 
Volume 
Reduce extraction time by reducing solvent 
volume to enable use of 96-well plates and 
associated automated liquid handling, as 
well as reducing evaporation time. 
Volume reduced from 3.2 mL to  
1.1 mL. Automated liquid handling 
utilised. Extraction time halved to 1 day. 
Yes 4.3.1.1 
Evaporation 
temperature 
Reduce evaporation time. 
Higher temperatures (60C) led to 
increased matrix interference. 
No 4.3.1.1 
Extract reconstitution volume 
Increase sensitivity by reducing 
reconstitution volume to increase extract 
concentration. 
Reduced volume increases background 
noise, lowering signal-to-noise. 
No 4.3.1.1 
LC 
Flow rate 
Increase sensitivity, as a result of higher 
ionisation efficiencies at lower flow rates. 
Monitor multiple charge states to ensure 
optimal is selected. 
No overall boost in sensitivity was 
observed due to increased peak 
broadening at lower flow rates. Original 
charge state was optimal. 
No 4.3.1.2 
Formic acid 
composition 
Increase sensitivity, by increasing positive 
electrospray ionisation at lower pH. 
Sensitivity reduced at lower pH. No 4.3.1.2 
Column wash 
time 
Reduce run time by reducing column wash, 
enabled by lower matrix build up by use of 
automated liquid handling during extraction.  
Column wash reduced by 4.2 min, 
saving 6.7 hr of analysis time per 96 
sample batch. 
Yes 4.3.1.2 
Internal standard 
Increase precision and accuracy, and 
robustness using SIL rather than an 
analogue glucagon IS. 
SIL IS gave better performance under 
conditions of high matrix effect. 
Yes 4.3.1.1 
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The protein precipitation solvent volume used to extract the 400 µL plasma samples was 
lowered from 3.2 mL to 1.1 mL. Such low solvent:plasma ratios were not previously 
investigated as they would usually lead to high matrix effects, however the subsequent use 
of SPE as part of the 2D extraction procedure minimised these. This alteration allowed the 
assay to be transferred from individual 5 mL tubes into a 96-well plate, significantly 
reducing assay set-up time. It also enabled the use of an automated liquid handling system 
to transfer the protein precipitation supernatant, further reducing extraction time and 
increasing robustness. Additionally, the supernatant evaporation time was reduced to ca. 
90 min due its lower volume, negating the need for an overnight evaporation. Overall, the 
extraction time was halved to one working day, which is similar to the incubation period 
for some glucagon immunoassays [3]. 
The reconstituted samples from this modified method contained less insoluble material 
than observed with the original method and upon analysis an interference peak (1.6 min) 
close to glucagon’s retention time (1.7 min) was eliminated (Figure 4.2a vs b). This may be 
due to the reduced transfer of solid protein precipitate (and associated interferences) using 
the automated system than with manual transfer.  
The protein precipitation solvent evaporation temperature was increased from 40 C to  
60 C to attempt to further reduce evaporation time. No significant differences in analyte 
signal (Figure 4.2b vs c) or QC accuracies were observed, however the IS showed slightly 
lower signal and slightly greater tailing. As the reduction in evaporation time was 
relatively small (75 min vs 95 min), it was decided to maintain the temperature at 40 C. 
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Figure 4.2 Effect of the extraction method on the interference, glucagon analyte and 
glucagon internal standard peaks. 
a) Original extraction procedure (manual transfer). An interference peak is observed close to 
glucagon’s retention time. 
 
b) Modified extraction procedure (automated liquid handling system transfer). The interference 
peak has been eliminated. This may be due to the reduced transfer of solid protein precipitate (and 
associated interferences) using the automated system than with manual transfer. 
 
c) Extraction as b), but protein precipitation solvent evaporation temperature was increased from  
40 C to 60 C. Analyte signal was similar, but the internal standard peak showed slightly lower 
signal and slightly greater tailing at 60 C. As the reduction in evaporation time was relatively 
small (75 min vs 95 min), it was decided to maintain the temperature at 40 C. 
 
A dual x axis is shown on the chromatograms. The upper part displays the time (e.g. 1.20 – 2.15 
min for panel a)) and the lower part displays the scan number (e.g. 437 – 783 for panel a)). 
 
Analyte transition, 697.5693.8. Internal standard transition, 702.5698.9. Transitions are both 
attributed to [M+5H]
5+  [M+5H-NH3].
5+
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Lower reconstitution volumes were investigated to attempt to boost sensitivity. However, 
whilst the signal increased, the background noise increased to a greater extent, leading to a 
reduction in signal-to-noise with a constant 40 µL injection volume (18.4, 15.5 and 12.9, at 
200, 150 and 100 µL reconstitution volumes respectively for a 100 pg/mL sample). 
Therefore the original 200 µL reconstitution volume was retained. 
A SIL glucagon IS was acquired to investigate whether this improved performance over 
the analogue IS used previously. Performance was similar under standard conditions, 
however the SIL IS gave better performance when matrix effects were high, as modelled 
by lower reconstitution volumes (Table 4.2). The SIL was therefore selected to maximise 
robustness.  
Table 4.2 Performance of analogue and SIL glucagon internal standards under 
conditions of high matrix effect (low reconstitution volumes).  
The analogue and SIL glucagon ISs performed similarly as reconstitution volumes were reduced 
from 200 to 150 µL, as evidenced by little change in the peak area ratios (PARs). Both IS’s 
therefore compensate for analyte signal alteration by the matrix at moderately high matrix 
concentrations (150 µL reconstitution volume). However under high matrix concentrations (100 µL 
reconstitution volume), only the SIL internal standard effectively compensated, and this was 
therefore selected to maximise method robustness. 
 
Reconstitution 
Volume 
(µL) 
Glucagon Internal Standard 
Analogue SIL 
100 pg/mL 750 pg/mL 100 pg/mL 750 pg/mL 
% 200 
µL 
PAR 
%CV % 200 
µL 
PAR 
%CV % 200 
µL 
PAR 
%CV % 200 
µL 
PAR 
%CV 
200 100.0 2.0 100.0 5.7 100.0 1.6 100.0 4.1 
150 97.7 1.7 99.8 0.2 103.7 1.6 102.8 1.1 
100 78.1 3.6 89.8 6.9 98.5 1.3 104.3 2.6 
PAR= Analyte peak area/Internal standard peak area 
A perfect internal standard would fully correct for matrix effects, and therefore PAR would be unchanged 
with reconstitution volume. 
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4.3.1.2 LC Optimisation 
In order to assess whether lower LC flow rates increased sensitivity, flow rates at 0.25 and  
0.4 mL/min were investigated, in addition to the original 0.8 mL/min flow rate. These were 
noted to increase the relative formation of the highly charged 5+ ion (m/z 697), as expected 
due to prolonged interaction with the electrospray probe allowing greater charge 
accumulation. Peak areas increased with lower flow rates (Figure 4.3a), however peak 
broadening was significant, despite flow rate only being reduced for a short time (during 
analyte elution), and therefore no overall significant increase in peak height (sensitivity) 
occurred (Figure 4.3b). The flow rate was therefore maintained at 0.8 mL/min for future 
work. 
 
Figure 4.3 Effect of LC flow rate on glucagon peak (a) area and (b) height. 
a) Low flow rates increased peak areas from higher glucagon charge states (lower m/z), as expected 
due to prolonged interaction with the electrospray probe allowing greater charge accumulation. 
b) Low flow rates did not significantly increase peak heights from low glucagon charge states. The 
increases in peak area described in a) were concurrent with greater peak broadening. As peak 
height (sensitivity) did not improve, the flow rate was maintained at 0.8 mL/min for future work. 
Flow rate is 0.8 mL/min except at elution, where it is as shown in the Figure. 697, 871 and 1161 are 
ion m/z  
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Similarly, the percentage of formic acid in the mobile phases was investigated as an 
attempt to improve sensitivity (Figure 4.4). Reducing formic acid from 1% to 0.2% 
increased the intensity of all charge states, including the most highly charged 5+ (m/z 697) 
charge state, without significantly affecting the charge state distribution. Higher 
percentages of formic acid may increase ionisation of matrix components, limiting ion 
current available for analyte ions. However the proportion of the 5+ (m/z = 697) charge 
state reduced in abundance when formic acid was lowered further to 0.1%, as the lower 4+ 
(m/z 871) charge state was favoured. Peak height and peak area were similarly affected, as 
there was no effect on peak broadening. 0.2% FA remained optimal for the 5+ (m/z = 697) 
charge subsequently selected for quantitation (Section 4.2.7). 
 
Figure 4.4 Effect of the mobile phase formic acid content on glucagon peak (a) area and 
(b) height.  
a) Reducing the formic acid mobile phase concentration from 1% to 0.2% increased peak areas 
from all charge states. High formic acid concentrations may increase ionisation of matrix 
components, limiting ion current available for analyte ions. Reducing the concentration further to 
0.1% reduced the formation of the most highly charged ion (5+ (m/z = 697)), as the lower  
4+ (m/z 871) charge state was favoured.  
b) Peak height was affected by mobile phase formic acid content similarly to peak area (described 
in a) above), as formic acid content did not affect peak broadening. 0.2% FA remained optimal for 
the 5+ (m/z = 697) charge subsequently selected for quantitation (Section 4.2.7). 
Mobile phases are A=ACN and B=water, each modified with formic acid to the percentage shown 
in the figure. 697, 871 and 1161 are ion m/z. 
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The original LC method (Section 2.2.2) included a 5 min column wash step at the end of 
each injection. This was found necessary to reduce column fouling, and resulted in a run 
time of 7.1 min. The column wash step was reduced to 0.8 min, which as expected led to 
the deterioration of peak shape for samples extracted using the original extraction method 
(Figure 4.5a vs. b). However peak shape was maintained for samples extracted using the 
re-optimised extraction method (Figure 4.5c vs. d), which included automated liquid 
transfer. This was attributed to the reduction of the inadvertent transfer of protein 
precipitate solid, and subsequent reduction of matrix build up on the column. Maintenance 
of peak height (sensitivity) and peak area was similar between the extraction methods 
across the relatively small number of injections investigated. Peak height (sensitivity) 
differences across the injections of an extraction method were not considered significant 
considering experimental variability, however peak height (sensitivity) was expected to 
worsen with further injections for samples extracted using the original method due to 
further peak shape deterioration. As the short LC method maintained the peak shape for 
samples extracted using the re-optimised extraction method, this was selected for future 
work, saving 6.7 hours per 96 sample batch, significantly improving throughput. 
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Figure 4.5 Effect of short LC column wash step (0.8 min) on SIL glucagon 
chromatograms (2 ng/mL) from samples extracted using the original and modified extraction 
methods. 
a+b) Chromatograms from samples extracted using the original extraction method, and injected 
using a LC method with a short column wash step (0.8 min). The peak shape deteriorates, and peak 
broadening increases, between injections 9 and 33. This was attributed to ineffective removal of 
extract matrix components from the column. 
 
c+d) Chromatograms from samples extracted using the modified extraction method, and injected 
using a LC method with a short column wash step (0.8 min). Peak shape, including width, is 
maintained between injections 9 and 33. This was attributed to the modified method extracts 
containing a reduced quantity of matrix components compared to extracts from the original 
method; these could therefore be effectively removed during short column wash steps.  
 
Note: Samples from the original (a+b) and modified (c+d) extraction method were injected on 
different occasions, so the responses peaks heights and areas between the methods are not directly 
comparable.  
A dual x axis is shown on the chromatograms. The upper part displays the time (e.g. 0.8 – 2.7 min 
for panel a)) and the lower part displays the scan number (e.g. 292 – 983 for panel a)). 
  
a) Original 
extraction  
method 
(injection 9)   
b) Original 
extraction  
method 
(injection 
33)   
 
Peak height=  
2.7 e4 cps  
Peak area = 
8.6 e4 counts 
Peak width= 
0.15 s 
 
 
 
 
 
Peak height=  
2.1 e4 cps (78% a) 
 
Peak area= 
 8.1 e4 counts (94% a) 
 
Peak width= 
0.50 s 
0 
  
 
 
 
Peak height=  
3.3 e4 cps 
Peak area = 
4.1 e4 counts 
Peak width= 
0.10 s 
 
 
 
 
 
Peak height= 
2.6 e4 cps (79% c) 
Peak area=  
3.6 e4 counts (88% c) 
Peak width= 
0.13 s 
 
 
 
 
c) Re-optimised  
extraction 
method 
(injection 9)   
d) Re-optimised  
extraction 
method 
(injection 33)   
190 
4.3.2 Method Development: Supercharging Mobile Phase Additives (Initial 
Optimisation) 
 
One of the challenges for sensitive LC-MS/MS peptide bioanalysis is that signal is split 
over multiple charge states. Supercharging mobile phase additives, for example m-NBA, 
are known to alter the charge state distribution favouring higher charge states  
(Section 1.4.1.3). For m-NBA this is thought to be due to an increase in surface tension of 
the droplets in the electrospray source, decreasing the radius prior to coulombic explosion, 
and consequently leading to charge concentration [4]. Sensitivity increases may result if 
the charge state distribution is reduced, or if the signal is increased due to improved analyte 
ionisability, as described elsewhere for one large peptide in plasma extract [5]. However 
for glucagon whilst alterations in the charge state distribution (3+, 4+, 5+ to 4+, 5+, 6+) 
were observed and an improvement in analyte signal in extracts was noted, no overall 
increase in sensitivity (signal to noise) resulted due to similar increases in background 
noise [5]. 
 
It was decided to investigate the use of m-NBA to improve glucagon sensitivity with the 
re-optimised extraction method and to more fully investigate the effect of altering the  
m-NBA and FA content of the mobile phases. Furthermore, it was planned to use the  
m-NBA method to provide a sensitive qualifier SRM to ensure assay specificity, as 
described in Section 4.3.6, so an optimal method was required. 
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The percentage of m-NBA in the mobile phases was found to have a large effect on the 
charge state distribution of glucagon in solution (Figure 4.6). As expected higher 
percentages favoured the most highly charged species (6+, m/z 581). At low levels of  
m-NBA (0-0.050%) the response of both the 6+ (m/z 581) and 5+ (m/z 697) ions increased 
with m-NBA concentration, presumably due to an increase in overall ionisation efficiency. 
Whereas at higher levels of m-NBA the increase of the 6+ (m/z 581) charge state was at the 
expense of the others.  
 
Figure 4.6 The effect of m-NBA mobile phase content on glucagon charge state 
distribution in solution. 
The percentage of m-NBA in the mobile phases had a large effect on the peak areas from glucagon 
charge states in solution. At low levels of m-NBA (0-0.050%) the response of both the 6+ (m/z 
581) and 5+ (m/z 697) ions increased with m-NBA concentration, presumably due to an increase in 
overall ionisation efficiency. Whereas at higher levels the most highly charged species (6+, m/z 
581) was favoured at the expense of lower charge state species. 
These data are from 3 different experiments (Exp1 (full scan): 0 & 0.100% m-NBA, Exp2 (SRM): 
0.025 & 0.050% m-NBA, Exp 3 (SRM):0.05 & 0.100% m-NBA). SRM transitions were 697693 
and 581575. Data has been scaled appropriately, using common conditions between experiments, 
to account for signal variations. 
Data points were only collected for the 3+ (m/z 1161) and 4+ (m/z 871) ions at 0 and 0.100%  
m-NBA concentrations, as these ions were least intense and were therefore discarded early on in 
method development. 
 581, 697, 871 and 1161 are ion m/z. 
.  
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.10
R
el
a
ti
v
e 
P
ea
k
 A
re
a
 R
es
p
o
n
se
 
% m-NBA in Mobile Phases (all contain 0.1% FA) 
Relative Peak Area Response vs m-NBA percentage in Mobile 
Phases 
581
697
871
1161
192 
The effect of adjusting the percentage of formic acid was relatively small using standard 
mobile phases for glucagon in solution (Figure 4.4), however when m-NBA was present 
the effect was significant (Figure 4.7). This contrasts with some studies which find that pH 
optimisation is unimportant in the presence of supercharging reagents, as solvated protons 
in unadulterated phases are sufficient for ionisation [4]. However, it is in agreement with 
other studies, which explain the effect due to the reduction of electrospray surface tension 
upon addition of acid [6]. 
 
Figure 4.7 The effect of formic acid content on glucagon SRM peaks area using m-NBA 
based mobile phases. 
The effect of altering formic acid concentrations on peak areas in the presence of m-NBA was 
significant. In contrast, no significant effect was observed in the absence of m-NBA (Figure 4.4a). 
Whilst some formic acid is required, peak areas generally increased with lower concentrations; this 
may be due to acid reducing electrospray droplet surface tension, reducing the ability to form 
supercharged droplets.  
 
a) In the presence of 0.05% m-NBA, 0.010% FA gave the highest peak area for the 5+ (m/z 697)  
charge state, with 0.025% FA giving slightly higher peak areas for the more highly charged 6+ (m/z 
581) charge state. 
 
b) In the presence of 0.10% m-NBA, both charge states gave highest peak areas with 0.010% FA 
 
Mobile phases are modified with either (a) 0.05% m-NBA, (b) 0.01% m-NBA and FA as shown. 
581/575 and 697/693 are SRM transitions from the 5+ and 6+ charge states respectively. 
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4.3.3 Method Development: Supercharging Mobile Phase Additives 
(Optimisation for Glucagon and GLP-1) 
LC-MS analysis of GLP-1 showed that the [M+3H]
3+
, [M+4H]
4+
 and [M+5H]
5+
 charge 
states (m/z 1009.5, 825.1, and 660.0) were observed using formic acid based mobile 
phases. The latter two being most intense, and of similar intensity to each other  
(Figure 4.8a). 
 
 
Figure 4.8 GLP-1 full scan MS spectra acquired with a) standard and b) supercharging 
mobile phases.  
a) GLP-1 [M+3H]
3+
, [M+4H]
 4+
 and [M+5H]
 5+ 
charge states
 
were
 
dominant when MS spectra was 
acquired using formic acid mobile phases (Mobile A= 0.2% FA (ACN), Mobile B= 0.2% FA (aq)). 
b) Supercharging (m-NBA) mobile phases (Mobile A= ACN:FA:m-NBA (100:0.1:0.1,v/v/v), 
Mobile B= H2O:ACN:FA:m-NBA (95:5:0.1:0.1,v/v/v/v) led to a shift in charge state distribution, 
with the higher GLP-1 charge states, [M+4H]
4+
, [M+5H]
5+
 and [M+6H]
6+
, being dominant.  
 +Q1: 1.233 to 1.305 min from Sample 1 (SSSINT1 (10,000 ng/mL)) of 141109GLP1Scans-003.wiff (Turbo Spray) Max. 6.4e6 cps.
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As with glucagon (Section 2.3.1.1), very little fragmentation was observed at lower 
collision energies and once a critical energy was reached numerous low intensity products 
were observed. The effect on the GLP-1 spectra upon modifying mobile phases with  
m-NBA was investigated, which similar to glucagon, demonstrated a shift in charge state 
distribution (Figure 4.8 a vs b). 
 
The effect of altering the m-NBA and formic acid content of the mobile phases on 
glucagon and GLP-1 solutions and extracts was evaluated. Mobile phases modified with 
0.05% or 0.01% m-NBA were selected for evaluation as these gave the most intense 
analyte signal when glucagon solutions were analysed (Section 4.3.2). The mobile phases 
also contained either 0.01% FA, found to be optimal for glucagon solution analysis 
(Section 4.3.2) or 0.1% FA. The higher acid concentration was included to investigate 
whether this was needed for effective analyte ionisation in extracts due to competition 
from matrix components. 
 
The effect of altering mobile phases was similar for surrogate matrix (solution) samples 
and plasma extracts for both glucagon (Figure 4.9) and GLP-1 (Figure 4.10). In most cases, 
it was noted that plasma extracts gave a lower signal, although this will at least in part be 
due to the loss of compound during the extraction, rather than differences in ionisation 
between the matrices. Mobile phases containing 0.05% m-NBA and 0.01% FA were found 
to give maximum signal, regardless of transition, nature of sample (plasma or solution), 
and analyte. The presence of matrix, therefore, did not alter the supercharging process. It 
was noted that some transitions were affected by the alteration in mobile phases more than 
others; demonstrating that supercharging of the analyte alters the intensity of various 
product ions formed. 
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Figure 4.9 Glucagon peak areas for solution and plasma extracts analysed using mobile 
phase modified as shown. 
Altering the mobile phases had similar effects on peaks areas for both glucagon solutions and 
glucagon plasma extracts. Mobile phases containing 0.05% m-NBA and 0.01% FA gave the highest 
peak areas for both solutions and plasma extracts for all transitions monitored. Although plasma 
extracts gave lower peak areas than solutions, this is at least partly due to losses upon extraction. 
 
Mobile Phase A was ACN and Mobile phase B was water:ACN (95:5, v/v), both modified with  
m-NBA and FA as shown in the figure. SRM transitions and precursor ion charge states are as 
shown. 
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Figure 4.10 GLP-1 peak areas for solution and plasma extracts analysed using mobile 
phase modified as shown. 
Altering the mobile phases had similar effects on peaks areas for both GLP-1 solutions and GLP-1 
plasma extracts. Mobile phases containing 0.05% m-NBA and 0.01% FA gave the highest peak 
areas for both solutions and plasma extracts for all transitions monitored, expect for 
660.100/656.700 for plasma extracts which had marginally higher peak area when mobile phases 
were modified with 0.05% m-NBA and 0.10% FA. Plasma extracts gave lower peak areas than 
solutions; this is at least partly due to losses upon extraction. 
 
Mobile Phase A was ACN and Mobile phase B was water:ACN (95:5, v/v), both modified with  
m-NBA and FA as shown in the figure. SRM transitions and precursor ion charge states are as 
shown. 
  
0.0E+00
1.0E+03
2.0E+03
3.0E+03
4.0E+03
5.0E+03
6.0E+03
7.0E+03
8.0E+03
9.0E+03
1.0E+04
1.1E+04
0.1%
MNBA
0.1% FA
STD 7
Solution
0.1%
MNBA
0.1% FA
STD 7
Extract
0.1%
MNBA
0.01% FA
STD 7
Solution
0.1%
MNBA
0.01% FA
STD 7
Extract
0.05%
MNBA
0.01% FA
STD 7
Solution
0.05%
MNBA
0.01% FA
STD 7
Extract
0.05%
MNBA
0.10% FA
STD 7
Solution
0.05%
MNBA
0.10% FA
STD 7
Extract
P
ea
k
 A
re
a
 (
co
u
n
ts
) 
GLP-1 (5+) 660.1 / 656.7 GLP-1 (5+) 660.1 / 751.5
GLP-1 (4+) 825.1 / 946.4 GLP-1 (4+) 825.1 / 458.2
GLP-1 (3+) 1099.5 / 1093.7 GLP-1 (6+) 550.5 / 547.5
GLP-1 (6+) 550.5 / 601.5 GLP-1 (6+) 550.5 / 639.3
197 
In summary, initial results suggested that higher levels of m-NBA favoured higher charge 
states (Figure 4.6) with the 5+ and 6+ charge state of glucagon being most dominant at 
0.05% and 0.10% m-NBA respectively (Figure 4.7). However further experiments 
suggested that 0.05% m-NBA was optimal for both charge states (Figure 4.9 and Figure 
4.10). Significant changes in signal intensity occurred with the alteration of mobile phase 
formic acid content, which did not occur when using standard mobile phases (Figure 4.7 vs 
Figure 4.4). Interestingly mobile phases modified with low amounts of formic acid (e.g. 
0.01%) gave optimal signal for both analytes, regardless of whether they were in solution 
or plasma matrix, although the absence of acid led to very low signal demonstrating its 
necessity for efficient ionisation. Overall mobile phases modified with 0.05% m-NBA 
0.01% FA gave optimal signal in plasma and extract for both analytes (Figure 4.9 and 
Figure 4.10). 
Plasma extracts were analysed using both the optimal m-NBA and standard FA modified 
mobile phase methods. Unfortunately, despite the extensive optimisation the  
m-NBA modified mobile phase method did not offer significant sensitivity increases for 
either analyte (Table 4.3) 
Table 4.3 Signal-to-noise in various SRMs obtained by analysis of plasma extracts using 
m-NBA or the original formic acid modified mobile phases. 
Despite extensive optimisation, glucagon and GLP-1 plasma extracts gave similar signal-to-noise 
when analysed using the optimal m-NBA modified mobile phases, as when analysed using the 
original FA only modified phases. 
However, the alternative transitions provided by m-NBA modified method, could be used as 
sensitive qualifier transitions to demonstrate the selectivity of the FA only modified method.  
Transitions in red were maintained in the m-NBA modified qualifier method; whereas those in blue 
were maintained in quantitative FA only modified method. Although these transitions did not 
always give the best S/N, they gave best overall performance when linearity and precision and 
accuracy were considered. 
Glucagon 
transition 
S/N GLP-1 
transition 
S/N 
0.2% FA 0.05% 
MNBA 
0.01% FA 
0.2% FA 0.05% 
MNBA 
0.01% FA 
581.1/575.3 N/A 31.1 550.5/547.5 N/A 18.0 
581.1/578.2 N/A 26.9 550.5/601.5 N/A 14.5 
697.5/639.8 17.6 15.4 550.5/639.3 N/A 10.8 
   660.1/656.7 12.0 3.4 
   660.1/751.5 7.0 8.1 
   825.1/458.2 N/A N/A 
   825.1/946.4 4.1 N/A 
   1099.5/1093.7 N/A N/A 
Mobile phases are A=ACN and B=water (or water/ACN 95/5 for m-NBA modification), modified as shown 
in the table. N/A - not applicable, as no peak was observed 
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Although it was disappointing that sensitivity was not improved, the m-NBA method 
provided access to alternative transitions, which could be used as qualifier transitions to 
ensure assay specificity, as detailed in Section 4.3.6. 
The method was therefore further refined to maximise performance. The SRM method was 
split into separate methods for each mobile phase type, with transitions highlighted in red 
retained in the m-NBA method, and those in blue retained in the FA method. Although 
these transitions did not always give the best S/N, they gave best overall performance 
when linearity and precision and accuracy were considered. Splitting methods also allowed 
the dwell time to be increased for each transition, improving sensitivity. Scheduled SRM 
was replaced with MS periods, as this was also found to improve sensitivity. Optimisation 
of the m/z for each transition led to the FA and m-NBA methods described in full in 
Section 4.2.7 and Section 4.2.8 respectively. Method performance was further 
characterised during the qualification (Section 4.3.5). 
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4.3.4 Quantitation Strategy 
The endogenous nature of glucagon presents additional challenges as an authentic matrix 
free of analyte cannot be acquired, and therefore approaches such as standard addition, 
surrogate matrix or surrogate analyte quantitation must be considered as described in 
Section 1.7.2 and Section 2.3.2. This assay used the surrogate matrix based approach for 
glucagon quantitation, as also used in Chapter 2, where calibration standards are prepared 
in an analyte-free surrogate matrix, allowing low levels of glucagon in plasma samples to 
be quantified without extrapolation. Ideally surrogate calibrants and surrogate QC samples 
would be extracted alongside plasma samples, but this was not possible due to non-specific 
binding of the analyte in surrogate matrix to the extraction materials. Therefore, non-
extracted surrogate samples were used, which were added to the plate after plasma samples 
had been extracted. 
Similarly, in such strategies it is common to evaluate the performance of plasma samples 
diluted with surrogate matrix to demonstrate parallelism between surrogate and authentic 
matrix [2][7][8]. However, this was not possible as dilution prevented the protein 
precipitation, which was required in the extraction procedure. Therefore, the performance 
of QCs spiked with analyte on top of the endogenous levels against the surrogate 
calibration line was considered sufficient. 
Acceptable sensitivity is usually demonstrated by assessing whether the analyte response at 
the LLOQ level is at least 5 times the average response due to background noise [2]. It is 
then assumed that an unknown sample at the LLOQ concentration would also have a 
similarly acceptable response. However, this will not necessarily be the case for surrogate 
matrix assays, due to differences in the recovery and matrix suppression between the 
surrogate and authentic matrices. The method described in Chapter 2 had a mean analyte 
recovery of 51.2% and matrix suppression (matrix factor=0.746), and therefore the S/N at 
the LLOQ was 13.1 to ensure that S/N for an authentic sample at the LLOQ level 5 
(assuming an unchanged background level) (Section 2.3.3). However using the re-
optimised extraction method the IS response from surrogate matrix and plasma samples 
were similar (Figure 4.11) demonstrating that recovery losses during plasma extraction 
were compensated by matrix enhancement. The increase in the signal-to-noise 
requirements of surrogate matrix LLOQs were therefore not required, and allowed 
establishment of a 15 pg/mL LLOQ with signal-to-noise 5.  
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The assay was not sensitive enough to detect endogenous concentrations of GLP-1, 
therefore it was quantified using an exogenous quantitation strategy, where both calibrants 
and QCs were prepared in the authentic plasma matrix.  
 
 
  
Figure 4.11 SIL glucagon internal standard response in a) a non-extracted surrogate 
matrix sample and b) an extracted plasma sample at the same concentration (2 ng/mL). 
There was no significant difference between SIL peak heights and SIL peak areas between non-
extracted surrogate matrix samples and extracted plasma samples. Losses during extraction of 
plasma samples must therefore be compensated by matrix enhancement from plasma extracts. 
Consequently, raised signal-to-noise requirements at the surrogate matrix LLOQ, which were 
required with the original method (Section 2.3.3), were no longer required. With the re-optimised 
method, surrogate matrix LLOQs with signal-to-noise 5 should ensure signal-to-noise 5 from 
extracted plasma samples containing glucagon at the LLOQ level. 
 
A dual x axis is shown on the chromatograms. The upper part displays the time (e.g. 1.05 – 1.95 
min for panel a)) and the lower part displays the scan number (e.g. 324 – 601 for panel a)). 
  
a) 
b) 
Non-extracted Surrogate 
Matrix Sample 
Peak height= 3.0e4 cps 
Peak area= 4.4e4 counts 
Extracted Plasma Sample 
Peak height= 3.0e4 cps 
Peak area= 4.2e4 counts 
(95% a) 
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4.3.5 Qualification 
The FDA [1] and EMA [2] bioanalytical validation guidelines do not formally consider 
large molecule or biomarker analysis by LC-MS/MS. However, they are often used as the 
basis for such studies, as in this current work, as many experiments are applicable and 
alternative regulatory guidelines do not exist. When setting acceptance criteria for 
biomarker assays, it is important to consider the natural variability of the biomarker. For 
glucagon, plasma concentrations can vary widely (3-130 pg/mL), and therefore a very 
stringent acceptance criteria was not considered necessary. Considering this and the 
analytical challenges associated with the surrogate nature of the assay, a 20% value was 
used for glucagon precision and accuracy across all levels, which is often used for 
immunoassays. For GLP-1, a 25% criterion was selected at all levels, due to the analytical 
challenges presented by the lack of a SIL or closely related analogue IS. 
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4.3.5.1 Glucagon 
The performance of the developed method was initially assessed using formic acid-based 
mobile phases. The assay was linear over the 15-2000 pg/mL calibration range selected 
(Figure 4.12a). 
 
 
Figure 4.12 Representative glucagon and GLP-1 calibration lines.  
a) Glucagon surrogate matrix calibration line (15-2000 pg/mL) (analyte transition: 697.5694.0, 
SIL glucagon IS transition: 702.2698.8) 
b) GLP-1 plasma calibration line (25–2000 pg/mL) (analyte transition: 660.6752.0, analogue 
glucagon IS transition: 677.4673.8). 
 
Both calibration lines were linear, with back calculated concentrations of all calibration standards 
within 15% (20% for LLOQ) of their nominal concentrations for glucagon, or within 25% for  
GLP-1, thereby passing acceptance criteria. 
a) Glucagon calibration line 
b) GLP-1 calibration line 
 
Analyte Concentration (pg/mL) 
Analyte Concentration (pg/mL) 
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Signal to noise was ≥5 at the LLOQ level (Figure 4.13a). Precision and accuracy (%CV 
and %RE) were within the 20% acceptance criteria across all levels assessed (Table 4.4). 
 
 
Figure 4.13 Glucagon and GLP-1 LLOQ chromatograms.  
a) Glucagon surrogate matrix sample at 15 pg/mL (697.5694.0) (S/N=7.6). 
b) GLP-1 plasma sample at 25 pg/mL (660.6752.0) (S/N= 5.6). 
Glucagon and and GLP-1 showed acceptable signal-to-noise at LLOQ (S/N5) 
 
A dual x axis is shown on the chromatograms. The upper part displays the time (e.g. 1.05 – 1.75 
min for panel a)) and the lower part displays the scan number (e.g. 324 – 539 for panel a)). 
  
a) Glucagon LLOQ 
(15 pg/mL) 
S/N =7.6 
b) GLP-1 LLOQ 
(25 pg/mL) 
S/N= 5.6 
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Table 4.4 Precision and accuracy of surrogate matrix and extracted plasma glucagon 
samples analysed using LC-MS/MS with either the original FA modified mobile phases, or  
m-NBA modified mobile phases. 
Precision and accuracy (%CV and %RE) were within the 20% acceptance criteria across all levels 
assessed, except for QC dilution (DIL) when analysed with m-NBA modified mobile phases. 
Sample ID Surrogate/ 
Plasma 
Sample  
Spiked 
concentration 
(pg/mL) 
0.2% FA Phases 
Glucagon 
(697.5/694.0) 
0.05% m-NBA 
0.01% FA phases 
Glucagon 
(581.5/578.5) 
%Nominal %CV %Nominal %CV 
QC LLOQ Surrogate 15 110.3 11.9 96.9 15.4 
QC LOW Surrogate 45 113.8 6.2 110.9 11.8 
(QC LLOQ)* Plasma 25 
1
 92.6 7.0 90.6 10.0 
(QC LOW)* Plasma 75 
1
 92.4 11.3 99.6 10.9 
QC MED Plasma 200 
1
 91.4 8.7 100.0 9.7 
QC MED  
(lithium heparin) 
Plasma 200 
2
 92.6 9.0 119.0 9.3 
QC MED  
(inter matrix) 
Plasma 200 
3
 106.3 4.5 111.7 5.3 
QC DIL Plasma  1750 
4
 84.9 6.7 78.1 8.3 
QC HIGH Plasma 1750 
1
 98.0 10.7 106.1 12.2 
*  = QC level created for GLP-1 analysis, but also monitored for glucagon to improve assay characterisation 
1 = 31.9 pg/mL / 37.5 pg/mL endogenous glucagon measured using formic acid / m-NBA phases, and added 
to the spiked concentration  
2 = Endogenous glucagon not detected in lithium heparin plasma used 
3 = Adjusted for endogenous glucagon concentration determined in each individual matrix 
4 = No endogenous glucagon detected in matrix used for dilution QCs 
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Matrix enhancement was observed, however this was compensated by the enhancement of 
the SIL IS, so it did not affect quantitation (Table 4.5). The assay gave acceptable 
performance across six individuals’ matrices fortified with 200 pg/mL glucagon, and also 
in lithium heparin plasma, providing further evidence that the assay was not significantly 
affected by matrix changes (Table 4.4) 
There were no interferences in the selectivity samples near glucagon’s retention time that 
could affect the quantitation. Recovery, determined at 200 pg/mL, was 50.7%. 
Table 4.5 Glucagon matrix effects determined using LC-MS/MS with either the original 
FA modified mobile phases, or m-NBA modified mobile phases. 
IS-normalised matrix factors were close to 1, demonstrating that the internal standard compensated 
for analyte response modification by the independent matrices. The IS-normalised MF CVs were 
20%, demonstrating that the extent of compensation was similar between matrices. 
Matrix 
ID 
0.2% FA Phases 
Glucagon (697.5/694.0) 
0.05%  m-NBA 
 0.01% FA phases 
Glucagon (581.5/578.5) 
MF 
(Analyte 
Peak 
Area 
Only) 
MF 
(IS 
Peak 
Area 
Only) 
IS-
Normalised 
MF 
MF 
(Analyte 
Peak 
Area 
Only) 
MF 
(IS 
Peak 
Area 
Only) 
IS-
Normalised 
MF 
F1 1.58 1.48 1.07 1.09 0.985 1.10 
F2 1.36 1.43 0.951 1.01 1.05 0.961 
F4 1.33 1.34 0.992 0.924 0.899 
 
 
1.03 
F5 1.30 1.47 0.882 1.16 1.19 0.979 
M1 1.33 1.21 1.10 0.922 0.792 1.16 
M4 1.32 1.20 1.09 0.656 0.591 1.11 
Mean 1.37 1.36 1.01 0.960 0.918 1.06 
SD 0.104 0.127 0.0881 0.176 0.209 0.0806 
%CV 7.6 9.3 8.7 18.4 22.8 7.6 
Samples were post spiked at the 200 pg/mL level 
MF = Corrected peak area in presence of plasma matrix ions* / mean peak area in absence of plasma matrix 
ions 
* Corrected peak area in presence of plasma matrix ions = Peak area in presence of plasma matrix ions and 
spiked analyte - endogenous peak area. 
IS-normalised MF = MF Analyte / MF IS 
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The performance of the method was similarly assessed using mobile phases modified with 
m-NBA, and comparable performance was observed (Table 4.4 and Table 4.5) 
demonstrating the methods suitability for providing a qualifier SRM to further assure 
selectivity as discussed in Section 4.3.6 
Glucagon was unstable at room temperature (65.9%) but stable on ice (110.1%) when 
incubated for 4 hr 50 min in plasma, which sufficiently encompassed processing times for 
all samples extracted. Glucagon’s stability on ice for this time period is consistent with 
observations by some others [9]. However, it was a little surprising that there were no signs 
of instability, as previously glucagon degraded to as much as 76% when handled on ice for 
just 90 min longer (6 hr 20 min) (Section 2.3.3 and Section 3.3.4). Although it cannot be 
excluded that other differences (e.g. variations in inherent protease activity between 
matrices) also contributed towards the differences in stability, as the original time period 
was not re-assessed. Such possibilities are explored further in the Future Work Chapter  
(Section 5.2.5). 
The ability to re-inject extracts was demonstrated after storage for 42 days at 4C  
(Table 4.6). Samples could be diluted ten-fold without affecting quantitation, enabling 
analysis in cases of low sample volume (Table 4.4). 
 
Table 4.6 Ability to re-inject sample extracts after storage for 42 days at 4 C. 
Extracts could be analysed after 42 days storage at 4 C with precision and accuracy (%CV and 
%RE) within the acceptance criteria (20% for glucagon and 25% for GLP-1) across all levels.  
  
Surrogate/ 
Plasma Matrix 
Spiked 
Concentration  
(pg/mL) 
Glucagon GLP-1 
 %Nominal %CV %Nominal %CV 
Surrogate 15 107.1 11.6 N/A N/A 
Surrogate 25 106.0 11.3 N/A N/A 
Surrogate 45 111.3 7.8 N/A N/A 
Plasma 25# 86.5 7.6 116.6 7.4 
Plasma 75# 87.7 10.1 99.3 24.8 
Plasma 200# 89.6 10.0 98.4 7.3 
Plasma 1750# 99.0 13.6 104.7 22.2 
Extracts analysed using FA only modified mobile phases. 
#31.4 pg/mL endogenous concentration added to glucagon QC concentration 
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4.3.5.2 GLP-1  
Following optimisation and evaluation of sensitivity and linearity, the 660.6656.9 and 
660.6752.0 SRM transitions were found to be similarly optimal, with sufficient 
sensitivity obtained at 25 pg/mL for extracted plasma samples. Previously, either the  
825.4946.3 transition alone [10][11], or the 825.2946.4 transition summed with  
825.2643.2 [12] were found optimal. Differences in the LC-MS/MS systems used, 
including the use of nano or microflow LC in the previous studies, as well as variations in 
the nature of samples used for evaluation, may help to explain the discrepancies. 
A SIL IS or a closely related analogue was not available for GLP-1. The glucagon internal 
standards were therefore selected to investigate whether they offered advantages over IS-
free quantitation for GLP-1. The GLP-1 assay was characterised for precision and accuracy 
using two different GLP-1 SRM transitions for each mobile phase to ensure the most 
appropriate was selected.  
Precision and accuracy (%CV and %RE) using FA mobile phases was acceptable (25%) 
for all but one analyte SRM and internal standard combinations, with the 660.6752.0 
GLP-1 SRM with the analogue glucagon internal standard giving the best overall 
sensitivity and performance (Table 4.7). The assay was linear over the 25-2,000 pg/mL 
calibration range assessed (Figure 4.12b) and signal to noise was ≥5 at the LLOQ level 
(Figure 4.13b) using this transition. 
Performance was generally worse using m-NBA modified phases, especially at the LLOQ 
level (Table 4.8). This is likely due to the glucagon internal standards performing 
differently under supercharging conditions to the GLP-1 analyte. Such phases were, 
therefore, not investigated further for GLP-1. The method using the FA mobile phases with 
the analogue glucagon internal standard was retained for future work. 
.
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Table 4.7 Precision and accuracy of extracted plasma GLP-1 samples analysed using FA modified mobile phases with either the SIL or 
analogue glucagon internal standard. 
Precision and accuracy (%CV and %RE) using FA mobile phases was acceptable (25%) for all but one analyte SRM and internal standard combination, with 
the 660.6752.0 GLP-1 SRM with the analogue glucagon internal standard giving the best overall sensitivity and performance. 
 
Sample ID Surrogate/ 
Plasma 
Sample 
Nominal 
concentration 
(pg/mL) 
0.2% FA phases 
GLP-1 (660.6/656.9) 
0.2% FA phases 
GLP-1 (660.6/752.0) 
No IS SIL IS Analogue IS No IS SIL IS Analogue IS 
%Nom %CV %Nom %CV %Nom %CV %Nom %CV %Nom %CV %Nom %CV 
QC LLOQ Plasma 25 102.2 18.2 88.0 11.6 86.9 16.7 131.4 20.1 118.6 20.0 112.7 24.6 
QC LOW Plasma 75 102.6 13.1 113.1 13.6 113.8 11.7 103.7 22.4 110.2 11.3 107.4 13.6 
QC MED Plasma 200 107.9 16.6 107.4 7.7 109.6 8.4 108.6 10.7 107.3 2.0 107.2 6.7 
QC MED  
(Lith Hep) 
Plasma 200 NA NA NA NA NA NA 72.9 15.6 81.9 12.6 75.2 12.9 
QC MED 
 (inter matrix) 
Plasma 200 NA NA NA NA NA NA 149.1 15.4 134.5 16.0 122.9 16.3 
QC DIL Plasma 10,000 73.1 9.6 72.1 10.5 74.7 11.8 76.6 6.7 75.7 8.8 76.8 10.0 
QC HIGH Plasma 1,750 99.7 15.6 111.6 2.7 113.9 5.8 102.9 15.5 113.8 3.6 113.8 6.7 
%Nom= % nominal concentration 
Green statistics are within 25% RE or <25%CV. Red statistics are outside these criteria 
NA –not analysed, as 660.6/752.0 was determined to be optimal before these experiments were conducted 
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Table 4.8 Precision and accuracy of extracted plasma GLP-1 samples analysed using m-NBA modified mobile phases with either the SIL or 
analogue glucagon internal standard. 
Precision and accuracy (%CV and %RE) were generally worse using m-NBA modified mobile phases than FA only modified phases (Table 4.7), especially at 
the LLOQ level. This is likely due to the glucagon internal standards performing differently under supercharging conditions to the GLP-1 analyte. Such phases 
were, therefore, not investigated further for GLP-1. 
Sample ID Surrogate/ 
Plasma 
Sample 
Nominal 
concentration 
(pg/mL) 
0.05% m-NBA 0.01% FA phases 
(550.6/601.6) 
0.05%  m-NBA 0.01% FA phases 
(550.6/639.3) 
No IS SIL IS Analogue IS No IS SIL IS Analogue IS 
 %Nom %CV %Nom %CV %Nom %CV %Nom %CV %Nom %CV %Nom %CV 
QC LLOQ Plasma 25 88.0 25.6 75.1 36.6 75.1 33.8 75.0 43.2 57.5 39.8 63.4 33.0 
QC LOW Plasma 75 83.9 17.3 107.0 19.6 103.9 15.8 71.0 15.5 104.4 25.3 96.0 22.8 
QC MED Plasma 200 80.2 14.1 94.8 8.8 94.4 7.2 75.0 13.6 91.4 11.5 88.3 12.8 
QC MED 
(Lith Hep) 
Plasma 200 NA NA NA NA 59.9 19.4 NA NA NA NA NA NA 
QC MED  
(inter matrix) 
Plasma 200 NA NA NA NA 177.1 37.5 NA NA NA NA NA NA 
QC DIL Plasma 10,000 63.8 12.4 75.8 7.4 74.6 8.3 63.6 13.7 83.1 7.2 76.6 7.9 
QC HIGH Plasma 1,750 80.1 12.8 99.6 16.8 107.4 12.2 78.7 13.6 103.2 18.4 106.8 14.1 
%Nom= % nominal concentration 
Green statistics are within 25% RE or <25%CV. Red statistics are outside these criteria 
NA –not analysed, as FA only modified phases were deemed optimal before these experiments were conducted 
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GLP-1 matrix suppression was observed, whereas the analogue glucagon IS experienced 
matrix enhancement. However the ratio between the two (IS-Normalised MF) was similar 
across the matrices (CV=16%), so there was no effect on quantitation (Table 4.9). In 
addition the assay gave acceptable performance across six individual matrices, and six 
replicates of lithium plasma spiked with 200 pg/mL analyte (Table 4.7). 
Table 4.9 GLP-1 matrix effects determined using LC-MS/MS with the original FA 
modified mobile phases and the analogue glucagon internal standard. 
GLP-1 matrix suppression was observed, whilst analogue glucagon IS enhancement was noted. 
Consequently, IS-normalised MF were not close to 1. However the CV of the IS-normalised MF 
was 25%, demonstrating that the extent of IS compensation was similar between different 
matrices. Therefore quantitation would be unaffected, as extracted standards and samples would be 
similarly affected by the GLP-1 matrix suppression and IS matrix enhancement. 
Matrix ID 0.2% FA Phases 
GLP-1 (660.6/752.0) with analogue glucagon IS 
MF 
(Analyte 
Peak 
Area 
Only) 
MF 
(IS 
Peak 
Area 
Only) 
IS-Normalised 
MF 
F1 1.14 1.41 0.808 
F2 0.869 1.33 0.653 
F4 0.876 1.40 0.628 
F5 0.735 1.34 0.548 
M1 1.02 1.24 0.827 
M4 0.765 1.19 0.641 
Mean 0.901 1.32 0.684 
SD 0.154 0.0860 0.110 
%CV 17.1 6.5 16.1 
Samples were post spiked at the 200 pg/mL level 
MF = Corrected peak area in presence of plasma matrix ions* / mean peak area in absence of plasma matrix 
ions 
* Corrected peak area in presence of plasma matrix ions = Peak area in presence of plasma matrix ions and 
spiked analyte - endogenous peak area 
IS-normalised MF = MF Analyte / MF IS 
Green statistics have IS-normalised MFs within 25% of 1, or %CV25%. Red statistics are outside these 
criteria 
 
There were no interferences in the selectivity samples at the GLP-1 retention time. As 
expected [9]. GLP-1 was unstable at room temperature (9.6%) but stable on ice for 4 hr 50 
min (94.7%). The ability to re-inject extracts was demonstrated after 42 days storage at  
4 C (Table 4.6). GLP-1 recovery determined at 200 pg/mL (53.7%) was similar to 
glucagon’s, and it was demonstrated that samples could be diluted ten-fold without 
affecting quantitation (Table 4.7). 
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4.3.6 Analysis of Plasma from Volunteers to Determine Endogenous Glucagon 
Concentrations  
Plasma was collected from 11 healthy males and 11 healthy females and glucagon levels 
determined using the qualified LC-MS/MS method with standard FA mobile phases. 
Plasma glucagon concentrations were between 15 pg/mL (BLQ) and 47.1 pg/mL 
(Table 4.10), similar to ranges reported in the literature (3 to 130 pg/mL [3] or 27 to 87 
pg/mL [10]). 
Table 4.10 Endogenous glucagon concentrations from healthy volunteers, and ISR 
assessment. 
Endogenous glucagon concentrations from healthy volunteers were within the range expected from 
literature (3 to 130 pg/mL or 27 to 87 pg/mL). Reanalysis of a subset of samples after storage 
gave reanalysed (ISR, incurred sample reproducibility) concentrations within 20% of their original 
value for 6/9 (66.6%) samples, demonstrating reproducible quantitation. 
Sample Days stored  
(-80 C) 
 before  
original  
analysis  
Original 
Concentration 
(pg/mL) 
 
Days stored 
at -80 C 
 between  
analyses 
ISR 
 concentration  
(pg/mL) 
%  
Difference 
ISR 
Pass/ 
Fail 
M1  95 19.1 152 25.3 27.9 Fail 
M2 74 BLQ (8.50) 152 - - - 
M3  74 25.7 - NS - - 
M4  11 42.8 152 39.1 -9.0 Pass 
M5 11 34.1 249 44.8 27.2 Fail 
M6 11 27.2 249 27.8 2.2 Pass 
M7 15 BLQ (12.5) - - - - 
M8 36 BLQ (No Peak) - - - - 
M9  36 BLQ (No Peak) - - - - 
M10 38 BLQ (14.1) - - - - 
M11 38 45.9 6 50.4 9.3 Pass 
F1 95 BLQ (14.7) - - - - 
F2 95 40.0 152 41.9 -4.6 Pass 
F3 74 15.1 152 15.7 3.9 Pass 
F4 11 33.8 152 23.4 -36.4 Fail 
F5 11 BLQ (No Peak) - - N/A - 
F6 10 BLQ (10.3) - - - - 
F7 15 BLQ (9.46) - - N/A - 
F8 15 26.9 99 24.7 -8.5 Pass 
F9 36 BLQ (14.7) - - - - 
F10 38 BLQ (14.5) - - - - 
F11 38 15.5 6 BLQ (No Peak) - - 
% Difference = 100 * (ISR concentration-original concentration)/original concentration 
ISR fail = % difference outside 20%; ISR pass = % difference within 20%. 
NS= No Sample remaining for repeat analysis. 
Extrapolated concentrations are given in parenthesis.  
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Several samples contained evidence of glucagon, but the concentrations were BLQ  
(Figure 4.14). Numerical values were determined for indicative purposes by extrapolation 
of the calibration line, and are shown in parenthese in Table 4.10. The performance of the 
method at the 10 pg/mL level, as determined by evaluation of surrogate matrix QCs, was 
reasonable (mean accuracy 87.4%, CV= 29.7%), however poor performance resulted at the 
7.5 pg/mL level (Mean accuracy 68.6%, CV= 40.4%). This should be considered when 
evaluating plasma concentrations below the established range. 
As described in Section 4.3.4, the signal from surrogate matrix samples is equivalent to 
plasma samples at the same concentration for this assay. They, therefore, appropriately 
represent plasma samples at low concentrations (low S/N), such as those described above. 
Hence, the precision and accuracy determined from surrogate matrix samples at 7.5 and  
10 pg/mL is considered to apply to plasma samples at these levels. This is in contrast to 
Chapter 2, where plasma samples have lower S/N at the same concentration, and therefore 
such equivalence of precision and accuracy does not apply (Section 2.3.4).  
 
Figure 4.14 Glucagon chromatograms from a a) BLQ (14.7 pg/mL) and b) within range 
(40.0 ng/mL) sample. 
Although the sample in a) gave BLQ (<15 pg/mL) concentrations of glucagon, an integratable peak 
was observed, allowing indicative concentrations to be obtained by extrapolation of the calibration 
line. A dual x axis is shown on the chromatograms. The upper part displays the time (e.g. 1.10 – 
1.90 min for panel a)) and the lower part displays the scan number (e.g. 339 – 585 for panel a)).  
a) 
b) 
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Samples with glucagon concentrations levels above the LLOQ were reanalysed after 
storage to assess incurred sample reproducibility (ISR) (Table 4.10). 6/9 (66.6%) samples 
gave concentrations within 20% of the original concentration, therefore passing standard 
criteria. A further sample gave a BLQ value upon reanalysis, although as its original 
concentration was close to the 15 pg/mL LLOQ, this was within the expected range. The 
storage time before reanalysis varied from 6-249 days, but no trend between the % 
difference and storage time was observed. 
Similarly, a pooled plasma sample (n=6 replicates) gave a re-assayed concentration (33.3 
pg/mL, CV=9.4%) within 4.3% of its original concentration (31.9 pg/mL, CV=6.1%) 
following additional storage for 42 days at -80 C (Table 4.11). This further demonstrated 
the method’s good reproducibility at the endogenous glucagon level.  
Table 4.11 Inter-batch reproducibility of endogenous plasma glucagon determination. 
Reproducible quantitation of a pooled endogenous glucagon sample was demonstrated both within 
a batch and after storage. 
 
Replicate Measured Endogenous Glucagon Concentration (pg/mL) 
Initial Analysis Reanalysis after 42 Days 
storage at -80 C 
1 29.7 34.0 
2 31.1 36.5 
3 33.8 31.7 
4 32.7 35.7 
5 34.2 33.8 
6 29.9 27.9 
Mean 31.9 33.3 
SD 1.95 3.11 
CV 6.1 9.4 
% Difference 4.3 
% Difference= 100* ((Reanalysis concentration –Initial concentration) / Initial concentration) 
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For exogenous compounds, the absence of significant peaks at the analyte retention time 
can be used to demonstrate the selectivity of the method. This is not possible for 
endogenous compounds, and, therefore, additional SRM transitions can be monitored as 
qualifier transitions to ensure selectivity [13][14][15][16]. However, for glucagon the only 
SRM sensitive enough to determine endogenous concentrations using formic acid mobile 
phases was that monitored (697.5/694.0). The method with mobile phases modified with 
m-NBA enabled access to an alternative sensitive qualifier SRM transition (581.5/578.5), 
derived from a higher charge state, as well as providing alternative LC conditions. 
Reanalysis of extracts using this method demonstrated concentrations were not 
significantly different to those originally obtained providing additional evidence for the 
selectivity of the formic acid based mobile phase method (Table 4.12). To the author’s 
knowledge, the use of supercharging mobile phases to provide alternative qualifier SRMs 
has not been previously reported. 
Table 4.12 Determination of endogenous plasma glucagon concentrations using FA and 
m-NBA modified mobile phases and corresponding SRM transitions. 
The selectivity of the quantitative assay was demonstrated by the close agreement of endogenous 
glucagon concentrations determined by it, and those determined by the qualification assay. 
Sample Glucagon Concentration (pg/mL) % Difference 
Quantitative  
assay 
Qualification 
assay  
0.2% FA Phases 
 
 
Glucagon SRM 
697.5/694.0 
0.05% m-NBA 
0.01% FA Phases 
 
Glucagon SRM 
581.5/578.5 
F1 BLQ (14.7) BLQ (12.6) -14.3 
F2 40.0 43.3 8.2 
F3 15.1 17.2 13.9 
F4 33.8 32.8 -3.0 
F5 No Peak No Peak N/A 
M1 19.1 23.1 20.9 
M2 BLQ (8.50) No Peak N/A 
M3 25.7 26.8 4.3 
M4 42.8 46.2 7.9 
% difference= 100* (Qualification assay concentration – quantitative assay concentration)/quantitative assay 
concentration.  
Extrapolated concentrations given in brackets 
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4.3.7 Cross Validation against Established Immunoassays using Physiological 
Samples 
Plasma samples were available to cross-validate the LC-MS/MS method against 
established immunoassays. These originated from a physiological study assessing the 
preanalytical stability of glucagon and GLP-1 in the presence of various stabilisers and 
anticoagulants. These did not introduce a significant matrix effect affecting LC-MS/MS 
quantitation (Table 4.13). Samples originated from fasting healthy volunteers (endogenous 
glucagon), volunteers dosed with glucagon, and volunteers dosed with GLP-1. Results of 
the stability investigations at the endogenous glucagon level have been recently reported. 
[17]. Two immunoassays using different assay formats were used to cross-validate each 
analyte against the LC-MS/MS method, to help provide confidence, or otherwise, of the 
immunoassays results. 
Table 4.13 Performance of QCs in stabilised plasma vs. non-stabilised plasma. 
QC samples were prepared in matrix from physiological study samples containing various 
stabilisers and anticoagulants. Measured concentrations were within 20/25% for glucagon/GLP-1 
of those obtained from non-stabilised EDTA QC samples, therefore demonstrating that the change 
of matrix did not significantly affect quantitation. 
 
Anticoagulant Stabiliser Freeze-thaw 
cycles 
% Non-stabilised  
EDTA plasma  
batch acceptance  
QC (200 pg/mL) 
concentration 
Glucagon GLP-1 
EDTA None 0 113.3 77.9 
EDTA A 0 94.8 99.7 
EDTA D 0 102.9 104.9 
EDTA AD 0 109.1 107.0 
EDTA AD 1 101.1 86.2 
EDTA AD 2 109.5 95.0 
Lithium Heparin None 0 81.7 84.1 
Lithium Heparin A 0 98.1 97.1 
Lithium Heparin D 0 91.1 105.9 
Lithium Heparin AD 0 98.0 113.7 
200 pg/mL glucagon/GLP-1 was spiked into a variety of matrices from physiological study samples 
containing various stabilisers and anticoagulants, as shown above. Measured concentrations were compared 
to those from batch acceptance QCs spiked in non-stabilised EDTA plasma at 200 pg/mL. Endogenous 
concentrations were taken into account when calculating QC performance. 
 
A= Aprotinin inhibitor. D= DPP IV inhibitor. AD= Aprotinin + DPP IV inhibitor  
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For endogenous glucagon quantitation, the HTRF immunoassay demonstrated limited 
utility as only 16/50 samples were above the LLOQ (12.0 pg/mL). In contrast, the majority 
of the samples analysed by the Millilpex assay (38/45) and LC-MS/MS method (39/50) 
gave quantifiable (≥LLOQ) concentrations (≥13.0 pg/mL and ≥10.0 pg/mL respectively) 
(Figure 4.15). Whilst this may be expected for the LC-MS/MS method, with its lower 
LLOQ, the Milliplex had a higher LLOQ. This discrepancy may be due to differences in 
the standardisation of reference materials between the immunoassays and/or the Milliplex 
being more susceptible to interferences. Only data above the LLOQ is discussed below, 
and is shown in Figure 4.16, as large errors would likely be associated with lower 
concentrations.
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Figure 4.15 Comparison of endogenous glucagon concentrations determined by LC-MS/MS, Milliplex and HTRF immunoassays (all 
concentrations). 
The HTRF immunoassay demonstrated limited utility as only 16/50 samples were above its LLOQ (12.0 pg/mL). In contrast, the majority of the samples 
analysed by the Millilpex assay (38/45) and LC-MS/MS method (39/50) were above their LLOQs (13.0 pg/mL and 10.0 pg/mL respectively). Data above the 
LLOQs only are displayed in Figure 4.16. 
 
Samples were analysed from 5 volunteers (1-5), which contained either EDTA (E) or lithium heparin (L) anticoagulant in addition to various stabilisers (not 
shown). Different stabiliser combinations were used (or freeze-thaw cycles undertaken) in samples of the same Sample Type, i.e. the six 4E samples are all 
unique. See Section 4.2.11 for further details on the nature of the samples. 
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Figure 4.16 Comparison of endogenous glucagon concentrations determined by LC-MS/MS, Milliplex and HTRF immunoassays (concentration 
above the assay LLOQs only). 
 
In contrast to Figure 4.15, only data above the assay LLOQs are displayed in the figure above, as large errors would likely be associated with concentrations 
beneath the LLOQ. Differences in measured glucagon concentrations between the assays are explored via the pairwise comparisons in Figure 4.17. 
 
Samples were analysed from 5 volunteers (1-5), which contained either EDTA (E) or lithium heparin (L) anticoagulant in addition to various stabilisers (not 
shown). Different stabiliser combinations were used (or freeze-thaw cycles undertaken) in samples of the same Sample Type, i.e. the six 4E samples are all 
unique. See Section 4.2.11 for further details on the nature of the samples. 
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The endogenous glucagon concentrations measured by all three methods were within 
literature ranges (3-130 pg/mL [3] or 27-87 pg/mL [10]) (Figure 4.17). Where both the 
HTRF and LC-MS/MS methods gave quantifiable (≥LLOQ) concentrations, these were of 
similar magnitude with no notable inter-volunteer or anticoagulant effects  
(Figure 4.17a). Likewise the LC-MS/MS and Milliplex methods gave similar 
concentrations for samples from volunteers 1, 2, and 5, and from the EDTA samples from 
volunteer 3 (Figure 4.17b). However, the Milliplex gave significantly higher 
concentrations for lithium heparin samples obtained from volunteer 3, and for all samples 
from volunteer 4.  The Milliplex assay also showed a positive bias for samples from 
volunteer 4 in comparison to the HTRF when quantifiable (≥LLOQ) results were compared  
(Figure 4.17c). This suggests that the matrix from volunteer 4 affects Milliplex quantitation 
due to the presence of low level interferences sharing an epitope with glucagon or due to 
other non-specific interferences, as has been suggested previously [3]. Similarly, 
interferences may be present in lithium heparin samples from volunteer 3, affecting 
immunoassay quantitation. The poor sensitivity of the HTRF, and potential susceptibility 
of the Milliplex assay to matrix interferences, demonstrates some of the challenges in 
selecting appropriate immunoassays for LC-MS/MS cross validation.  
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Figure 4.17 Pairwise comparisons of endogenous glucagon concentrations determined by 
LC-MS/MS and two immunoassays. 
a) HTRF vs LC-MS/MS. Glucagon concentrations were of similar magnitude, with no notable 
inter-volunteer or anticoagulant effects. 
b) Milliplex vs. LC-MS/MS. Similar concentrations were obtained for samples from volunteers 1, 
2, and 5, and from the EDTA samples from volunteer 3. However, the Milliplex assay gave 
significantly higher concentrations for lithium heparin samples obtained from volunteer 3, and for 
all samples from volunteer 4. 
c) HTRF vs. Milliplex. Similar concentrations were obtained from volunteers 1,3 and 5. As with b) 
the Milliplex assay showed a positive bias for samples from volunteer 4, suggesting the matrix 
from volunteer 4 contains interferences affecting Milliplex quantitation. 
Samples were analysed from 5 volunteers (1-5), which contained either EDTA (E) or lithium 
heparin (L) anticoagulant in addition to various stabilisers (not shown). Different stabiliser 
combinations were used (or freeze-thaw cycles undertaken) in samples of the same Sample Type, 
i.e. the four 4E samples are all unique. See Section 4.2.11 for further details on the nature of the 
samples. Only samples with quantifiable (≥LLOQ) results for both assays being compared are 
displayed. Full results are shown in Figure 4.15.  
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Concentrations of the samples from the volunteer dosed with glucagon strongly correlated 
between the two immunoassays, and similar absolute concentrations were determined 
(Figure 4.18a). This may be due to the absence of matrix interferences affecting the 
Milliplex assay from this volunteer, or interferences becoming negligible at higher 
glucagon concentrations. The LC-MS/MS method showed some similarity in concentration 
trends between samples, although results were less comparable, and absolute 
concentrations were generally higher. This may reflect differences in the natures of the 
techniques; immunoassays detect specific epitopes whereas the LC-MS/MS method targets 
the whole molecule. It has been recently suggested that epitope masking caused by 
glucagon aggregation may artificially lower immunoassay assay concentrations in plasma 
samples fortified with high levels of glucagon [18]. A similar process may occur in 
samples from dosed patients also containing high levels of glucagon. In addition to 
generally higher LC-MS/MS concentrations, this could also explain differences in 
concentration trends if aggregation occurred to various degrees in different samples. 
Samples from the two volunteers dosed with GLP-1 showed similar concentration trends 
between the samples across the three methods (Figure 4.18b). Absolute concentrations 
showed a systematic bias of LC-MS/MS > Millipore > Milliplex. This could be due to 
differences in the standardisation of reference materials. Although it was also noted that 
lithium heparin samples from subject 7 showed similar immunoassay concentrations, 
suggesting a susceptibility of the assays to inter-volunteer and anticoagulant related matrix 
effects. The limited agreement of the immunoassays restricted their value for further cross-
validation of the LC-MS/MS method. 
Overall, the cross-validation provided only limited confirmation for the performance of the  
LC-MS/MS method. However this was not unexpected as the poor performance of some 
immunoassays provided the main rationale for development of the LC-MS/MS method. 
Further investigations are needed with larger data sets, various sample types, and 
additional assays, to better characterise the performance of the developed LC-MS/MS 
method. 
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Figure 4.18 Comparison of concentrations determined by LC-MS/MS and two 
immunoassays in samples from volunteers dosed with a) glucagon and b) GLP-1. 
a) Concentrations of dosed glucagon strongly correlated between the two immunoassays, and 
similar absolute concentrations were determined. The LC-MS/MS method showed some similarity 
in concentration trends between samples, although results were less comparable, and absolute 
concentrations were generally higher. This may reflect differences in the natures of the techniques; 
immunoassays detect specific epitopes whereas the LC-MS/MS method targets the whole 
molecule. 
b) Concentration trends of dosed GLP-1 were similar between the three methods. Absolute 
concentrations showed a systematic bias of LC-MS/MS > Millipore > Milliplex. However it was 
noted that lithium heparin samples from subject 7 showed similar immunoassay concentrations, 
suggesting a susceptibility of the assays to inter-volunteer and anticoagulant related matrix effects. 
The limited agreement of the immunoassays restricted their value for further cross-validation of the 
LC-MS/MS method. 
Samples were analysed from one volunteer (labelled 6) dosed with glucagon and two volunteers 
(labelled 7 & 8) dosed with GLP-1. Samples contained either EDTA (E) or lithium heparin (L) 
anticoagulant in addition to various stabilisers (not shown). Different stabiliser combinations were 
used (or freeze-thaw cycles undertaken) in samples of the same Sample Type, i.e. the six 6E 
samples are all unique. See Section 4.2.11 for further details on the nature of the samples. 
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4.4 CONCLUSION 
This chapter describes a multiplexed LC-MS/MS method for the quantitation of 
endogenous glucagon, dosed glucagon, and/or dosed GLP-1 in human plasma without 
immunoenrichment. The sensitivity achieved (glucagon: 15 pg/mL qualified LLOQ,  
GLP-1: 25 pg/mL qualified  LLOQ) is the highest reported for both peptides for such an 
extraction. The methodology has been improved over the initial method described in 
Chapter 2 through a significant shortening of extraction time, inclusion of a stable isotope 
labelled internal standard and a reduction in LC-MS/MS cycle time. The one day 
extraction compares well against many immunoassays, which often incur overnight 
incubation steps, as required by the Millipore and Milliplex assays used in this study. 
Samples extracted for LC-MS/MS analysis can be run overnight providing data in a similar 
time frame to immunoassays that require overnight incubation.  
Good precision and accuracy was obtained over the calibration range, and recovery, matrix 
effects, and bench top stability were acceptable. Rather surprisingly, in contrast to  
Chapter 2 (Section 2.3.3) and Chapter 3 (Section 3.3.4) there was no indication of 
glucagon degradation when plasma samples were handled on ice. The stability of glucagon 
in plasma clearly requires further investigation, as detailed in Future Work (Chapter 5, 
Section 5.2.4 and Section 5.2.5). 
Improvements in sensitivity for plasma samples did not occur upon modifying mobile 
phases with the supercharging reagent m-NBA, despite extensive optimisation. However, 
such phases enabled access to a sensitive qualifier SRM transition, which was used to 
ensure endogenous glucagon specificity. To the author’s knowledge supercharging mobile 
phase additives have not previously been used for such a purpose. 
Endogenous glucagon concentrations were within the expected range, and determination 
was highly reproducible after extended sample storage (up to 249 days at -80 C). 
A cross-validation was performed using physiological samples with the qualified  
LC-MS/MS method and two immunoassays for each analyte. Some similarities between 
the LC-MS/MS method and immunoassays were observed for endogenous glucagon, but 
dosed glucagon and dosed GLP-1 samples showed a trend towards higher concentrations 
when measured by LC-MS/MS. It was, however, noted that immunoassays also showed 
some differences between each other, limiting their value for cross validation. Such 
differences were not wholly unexpected, as performance concerns associated with 
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glucagon and GLP-1 immunoassays provided the main rationale for development of the 
LC-MS/MS method. The LC-MS/MS method is, therefore, considered to be a viable 
alternative to immunoassay based approaches. 
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4.5 APPENDIX: DEFINITIVE METHOD FOR GLUAGON AND 
GLP-1 QUANTITATION AND QUALIFICATION 
4.5.1 Solution Preparation  
Stock solutions of glucagon (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and 
glucagon internal standards (1 mg/mL), and stocks of GLP-1 (0.1 mg/mL), should be 
prepared in borosilicate glass vials using surrogate matrix [MeOH:H2O:FA:BSA, 
(20:80:0.1:0.1, v/v/v/w); typically 200 mL MeOH, 800 mL H2O, 1mL FA and 1 g BSA]. 
Analogue internal standard (IS) (HSQGTFSDYSKYLDSRRAQDFVQWLMNT)(des-thr
7
-
glucagon)  and stable isotope labelled (SIL) internal standard (HSQGT-[
13
C9;
15
N]F-
TSDYSKYLDSRRAQDFVQW-[
13
C6;
15
N]L-MNT) should be used.  
Combined glucagon and GLP-1 working solutions should be prepared by dilution with 
surrogate matrix to create nine calibration standard spiking solutions (300, 500, 900, 2000, 
6000, 12000, 20000, 37000 and 40000 pg/mL), and six quality control spiking solutions 
(300, 500, 900, 1500, 4000 and 35000 pg/mL). A mixed ISWS containing both analogue 
glucagon and SIL glucagon should be similarly prepared at 20 ng/mL.  
All stock and working solutions should be prepared to a volume of 10 mL and stored at  
-20 C when not in use. 
4.5.2 Plasma Preparation  
Plasma should be generated in-house, as commercially sourced plasma has high 
background noise levels masking endogenous glucagon. 
Blood should be collected using glass blood collection tubes (5 mL, EDTA anticoagulant). 
Following collection, tubes should be immediately placed on ice and then centrifuged at 
2300 x g for 10 min to obtain plasma, which should be stored at -80 C when not in use. 
4.5.3 Plasma Calibration Standards and QC Preparation 
Working solutions should be diluted 20-fold into plasma to produce calibration standards 
at 25, 45, 100, 300, 600, 1000, 1850 and 2000 pg/mL and QC concentrations at 25 
(LLOQ), 75 (LOW), 200 (MED), and 1750 (HIGH) pg/mL.  
Plasma calibration standards are used for GLP-1 quantitation, whereas surrogate matrix 
calibration standards (Section 4.5.4) are used for glucagon quantitation due to the presence 
of endogenous analyte.  
Plasma QCs are used to assess GLP-1 assay performance, and are also used to assess 
glucagon assay performance after adjustment for the endogenous level.  
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4.5.4 Preparation of Surrogate Matrix Calibration Standards and QC 
Samples for Glucagon Quantitation  
Calibration standards, QC LLOQs and QC LOWs for glucagon quantitation are prepared 
after plasma sample extraction (i.e. at step 19 of the procedure in 4.5.5). 20 µL of the 
appropriate working solution is spiked into the collection plate, along with 20 µL mixed 
ISWS and 160 µL surrogate matrix. Taking into account the 2-fold concentration 
experienced by plasma samples (400 µL plasma sample is reconstituted into 200 µL 
solvent) this gives final calibration levels of 15, 25, 45, 100, 300, 600, 1000, 1850 and 
2000 pg/mL, and final QC levels of 15 (QC LLOQ) and 45 (QC LOW) pg/mL. 
4.5.5 Sample Extraction Procedure 
Steps 1, 2 and 4 should be performed on wet ice (ca. 4 C).  
1 Aliquot 400 µL plasma sample into a 2 mL 96-well polypropylene plate 
2 Add 20 µL ISWS 
3 Vortex mix at 1200 RPM for 1 min 
4 Add 1.1 mL ACN:H2O:NH4OH (72:25:0.1,v/v/v) 
5 Seal plate using a plastic sealing mat and mix at ~1200 RPM for 3 x 30 sec 
6 Sonicate for 5 min 
7 Centrifuge 2300 x g for 10 min 
8 Transfer 1200 µL supernatant to a 2 mL 96-well plate using an automated liquid 
handling system (Quadra Tower, TomTec) 
9 
Evaporate the extracts to dryness under a stream of nitrogen gas at 40 °C (Porvair 
MiniVap blow down at 60 litres per minute recommended (ca. 90 min evaporation 
time)) 
10 Reconstitute the extracts in 800 µL 2% NH4OH (aq) 
11 Seal the plate and vortex mix at 1200 rpm for 1 min 
12 Condition a Bond Elut Plexa SEH SPE plate (96-round well, 30 mg) with 1 mL MeOH 
13 Equilibrate the SPE plate with 1 mL water 
14 Load the reconstituted protein precipitation extracts on to the SPE plate 
15 Wash the SPE plate with 1 mL 5% MeOH (aq) 
16 Elute from the SPE plate with 2 x 225 µL ACN:H2O:FA (75:25:0.1, v/v/v) into a 1 mL 
96-well LoBind plate 
17 
Evaporate the extracts to dryness under a stream of nitrogen gas at 40 °C (Porvair 
MiniVap blow down at 60 litres per minute recommended (ca. 60 min evaporation 
time)) 
18 Reconstitute the extracts in 200 µL 0.2% FA (aq) 
19 Prepare Surrogate matrix calibration and QC samples as described in Section 4.5.4 
20 Seal the plate and vortex mix at 1200 rpm for 1 min 
21 Centrifuge the extracts at 2300 x g for 10 min 
22 Analyse immediately by LC-MS/MS or transfer to storage at nominally 4 °C 
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4.5.6 HPLC Conditions 
Autosampler Waters Acquity Sample Manager  
Strong wash Acetonitrile (advised volume = 1000 µL) 
Weak wash Acetonitrile:water (10:90, v/v) (advised volume = 1000 µL) 
Injection mode Partial Loop with needle overfill (40 µL injection) 
Autosampler temperature 4ºC  
LC system Waters Acquity Binary Solvent Manager  
Flow rate 0.800 mL/min 
Analytical Column Waters UPLC BEH C18 1.7 µm (2.1 x 100 mm) 
Column temperature Nominally 60C 
Run Time 3.6 min 
 Quantitation Method  Qualification Method 
Mobile phase A  0.2% FA in ACN 0.01% FA in ACN with  
0.05% m-NBA 
Mobile phase B 0.2% FA (aq) 0.01% FA (95:5 H2O:ACN, v/v) 
Gradient Profile  
Time (min) Quantitation Method  Qualification Method 
%A %B Gradient 
1
 %A %B Gradient 
1
 
Initial 22 78 - 18 82 - 
2.00 32 68 6 28 72 6 
2.80 38 62 6 34 66 6 
2.85 95 5 11 95 5 11 
3.55 95 5 11 95 5 11 
3.60 22 78 11 18 82 11 
1
 A gradient profile of 6 describes that the gradient was altered at a constant rate from the gradient 
conditions at the preceding time point. A profile of 11 describes that the gradient changes only 
when the time point is reached; at this point it changes immediately to the new conditions. 
4.5.7 MS/MS Conditions 
Mass Spectrometer AB SCIEX 5500 
Ionisation Mode (Polarity) Electrospray (Positive) 
Electrospray Voltage 5500 V 
Source Temperature 600 ºC 
GS1 / GS2 60 / 40 psi 
Curtain gas setting 40 psi 
Collision gas setting 8 psi 
Q1/Q3 Resolution Unit/Unit 
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4.5.7.1 SRM Transitions (Quantitation Method) 
Period 1 (0- 2.00 min) 
ID 
Precursor 
ion 
(m/z) 
Product  
ion 
(m/z) 
Dwell 
time 
(ms) 
EP 
(V) 
DP 
(V) 
CE 
(V) 
CXP 
(V) 
Typical  
Retention 
Time (min) 
Glucagon  697.5 694.0 60 10 80 20 13 1.5 
Analogue glucagon IS 677.4 673.8 60 10 80 18 13 1.5 
SIL glucagon IS 702.2 698.8 60 10 80 20 13 1.5 
The SIL glucagon IS should be used as the internal standard for glucagon quantitation. 
 
Period 2 (2.00- 3.60 min) 
ID 
Precursor 
ion 
(m/z) 
Product  
ion 
(m/z) 
Dwell 
time 
(ms) 
EP 
(V) 
DP 
(V) 
CE 
(V) 
CXP 
(V) 
Typical  
Retention 
Time (min) 
GLP-1 (Transition 1) 660.6 656.9 100 10 100 16 13 2.3 
GLP-1 (Transition 2)  660.6 752.0 100 10 110 22 13 2.3 
GLP-1 quantitation should be performed using transition 2, as this was found to give best 
performance. The analogue glucagon IS should be used as the internal standard. 
4.5.7.2 SRM Transitions (Qualification Method) 
Period 1 (0- 1.75 min) 
ID 
Precursor 
ion 
(m/z) 
Product  
ion 
(m/z) 
Dwell 
time 
(ms) 
EP 
(V) 
DP 
(V) 
CE 
(V) 
CXP 
(V) 
Typical  
Retention 
Time (min) 
Glucagon  581.5 578.5 60 10 80 13 13 1.5 
Analogue glucagon IS 564.7 561.8 60 10 80 12 13 1.5 
SIL glucagon IS 585.5 582.4 60 10 80 13 13 1.5 
The SIL glucagon IS should be used as the internal standard for glucagon qualification. 
 
Period 2 (1.75- 3.60 min) 
ID 
Precursor 
ion 
(m/z) 
Product  
ion 
(m/z) 
Dwell 
time 
(ms) 
EP 
(V) 
DP 
(V) 
CE 
(V) 
CXP 
(V) 
Typical  
Retention 
Time (min) 
GLP-1 (Transition 1) 550.6 601.6 100 10 80 19 13 2.3 
GLP-1 (Transition 2) 550.6 639.3 100 10 70 19 13 2.3 
Neither transition gave satisfactory performance in the qualification method. The qualification 
method is therefore not suitable for GLP-1 qualification.  
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Chapter 5 Conclusions and Future Work 
 
 
  
232 
 
5.1 CONCLUSIONS  
5.1.1 Thesis Overview 
The aim of this project was the development of mass spectrometry-based methodologies 
for the high-throughput quantitation of peptides in biological matrices. Glucagon was 
selected as an initial model peptide for this research, because many existing assays 
(immunoassays) perform poorly despite the clinical importance of this peptide. This need 
for an alternative quantitative technique, and the many challenges associated with glucagon 
quantitation (including those related to its endogenous nature, low concentrations, 
instability in matrix, and metabolite formation) made it an appealing model peptide for 
study in the work reported in this thesis. Later, GLP-1 was added as a secondary analyte, 
as its immunoassays similarly suffer from poor performance, and it shares many other 
analytical challenges with glucagon. For certain applications, such as in the development 
of obesity treatments, simultaneous measurement of glucagon and GLP-1 is desirable and 
the multiplexed LC-MS/MS method developed as part of this project is ideally suited to the 
simultaneous determination of glucagon and dosed GLP-1.  
Here follows a summary of the chapters of the thesis: 
5.1.2 Chapter 1 
Chapter 1 introduced the nature of peptides, both as an endogenous species that have the 
potential to be biomarkers, and as therapeutics. The immunoassays used in this project for 
cross-validation were then described, before the chapter focussed on mass spectrometry- 
based methodologies. The principles of electrospray ionisation and of the various mass 
analysers and mass spectrometers used within this project were described. Peptide 
chromatography, extraction techniques, and quantitation strategies were then discussed, 
followed by peptide modifications and degradation. Finally, the chapter introduced 
glucagon and GLP-1 as model peptides, describing their biology, related therapeutics, and 
the numerous analytical challenges associated with their quantitation.  
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5.1.3 Chapter 2 
Chapter 2 described the development of the first peer-reviewed LC-MS/MS method for the 
quantitation of endogenous glucagon. A novel surrogate matrix-based quantitation 
approach was used to account for glucagon’s endogenous nature. This involved the use of 
non-extracted surrogate matrix calibration standards, with an analogue internal standard 
correcting for differences in recovery/matrix effects between these calibrants and extracted 
plasma samples. The use of non-extracted calibrants avoided analyte losses due to non-
specific binding to the extraction materials. A novel 2D extraction method was utilised, 
where protein precipitation was combined with SEH SPE. This enabled good recovery and 
robustness with relatively low matrix effect.  
The developed method was cross-validated against established immunoassays using 
samples from patients undergoing glucagon infusions. Pharmacokinetic profiles showed 
similar trends, although absolute concentrations were different. However, some differences 
were not unexpected, as performance concerns associated with immunoassays provided the 
rationale for the development of a mass spectrometry-based method.  
The performance of the LC-MS/MS method was assessed against experiments described in 
validation guidelines from regulatory agencies (EMA [1] and FDA [2]). The majority of 
the experiments were well within acceptance criteria. However, plasma samples showed 
some instability when handled on ice or following freezer storage, despite the presence of 
the stabiliser aprotinin. The method was therefore described as “qualified” rather than 
“validated”. 
5.1.4 Chapter 3 
To explore the instability of glucagon noted in Chapter 2, Chapter 3 investigated plasma 
protease-derived metabolites of glucagon and their formation under typical laboratory 
sample handling conditions. Despite this matrix being widely clinically used, this was the 
first study of glucagon metabolism in plasma. An understanding of metabolite formation 
may help to inform future stabilisation strategies, and/or the cross-reaction of metabolites 
may help to explain the poor performance of some glucagon immunoassays. 
Metabolite identification was initially performed using a quadrupole-linear ion trap mass 
spectrometer; however, this did not show sufficient resolution to unambiguously identify 
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metabolites. A high resolution Orbitrap instrument was, therefore, used for metabolite 
confirmation. The previously reported serum metabolite [pGlu]
3
glucagon3–29 was 
confirmed in stressed samples; however, significant amounts of glucagon3–29 were also 
detected, which had not been previously reported in serum. The latter was in fact the 
dominant metabolite at low levels of metabolism. Glucagon19-29 (miniglucagon) was also 
detected in plasma for the first time, as were the novel metabolites glucagon20-29 and 
glucagon21-29. All of the metabolites detected have intact C-terminals, and are therefore 
able to cross-react with C-terminal antibodies, which may help to explain the poor 
performance of immunoassays that rely on these antibodies. 
5.1.5 Chapter 4 
Whilst the glucagon method developed in Chapter 2 was the most sensitive LC-MS/MS 
method at the time, it was not sensitive enough to determine endogenous glucagon 
concentrations from all samples, and the extraction time (2 days) was relatively long and 
labour intensive. Extensive method development was, therefore, undertaken to attempt to 
improve sensitivity and throughput. In addition, the assay was expanded to add GLP-1 as a 
secondary analyte. 
A modified 2D extraction methodology was developed that enabled the use of an 
automated liquid handling system. This not only reduced extraction time, but also 
improved sensitivity as a result of reduced matrix suppression. The reduced matrix content 
in the extracts also enabled the elimination of a lengthy UHPLC column wash step, further 
improving throughput. The method was qualified against key experiments in regulatory 
guidelines and showed good performance, including good reproducibility at the 
endogenous glucagon level. The method was not sensitive enough to detect endogenous 
GLP-1, although it successfully quantified dosed GLP-1. The method is currently the most 
sensitive LC-MS/MS method for both analytes that avoids immunoenrichment. 
The mobile phase supercharging reagent m-NBA provided an alternative sensitive SRM 
transition. This was used as a qualifier transition to ensure specificity for endogenous 
glucagon quantitation, in a novel application of m-NBA modified mobile phases. 
The method was cross-validated at the endogenous glucagon, dosed glucagon and dosed 
GLP-1 levels against two immunoassays in each instance using samples from a 
physiological study. Some similarities between LC-MS/MS methods with the 
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immunoassays were shown. However, it is noteworthy that at the endogenous glucagon 
and dosed GLP-1 levels the immunoassays showed poor agreement with each other. 
5.1.6 Overall Summary  
This thesis describes the development of LC-MS/MS methodologies for the quantitation of 
peptides in biological matrices. The challenging peptides glucagon and GLP-1 were 
quantified in human plasma using UHPLC-SRM MS, along with a novel 2D extraction 
procedure, a novel surrogate quantitation method, and a novel application of m-NBA 
supercharging reagent to ensure specificity. The multiplexed method is the most sensitive 
LC-MS/MS method available that avoids immunochemistry, and is able to quantify 
endogenous levels of glucagon and dosed levels of glucagon and GLP-1 with good 
precision and accuracy. The performance differences between immunoassays noted during 
the cross-validations exemplifies the need to develop alternative, more specific 
technologies such as LC-MS/MS. Some of the discrepancies may be due to the cross-
reaction with metabolites, such as the novel glucagon metabolites identified using high 
resolution MS as part of this research. 
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5.2 FUTURE WORK 
5.2.1 Further Refinement, Expansion, and Characterisation 
The multiplexed glucagon and GLP-1 LC-MS/MS method described in Chapter 4 could be 
further refined, expanded, and characterised. 
The most sensitive instrument available for this research was the AB SCIEX 5500 mass 
spectrometer. However, our laboratory now has access to the latest model (6500), along 
with access to an alternative sensitive triple quadrupole mass spectrometer (Waters Xevo 
TQS). The greater sensitivity of these instruments may reduce assay LLOQs, possibly 
allowing quantitation of endogenous levels of GLP-1 in plasma without 
immunoenrichment. The use of high resolution instruments for quantitation could also be 
explored. Such instruments have modes that focus on the peptides of interest to maximise 
sensitivity, as well as full scan modes that achieve reasonable sensitivity but allow 
interrogation of the data at a later date for additional species (e.g. metabolites) increasing 
applicability [3]. 
The method could be further expanded to include additional proglucagon peptides of 
interest. A hybrid immunochemistry LC-MS/MS approach recently described the 
simultaneous quantitation of four proglucagon derived peptides [4], although a simpler 
method avoiding immunoenrichment would be preferable in terms of simplicity, 
throughput and cost. 
The differences in glucagon and GLP-1 concentrations obtained using the various 
immunoassay and mass spectrometric analytical methods is concerning, as this could lead 
to incorrect clinical decisions. Assays need to be better characterised with regards to inter-
subject and anticoagulant related matrix interferences, as well as for cross-reactivity with 
metabolites and degradation fragments. Characterisation may include the use of biological 
matrix reference materials containing independently certified amounts of analyte [5], 
although these are not currently available for glucagon or GLP-1. 
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5.2.2 Application of Developed Techniques to Alternative Peptides  
Variations of the 2D extraction methodology, non-extracted surrogate matrix quantitation 
approach and/or the use of supercharging mobile phase additives to provide sensitive 
qualifier transitions to ensure specificity, could be applied to other peptides. These may 
include therapeutic peptides, many of which are related to glucagon or GLP-1  
(Section 1.9.4) and the techniques, may therefore, only require limited redevelopment. 
5.2.3 GLP-1 Metabolites 
Novel glucagon metabolites were identified in Chapter 3, and their formation under typical 
laboratory sample handling conditions was characterised. A similar approach could be 
performed for GLP-1 metabolites. As with glucagon, GLP-1 metabolites may cross-react 
with immunoassay antibodies, which might help to explain the poor performance of some 
of these assays. Metabolites could also provide insights into in vivo processes, and assist 
with the development of stabilisation strategies, which could avoid the need to handle 
samples on ice. 
5.2.4 Effect of Sample Storage  
Chapter 2 demonstrated a drop in measured glucagon concentrations in stability samples to 
as low as 71% of the spiked amount following 1 weeks storage at -80 C. Another study 
similarly demonstrated a fall in glucagon concentration on storage, although this was 
significantly larger, to 50% of the spiked amount after just 72 hours at -80 C [6]. 
Intriguingly further significant degradation was not noted in either case, with similar 
concentrations measured after 7 and 51 days storage at -80 C (Section 2.3.3) or 1 and 3 
months storage [6]. The results suggest that the drop is not due to traditional enzymatic or 
thermal degradation instability, where a continued fall in concentration would be expected 
over time.  
The loss of glucagon does not appear to be related to the freeze-thaw shock itself, as no 
drop was observed following 1 hour storage [6]. It is, however, possible that it is due to the 
aggregation of glucagon upon freezing over a short time up to a limit, past which no 
further aggregation (drop) occurs. Glucagon is known to aggregate in some solutions, for 
example aqueous HCl (pH 2) at 37 C [7]. A lag time of approximately 50 minutes before 
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aggregation was observed in this solution, and if a similar process occurs in plasma it may 
explain why very short term freezing does not lead to a drop in measured concentrations. 
It is possible that analytical methods are affected differently by the phenomenon causing 
initial glucagon levels to fall, which may help to explain some of the discrepancies of 
glucagon stability described in the literature (Section 1.9.7), as well as the poor 
performance of some assays. For example, aggregates may become protein bound, and lost 
during protein depletion, or extraction reagents may break the binding. Similarly, 
aggregates may not be capable of interacting with immunoassay epitopes. There may also 
be an inter-matrix, anticoagulant, stabiliser, concentration, or endogenous/fortified peptide 
related effects.  
The effect of glucagon sample storage therefore requires further investigation, using a well 
characterised method, such as the LC-MS/MS method described in Chapter 4.  
5.2.5 Inter-matrix Effect on Plasma Stability 
Fortified samples are often used for stability assessments, as these are favoured by the 
EMA [1] and FDA bioanalytical guidelines [2], as the true concentrations of endogenous 
samples is unknown. The guidelines explain that stability samples should be created using 
the same matrix type and anticoagulant as clinical samples, but the effect of inter-matrix 
variability is not explicitly considered in them, nor in many validation strategy papers 
[8][9][10]. Consequently, stability samples are often prepared from pooled plasma [4][6] to 
ensure sufficient matrix volume, sometimes from a large number of individuals (e.g. n=20 
[6]). Such a pooled matrix was used for stability assessments described in this thesis. 
However, such studies mask differing enzyme activities of their constituents, and therefore, 
do not fully represent clinical samples from different volunteers. 
Initial investigations performed at LGC demonstrated a large inter-matrix effect when 
glucagon was fortified into plasma into various (n=6) plasma lots and incubated for 6 hours 
at room temperature, with between 3.2% to 77.0% of the spiked amount remaining after 
incubation. Stability was only loosely correlated to matrix age, suggesting enzyme activity 
is not lost in a linear fashion, and/or inherent differences between plasma are more 
important. Inter-matrix variability could help to explain some of the discrepancies in 
glucagon stability in the literature (Section 1.9.7), and indeed that observed between 
Chapter 2 (Section 2.3.3) (76.9% after 6hr 20 min on ice) and Chapter 4 (Section 4.3.5.1) 
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(110.1% after 4 hr 50 min on ice) depending on the matrix (or pools) selected for 
assessment. 
The nature of the analyte may affect susceptibility to inter-matrix variability, with some 
reporting that exogenous glucagon fortified into plasma is significantly less stable than 
endogenous glucagon [11]. This may explain why ISR assessment described in Chapter 4 
(Section 4.3.6) at the endogenous glucagon level did not appear to be affected by potential 
differences in inter-matrix stability. 
Further work could be performed to fully characterise inter-matrix variability, and to 
investigate techniques to reduce it. The results of such studies may eventually lead to 
changes in bioanalytical guidelines for assessing peptide stability in plasma. 
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6.2 EXTERNAL CONFERENCES AND PRESENTATIONS 
Event  Role Date Duration 
BSPR/EBI-Proteomics from Qualitative to 
Quantitative, Cambridge  
Delegate  July 2010 3 days 
East Midlands Proteomics Workshop, 
Loughborough 
Delegate Nov 2010 1 day 
The AB SCIEX TripleTOF 5600 System 
Seminar, Cambridge 
Delegate Mar 2011 1 day 
BSPR/EBI-Proteomics from Qualitative to 
Quantitative Cambridge 
Delegate July 2011 3 days  
ProteoMMX 2.0-Strictly Quantitative, 
Chester 
Delegate Mar 2011 3 days 
Agilent Clinical Symposium, London Delegate June 2012 1 day 
East Midlands Proteomics Workshop, 
Loughborough 
Oral Presentation
1
 Nov 2012 1 day 
Bioanalytical method development for 
therapeutic and endogenous peptides, 
Frankfurt 
Delegate Feb 2013  3 days 
East Midlands Proteomics Workshop, 
Loughborough 
Delegate Nov 2013 1 day 
BMSS Protein and Peptide Special Interest 
Group & BMSS Annual Meeting, Cheshire 
Presented Poster
2
 Mar 2014 3 days 
East Midlands Proteomics Workshop, 
Loughborough 
Delegate Nov 2014 1 day 
BMSS Annual Meeting, Birmingham Oral Presentation
3
 Sep 2015 3 days 
Young Scientist Symposium, European 
Bioanalysis Forum, Barcelona 
Oral Presentation
4
 Nov2015 1 day 
 
European Bioanalysis Forum, Barcelona Oral Presentation
4
 Nov 2015 3 days 
 
LGC Webinar, Fordham  Oral Presentation
4
 Feb 2016 30 mins 
Cambridge Quantitative MS Group, 
Cambridge  
Oral Presentation
4
 Feb 2016 1 day 
LGC Video clip, Fordham Oral Presentation
5
 May 2016 10 mins 
LGC Webinar, Fordham  Oral Presentation
5
 Oct 2016 30 mins 
1 - Development of a high throughput UHPLC-MS/MS (SRM) method for the quantitation of 
endogenous glucagon from human plasma 
2 - Development of an LC-MS/MS method for the quantitation of glucagon in human plasma 
3 - Overcoming challenges during the development of a SRM incretin and glucagon method 
4 - Little to LARGE - LC-MS/MS peptide method development for small molecule specialists 
5 - Supercharging reagents - increasing the sensitivity of peptide bioanalysis 
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The following posters were authored by me but presented by colleagues: 
 Development of a high throughput UHPLC-MS/MS (SRM) method for the 
quantitation of endogenous glucagon from human plasma, Poster, 20th 
International Reid Bioanalytical Forum, Guildford, September 2013. 
 
 Development of an LC-MS/MS method for the quantitation of glucagon in human 
plasma. European Bioanalysis Forum, Barcelona, November 2013. 
 
 Quantitation of glucagon in human plasma: immunoassay vs LC-MS/MS, BMSS, 
Eastbourne, September 2013. 
6.3 PRIZES AND AWARDS 
 Best Oral Presentation, East Midlands Proteomics Workshop, Loughborough, 
November 2012. 
 Best Oral Presentation, Young Scientist Symposium EBF, Barcelona, November 
2015. 
 Nominated for “LGC Science Award”, for raising LGC’s profile, Surrey, April 
2016 
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6.4 THE 21 PEPTIDE-FORMING AMINO ACIDS FOUND IN 
EUKARYOTES 
 
 
Figure 6.1 The 21 proteinogenic α-amino acids found in eukaryotes, grouped according to 
their side chains' pKa values and charges carried at physiological pH 7.4. 
Reproduced from https://en.wikipedia.org/wiki/Amino_acid, with permission. Accessed 17 April 
2017.
 
